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. Abstract 
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Ubiquitin conjugating (UBC) enzymes playa key role in eukaryotes during the post-
translational modification of proteins by covalent attachment of ubiquitin. A gene was 
identified in the double stranded DNA genome of African swine fever virus (ASFV) 
which was predicted to encode a protein with high homology to eukaryotic UBC 
enzymes. This ASFV encoded enzyme (UBCv) was expressed in E. coli and was 
shown to have ubiquitin conjugating activity in vitro. Antisera against recombinant 
UBCv were used to detect UBCv in ASFV infected cells. UBCv was shown to be a 
cytosolic protein present throughout the early and late stages of ASFV replication and 
was packaged in ASPV virions. Attempts to inhibit UBCv activity during ASFV 
infection using antisense oligonucleotides were unsuccessful, and a recombinant 
ASPV mutant with the UBCv gene disrupted by the luciferase reporter could not be 
isolated. However, ASFV replication was impaired late in infection in TS20 cells at 
a temperature which inhibits the ubiquitin conjugating pathway. 
No novel ubiquitinated proteins could be detected in ASFV infected cells by 
immunoblotting, although an unspecific increase of cellular ubiquitin conjugation was 
observed in early infection. However, virus factories were intensely stained late in 
ASFV infection by immunofluorescence using anti-ubiquitin antisera. In addition, 
several ubiquitinated structural proteins were detected in purified ASFV extracellular 
particles by both immunoblotting and immunogold electron microscopy. An 18 kDa 
ubiquitinated structural protein, probably localized in the virion periphery, was 
purified to homogeneity and the sequence of its N-terminal 10 amino acids was 
determined. The N-terminal sequence of this protein matched exactly the predicted 
product of a gene of unknown function encoded by the ASPV genome. 
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With the advent of international trade, the once remote and little known African swine 
fever (ASF) disease has become an important economic threat to the pig industry 
worldwide. The lack of prophylaxis for ASF and its potential devastating effect has 
spurred considerable interest in its causative agent, African swine fever virus (ASFV). 
The combined efforts of many laboratories since the 1960s have revealed many ASFV 
characteristics which indicate, much to the frustration of taxonomists, that ASFV is 
a resolutely unique virus. Molecular biology has recently opened several new insights 
into the understanding of the distinctive replication cycle of ASFV, one of which is 
the finding that ASFV encodes a ubiquitin conjugating enzyme. Since its discovery 
in eukaryotes a decade ago, the ubiquitin conjugation pathway has been found to play 
key roles in a growing number of apparently unrelated cellular processes. In addition, 
a disparate set of recent observations has led to the realization that ubiquitin 
conjugation is probably also relevant to virus infections. This view is supported by 
the particular case of ASFV which is the subject of this study. 
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1.1 African swine fever 
1.1.1 Geographical distribution and control 
The African swine fever (ASF) disease was first described in Kenya early this century 
(Montgomery, 1921) and was subsequently reported in many countries of sub-Saharan 
Africa (reviewed by Wardley et al., 1983; Vinuela, 1985a; Wilkinson, 1989). The 
disease was first introduced outside Africa in 1957 when infected waste food was fed 
to pigs near Lisbon airport, Portugal. Ingestion of infected pig meat by pigs is also 
the suggested cause of many of the ASF outbreaks in Europe, the Caribbean and 
South America. Most of these outbreaks were successfully eradicated (France, 
Belgium, the Netherlands, the Caribbean and Brazil) but ASF is currently enzootic 
in sub-Saharan Africa, Portugal, Sardinia and Spain. 
Since there is neither a vaccine nor a cure for ASF, the only effective 
measures for disease control are mass slaughter and strict import policies (Mackenzie, 
1993). These rudimentary measures are not only difficult to enforce but are also very 
expensive, as illustrated by the $45 million cost in 1978 of the Malta ASF eradication 
program. Similar ASF eradication programs, involving the destruction and re-stocking 
of the entire pig population, were also successfully carried out in the Dominican 
Republic, Cuba and Haiti. These eradication programmes were simplified by the 
insular nature of these countries. Despite colossal efforts, other countries such as 
Sardinia, Spain and Portugal have not managed to eradicate ASF, which underlines 
the need for new and effective methods of disease control. 
1.1.2 Causative agent, host range and transmission 
The difficulties encountered in the fight against the spread of ASF are partly due to 
the complex host range of ASFV. Domestic and wild pigs (Sus scrota) are the only 
animals in which ASFV infection produces disease. However, the virus also replicates 
in warthogs (Phacochoerus aethiopicus), bush pigs (Potamochoerus porcus) and soft 
ticks (Ornithodoros genus) but produces no apparent disease (Detray, 1963; Plowright 
et aZ., 1968, 1969). These apparently healthy carriers act as reservoirs of ASFV and 
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infected soft ticks are also an important disease vector since they can transmit ASFV 
to the pigs on which they feed (Wilkinson, 1981). Once ASFV is introduced into a 
pig population it may be transmitted in the absence of the tick vector by simple 
contact with infected pigs. 
The disease caused by ASFV in pigs varies from peracute to subacute or even 
chronic depending on the ASFV isolate. The primary route of ASFV infection in pigs 
is the upper respiratory tract. The virus replicates in the tonsils and rapidly spreads 
to the lymph nodes of the head. Virus propagation from the lymphatic system to the 
blood follows shortly and generalized infection may occur as soon as 48 hours after 
contact exposure. Cells of the lymphoreticular system are the main targets for ASFV 
replication. The first sign of disease is fever which is followed by internal 
haemorrhages caused by impairment of the endothelial cell functions. Death usually 
occurs within seven days of the onset of clinical signs although subacute disease may 
be more prolonged. 
While many isolates from Africa are highly virulent (100% mortality), other 
ASFV isolates such as in recent outbreaks in Spain and Portugal are less virulent 
(under 50 % mortality) although they still produce high morbidity (Mebus and Daidiri, 
1980). The pigs which recover from ASFV infection are thought to play an important 
role in the spread of ASFV since they may be persistently infected for periods of six 
months or more. Although recovered pigs are resistant to challenge with the 
homologous ASFV isolate, pigs challenged with heterologous isolates are usually not 
protected (Hess, 1971; Thomson et al., 1979). Pigs which die from ASFV infection 
do so before an effective immune response is mounted, but surprisingly pigs that have 
recovered from the disease do not appear to produce neutralizing antibodies against 
ASFV (DeBoer, 1967; DeBoer et ai., 1969). However, resistance to ASFV infection 
can sometimes be induced by passive immunization with immunoglobulins from pigs 
that have recovered from a homologous ASFV infection (Hess, 1971; Wardley et at., 
1985), which indicates that other antibody dependent immune mechanisms are 
involved in protection. One recent report claims that the infectivity of virulent ASFV 
isolates is neutralized in vitro with convalescent swine serum (Zsak et al., 1993), 
whereas previous findings have suggested the presence of antibodies which reduce but 
do not neutralize virus infectivity (DeBoer, 1967; Parker and Plowright, 1968; 
DeBoer et aI., 1969; Ruiz Gonzalvo et al., 1986). Further understanding of the 
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unusual and somewhat controversial immune response to ASFV will be necessary if 
an effective vaccine against ASFV is to be produced. 
1.2 African swine fever virus 
1.2.1 Particle structure 
The large icosahedral ASFV particles (figure 1.1) are similar to vertebrate iridovirus 
particles such as frog virus 3 (Breese and DeBoer, 1966; Pan et af., 1970; Carrasco sa 
et af., 1984). The intracellular ASFV particles are approximately 190 nm across and 
are composed of three main concentric structures. The spherical nucleoprotein core 
is approximately 80 nm in diameter and is surrounded by an internal lipid membrane 
which is closely associated with the external protein capsid. In addition, extracellular 
ASFV particles are enveloped with a loose external membrane similar in structure to 
the cell unit membrane. The icosahedral structure of ASFV particles is conferred by 
the periodical arrangements of 13 nm hexagonal capsomers which form the virus 
capsid. 
Extracellular ASFV particles contain at least 54 structural proteins with 
molecular weights ranging from 10 to 150 kDa (Tabares et aZ., 1980a; Carrascosa et 
af., 1985; Esteves et af., 1986). The term 'structural protein' refers to a protein 
present in virions, but does not necessarily imply that it participates in the virion 
structure. Approximately one quarter of the ASFV structural proteins are suspected 
to consist of cellular proteins, such as actin and tubulins, that are packaged into 
virions or are spuriously co-purified with virions (Tabares et af., 1980a; Carrascosa 
et at., 1985; Esteves et af., 1986). The location in the virion of certain major ASFV 
structural proteins was identified by electron-microscopy of immuno-gold labelled 
ASFV particles (Carrasco sa et af., 1986, 1993). The largest ASFV structural protein 
VP150 is situated in the virion nucleo-protein core and at the vertices of the capsid 
(one of these locations might be due to cross-reactivity with another virion protein), 
structural proteins VP37 and VP17 are found close to the internal lipid membrane, 
structural proteins VP72 is located in the virus capsid whereas VP12 is located 
outside the capsid, probably in the virus envelope. Extracellular ASFV particles do 
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not appear to contain any glycoproteins (Tabares et al., 1983; Del Val et al., 1986; 
Del Val and Vinuela, 1987) but two myristylated (28 and 13 kDa) and two 
phosphorylated (35 and 17 kDa) proteins are detected in virus particles (Salas, M.L. 
et al., 1988; Aguado et al., 1991). Finally in common with vaccinia virus (the 
prototype orthopoxvirus), several enzymatic activities are associated with ASFV 
particles (table 1.1), most of which are involved in the synthesis and processing of 
messenger RNA (discussed in §1.2.3). 
I Reference II 
Enzyme Activity 
I 
Kuznar et al., 1980 DNA dependent RNA polymerase 
Salas et al., 1981 Poly A polymerase 
Salas et al., 1981 RNA guanylyl transferase 
Neilan et al., 1993 
Salas et al., 1981 RNA guanine-7-methyltransferase 
Salas et al., 1981 RNA 2'-O-methyl-transferase 
Vinuela, 1985a Deoxyribonuclease 
Salas et al., 1983 DNA topoisomerase 
Kuznar et al., 1981 Nucleoside triphosphoh ydrolases 
Polatnick et al., 1974 Protein kinase 
Baylis et al., 1993a 
Table 1.1 Enzyme activities present in ASFV particles. 
The enzyme activities detected in ASFV particles are indicated together with the 
relevant bibliographic references. 
Figure 1.1 Structure of ASFV particles 
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e 
Inner membrane 
Nucleo- rotein core 
A schematic representation of ASFV extracellular particles is indicated together with 
the location of major ASFV structural proteins (see §1.2.1). 
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1.2.2 Genome structure 
The ASFV genome is composed of a linear double stranded DNA molecule (figure 
1.2) with an A+T content of approximately 60% (Enjuanes et al., 1976b; Vinuela, 
1985a, b). The genome is between 170 and 190 kb in length and both its ends are 
cross linked by terminal hairpin loops into a single polynucleotide chain (Ortin et al., 
1979; Gonzalez et al., 1986; Blasco et al., 1989). The terminal hairpin loops consist 
of two inverted and partially paired 17 bp sequences that are almost entirely 
composed of A and T bases. The hairpin loops are followed by terminal inverted 
repeats (identical but oppositely oriented sequences at the two ends of the genome) 
which contain several sets of tandem direct repeats of unknown function (Sogo et al., 
1984; Vinuela, 1985a; Dixon et al., 1993). Although additional arrays of tandem 
repeats are found in other parts of the genome, the sequences of the repeat units 
between the various arrays are unrelated. It is thought that these tandem repeats might 
act as recombination 'hot spots' or transcription regulatory signals. 
Restriction endonuclease mapping of the genomes of several ASPV isolates 
reveals frequent insertions and deletions of up to 8 kb in defined regions of the 
genome (Wesley and Pan, 1982; Dixon and Wilkinson, 1988; Blasco et al., 1989; 
Dixon et al., 1990; Sumption et al., 1990). With the exception of a single locus 90 
kb from the left end of the ASFV genome, the central 100 kb portion of the genome 
is conserved in length whereas the regions near the ends of the genome (right hand 
22 kb and left hand 48 kb) are more variable. Many of these variations are probably 
due to differences in the number of repeats in the arrays of direct tandem repeats. 
However, sequencing of the terminal genome regions indicates that many ASFV 
genome variations arise from deletions, duplications and translocations of redundant 
genes belonging to three different multigene families (MGF) (Almendral et al., 1990; 
Gonzalez et al., 1990; Vydelingum et al., 1993). Members of the MGF 360 (so· 
called because the genes of this family contain an average of 360 codons) are present 
at one or both ends of all the ASFV isolates sequenced. Members of MGF 110 are 
present in the majority of ASFV isolates although two virus clones were isolated 
which did not contain any MGF 110 members (Aguero et al., 1990). Loss of MGF 
110 did not reduce virulence of these virus clones in domestic pigs. Members of 
, 
MGF 100 are located at the right end of the genome of the Malawi LIL20/1 ASFV 
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isolate but sequence information for this MGF is not yet available from other isolates 
(Vydelingum et al., 1993). The function of these MGFs is unknown but their 
presence in many different isolates and the large part of the virus genome that they 
constitute (5 kb or more) suggests that they must be important for virus replication 
or transmission. Since the homologous genes of a MGF are all slightly different from 
each other, it is possible that these MGFs are a source of genetic diversity which 
allows ASFV to adapt to its various hosts and environments. The view that the ends 
of the ASFV genome are important for determining cellular tropism and host 
specificity but not for virus replication is supported by the observation that major 
deletions (up to 17 kb) occur in the genome termini upon adaptation of ASFV field 
isolates to tissue culture cells (Tabares et al., 1987). 
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Figure 1.2 Structure of the ASFV genome 
Panel A: Each strand of the ASFV DNA is represented by a single line. Panel B: 
detail (not to scale) of one of the genome termini shows the organization of terminal 
inverted repeats (TIRs), tandem arrays of direct repeats, cross linked terminal hairpin 
loops and multigene families (see § 1.2.2) 
Progeny virus 
particles 
Figure 1.3 The replication cycle of ASFV in the host cell 
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The diagram shows the various events (virus entry, early gene expression, DNA 
replication, late gene expression , virus morphogenesis and virus release) that take 
place during the replication of ASFV in a permissive host cell (see §1.2.3). 
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With the exception of the presence of extensive MGFs and internal arrays of 
repeated sequences, the overall genome structure of ASFV described above is very 
similar to that reported for poxviruses (reviewed by Moss, 1990a, b). 
1.2.3 Replication cycle 
The replication cycle of ASFV in its host cell (summarized in figure 1.3) is 
remarkably similar to the replication of poxviruses such as vaccinia virus (Moss, 
1990a). The sequence of events involved in the replication of ASFV is described 
below. 
Virus entry 
The natural. target for ASFV infection in pigs are cells of the macrophage and 
monocyte lineage (Malmquist and Hay, 1960; Moulton and Coggins, 1968; Wardley 
et ai., 1979; Pan, 1987). ASFV binds to the target cell via a saturable receptor that 
is present on cells permissive to ASFV infection, such as swine macrophages and 
certain tissue culture cell lines, but not on cells that are resistant to ASFV infection 
such as rabbit or human macrophages and tissue culture L-cells (Alcami et al., 
1989b, 1990). Although this ASFV cell receptor has not yet been identified, it was 
shown in vitro that opsonization of ASFV particles with anti-ASFV immunoglobulins 
class G (IgGs) did not affect virus infectivity, even when the macrophage 
immunoglobulin Fc receptors (FcRs) were pre-saturated with non-immune antibodies 
(Alcami and Vinuela, 1991). These experiments indicate that the macrophage FcR 
does not participate in vitro in virus attachment or in antibody-dependent enhancement 
(ADE) of infectivity. 
The virus attachment protein has been identified as a 12 kDa protein (VPI2) 
which is present as a 17 kDa dimer in virus particles (Carrasco sa et al., 1991). The 
sequence of the ASFV gene encoding the VP12 attachment protein indicates that a 22 
amino acid transmembrane domain is present in its 61 residues, suggesting that it is 
anchored in the ASFV envelope (Alcami et ai., 1992; Carrasco sa et al., 1993). The 
sequence of the gene encoding VP12 is highly conserved amongst tissue culture 
adapted and field isolates of ASFV (Angulo et al., 1992) and anti-VP12 antibodies 
are readily detected in ASFV infected pigs (Angulo et al., 1993). However, although 
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ASFV attachment to target cells is strongly inhibited in vitro by the addition of 
soluble recombinant VPI2, none of the antisera directed against VPl2 were shown 
to affect the binding of ASFV to the host cell or to neutralize virus infectivity 
(Angulo et al., 1993). This suggests that the VP12 determinants responsible for the 
recognition of the cellular receptor are not accessible to antibodies or that an 
alternative virus envelope protein is also involved in virus attachment (Carrascosa et 
a/., 1993). 
Following interaction with the cellular receptor, ASFV enters the cell by 
energy-dependent adsorptive endocytosis in coated pits and is later detected in 
endosomes and finally in lysosomes (Geraldes and Valdeira, 1985; Valdeira and 
Geraldes, 1985; A1cami et a/., 1989a). Non-enveloped virus is then detected in the 
cytosol and all these steps are completed in approximately 15 minutes. The release 
of virus particles from secondary lysosomes into the cytosol is inhibited by 
lysosomotropic agents such as chloroquine which indicates that a low pH trigger is 
necessary for fusion of the virus envelope with the lysosomal limiting membrane 
(Geraldes and Valdeira, 1985; Valdeira and Geraldes, 1985; A1cami et ai., 1989a). 
Early gene expression 
Once in the cytosol, the virus capsid is uncoated which leads to the solubilization of 
the nucleo-protein core. In addition to the virus genome, ASFV particles contain the 
enzymes and factors necessary for the synthesis of functional early messenger RNAs 
(see § 1.2.1). The resistance of ASFV transcription to a-amanitin, which inhibits the 
activity of the cellular RNA polymerase-II, demonstrates that ASFV gene expression 
is independent of the cellular transcription machinery contained in the host cell 
nucleus (Salas, J. et a/., 1988). Indeed, the replication of ASFV takes place in 
discrete cytoplasmic foci designated virosomes or virus factories. Each infectious 
ASFV particle is thought to initiate a small cytoplasmic virus factory which migrates 
towards the nucleus where it fuses with other ASFV factories to form prominent 
perinuclear inclusions (Carvalho et ai., 1988). The virus factories are rich in 
membranous material (thought to be derived from the endoplasmic reticulum or Golgi 
apparatus, Breese and DeBoer, 1966; Moura Nunes et a/., 1975) and are closely 
associated with microtubules and intermediate filaments (Carvalho et a/., 1988). 
ASFV infection also induces a major re-organisation of the cell cytoskeleton 
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illustrated by the decondensation of microtubules, the concentration close to the cell 
membrane of actin containing microfilaments and the retraction of intermediate 
filaments from the cell periphery to around the cell nucleus (Carvalho et al., 1988). 
These perturbations of the cytoskeleton by ASFV infection show similarities to those 
induced during infection by the iridovirus frog virus 3 (Murti and Goorha, 1983; 
Murti et al., 1988a), whereas alterations induced by poxviruses infection only affect 
the cell's microfilaments (Hiller et al., 1979, 1981). 
The solubilization of the ASFV nucleo-protein core in the cytosol allows the 
viral RNA polymerase contained within it to initiate the transcription of a subset of 
ASFV genes, designated early genes, which represent approximately 50% of the 
coding capacity of the ASFV genome (Salas et al., 1986). The early ASFV RNA 
transcripts are capped, methylated ( m 7 G p p p ~ ~ cap structure) and polyadenylated by 
enzymes contained in the nucleo-protein core (Salas et al., 1981) to yield fully 
functional mRNAs which are then translated by the host cell ribosomes into early 
proteins. Included amongst the 40 to 50 early proteins encoded by ASFV are virus 
structural components as well as enzymes necessary for replication of the virus DNA 
genome (Tabares et al., 1980b; Esteves et al., 1986; Santaren and Vinuela, 1986; 
Escribano and Tabares, 1987; Urzainqui et al., 1987). 
DNA replication 
Early synthesis of ASFV encoded nucleotide precursor synthesis enzymes, such as a 
ribonucleotide reductase, thymidine kinase and thymidylate kinase (Polatnick and 
Hess, 1979; Blasco et al., 1990; Boursnell et al., 1991; Yanez et al., 1993b) and a 
DNA polymerase (Polatnick and Hess, 1972) is followed by replication of the virus 
DNA genome which begins approximately 4 to 8 hours after infection (Tabares and 
. 
Sanchez Botija, 1979; Costa, 1990). Although replication of the ASFV genome takes 
place mainly in virus factories, the presence of a functional host cell nucleus is 
essential for synthesis of virus genomic DNA (Ortin and Vinuela, 1977). The 
presence early in infection (4 hours post-infection) of ASFV DNA in the nuclei of 
infected macrophages suggests that an early nuclear stage might be necessary for 
replication of the ASFV genome (Garcia-Beato et al., 1992b). In contrast, replication 
of the genome of poxviruses is strictly extranuclear although some factors (including 
the large subunit of the RNA polymerase II) may be recruited from the host cell 
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nucleus (Moss, 1990b). 
The analysis of ASFV genomes undergoing replication suggests the presence 
of head to head and tail to tail concatemeric DNA molecules (Ortin et al., 1979; 
Almendral et al., 1984; Gonzalez et al., 1986; Caeiro et al., 1990). During 
replication of poxvirus genomes, similar DNA concatemers are present and are 
probably intermediates formed during the replication process (Moyer and Graves, 
1981). The replication of poxvirus DNA is thought to be initiated after a specific 
single strand nick close to one or both of the terminal cross links. The extension of 
the free 3' end thus generated allows self-priming of newly-synthesized DNA and 
duplication of the whole genome into a linear mirror image concatemer. Monomeric 
genomes are excised from the intermediate concatemeric DNA forms by specific 
single strand nicking close to the genome termini, followed by ligation of the terminal 
hairpin loops to yield mature genomes. The structural similarities between the 
genomes of poxviruses and ASFV (see § 1.2.2) together with the presence of identical 
replicative intermediates suggest that ASFV DNA may be replicated by a mechanism 
analogous to that proposed for poxviruses. 
Late gene expression 
The onset of DNA replication marks a turning point in the pattern of ASFV gene 
expression (Tabares et al., 1980b; Esteves et al., 1986; Santaren and Vinuela, 1986; 
Escribano and Tabares, 1987). Many genes that were expressed immediately upon 
virus entry are shut off following the replication of ASFV DNA (,transient early' 
genes) while other previously silent genes only begin expression after DNA 
replication (,late' genes). Expression of a subset of early genes continues after DNA 
replication and are referred to as 'persistent early' genes. The early to late switch in 
gene expression does not proceed in the presence of inhibitors of DNA replication 
such as cytosine arabinoside which demonstrates that replication of the ASFV genome 
is necessary for the expression of late ASFV genes. The mechanism regulating the 
temporal switch in gene expression is unknown although it is expected that a 
succession of transcription factors regulate gene expression in a manner similar to that 
demonstrated for vaccinia virus (VV) (reviewed by Keck et al., 1990; Moss, 1990b; 
Moss et al., 1991). The VV cascade model of gene regulation is based on three 
temporal gene classes designated early, intermediate and late. The expression of VV 
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early genes is dependent on an early transcription factor (ETF) which is present in 
virus particles. Early gene expression results in replication of the VV DNA genome 
which provides a naked template necessary for the expression of at least three 
intermediate genes. The products of these three intermediate genes are late 
transcription factors (L TF) which activate expression of late genes. One of the late 
genes encodes for the ETF which is packaged in progeny VV particles, ready to 
activate early gene expression during the next round of infection. 
In contrast to early ASFV transcripts, which only map to specific regions 
covering half the genome, the synthesis of late mRNA occurs throughout the genome 
(Salas, et aZ., 1986). Unlike poxviruses the expression of cellular proteins is not shut 
off in ASFV infected cells late post-infection, although cellular expression is slightly 
reduced at very late times in infection (Esteves et aZ., 1986). Approximately 70 virus 
proteins are expressed late in ASFV infection, many of which consist of structural 
components (such as VP150 and VP72) that are integrated in progeny virus particles 
(Esteves et aZ., 1986; Santaren and Vinuela, 1986; Escribano and Tabares, 1987; 
Urzainqui et aZ., 1987). 
Virus morphogenesis and release 
The first completed progeny virus particles are detected in cytoplasmic virus factories 
approximately 8 to 10 hours after infection with ASFV (Breese and DeBoer, 1966; 
Moura Nunes et aZ., 1975). The details of the morphogenesis of ASFV virions are 
not well understood, essentially because of the lack of clear intermediate virus 
structures. Apart from apparently mature hexagonal virus particles which usually 
contain a nucleo-protein core, the virus factories only contain unidentified small 
spherical membrane vesicles presumed to represent early stages of virion formation. 
The hexagonal virions present in virus factories are often seen associated with arrays 
of ribosome-like particles, probably engaged in the synthesis of virus structural 
proteins (Breese and DeBoer, 1966). Apart from structural protein components, the 
progeny virus particles also encapsidate the virus DNA genome and ASFV encoded 
enzymes including those necessary for transcription of early mRNA in the next round 
of infection. At least 14 cellular proteins (including actin and tubulins) are also 
incorporated into mature virions, although it is not known whether these are necessary 
for infectivity or whether they are accidentally packaged into virus particles or are 
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contaminating cellular proteins which are not eliminated during virion purification 
(Tabares et ai., 1980a; Carrasco sa et ai., 1985; Esteves et ai., 1986). 
Approximately 12 hours after ASFV infection, mature virus particles start to 
migrate from the viral factories towards the cell membrane (Breese and DeBoer, 
1966; Moura Nunes et ai., 1975). The migration of virions is inhibited by colchicine 
(Arzuza et al., 1992) which suggests that the cellular microtubules network might be 
responsible for the translocation of mature ASFV particles. The mature virus particles 
are released from infected cells either by budding through the cell membrane, thus 
acquiring an external envelope, or by cell lysis giving rise to naked extracellular 
particles (Breese and DeBoer, 1966; Moura Nunes et al., 1975). The role of the 
external envelope in virus infectivity is still not clear since naked intracellular virus 
particles were found to be infectious (Moura Nunes et ai., 1975). Furthermore, the 
origin of the external envelope in extracellular virus particles has recently been put 
in question by two independent observations. Firstly, detailed observation of 
intracellular virus particles has suggested that ASFV might acquire a close-fitting 
external envelope inside the cytoplasm (Arzuza et al., 1992), as has been shown in 
other enveloped viruses including poxviruses (Moss, 1990a). By budding through the 
cell membrane, the extracellular ASFV particles would then gain an additional loose 
envelope which is not important for infectivity and is often subsequently lost. The 
second argument comes from the study of the intracellular localization of the ASFV 
attachment protein VP12 (Angulo et al., 1993) which is detected in virus factories 
and is associated with mature virus particles migrating to the cell membrane, but is 
not detected in the cell plasma membrane. Since the VP12 attachment protein is 
thought to be located in the external envelope of mature ASFV particles, this 
observation supports the hypothesis that the virus external envelope is incorporated 
intracellularly before ASFV buds from the infected cell. The apparent intracellular 
assembly of ASFV membranes is similar to that observed during the morphogenesis 
of vaccinia virus particles (Moss, 1990a). Although VV particles do not contain a 
protein capsid, intracellular VV particles are enwrapped by a double membrane layer 
which is thought to be derived from cisternal membranes of the intermediate 
compartment between the ER and the Golgi complex (Sodeik et al., 1993). A small 
proportion of VV particles then migrate to the cell plasma membrane and are 
enveloped by two additional membrane layers of unknown origin, one of which is lost 
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during VV release by fusion with the plasma membrane. Further examination of 
ASPV morphogenesis will be required to characterize the external virion layers and 
proteins which are likely play an important role in infection and in eliciting the host 
immune response. 
1.2.4 Post-translational modification of ASFV proteins 
In the course of ASFV replication at least eight VIruS induced proteins are 
phosphorylated in infected cells (Tabares et al., 1983; Salas, M.L. et al., 1988). Five 
of these phosphoproteins are packaged into virus particles, three of which are located 
in the external layers of the virion. It is not known whether these are phosphorylated 
by the protein kinase detected in purified ASPV particles, although this is suggested 
for two other small virus structural proteins which were found to be good substrates 
in vitro for the protein kinase packaged in virions (polatnick et ai., 1974; Salas, M.L. 
et al., 1988). One non-structural phosphoprotein of approximately 32 kDa (VP32) 
varies in apparent molecular weight amongst ASFV isolates, and is one of the most 
highly antigenic ASFV proteins (Alfonso et al., 1992; Prados et al., 1993). The 
VP32 phosphoprotein is expressed abundantly early in infection and forms a large 
homo-oligomeric complex of 220 .kDa (Andres et al., 1993). The location of VP32 
in ASPV infected cells is still unclear since it has been proposed to be either 
membrane anchored (Santaren and Vinuela, 1986; Alcaraz et ai., 1992a, b; Alfonso 
et al., 1992), intracellular (Prados et al., 1993) or even secreted (Alfonso et al., 
1992). The possible membrane location of VP32, as well as its high antigenicity and 
antigenic variation suggest that it may participate in the host immune response against 
ASPV. 
At least five of the proteins induced early in ASFV infected cells are 
glycosylated and infectious virus production is greatly reduced by glycosylation 
inhibitors such as glucosamine or tuncamycin (Tabares et al., 1983; Del Val et al., 
1986; Del Val and Vinuela, 1987). Although two glycolipids of cellular origin are 
present in purified extracellular ASPV particles (see §1.2.1), no glycoproteins are 
detected in the virions which is an unusual property for an enveloped virus. Since 
viral glycoproteins are often surface proteins involved in cell recognition and in 
inducing a host protective immune response, it is possible that the lack of 
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glycosylated structural proteins plays a role in the evasion of ASFV from the immune 
system. A total of ten late and one early virus induced proteins in infected cells were 
shown to be fatty acid acylated with myristic acid but none were modified with 
palmitic acid (Aguado et al., 1991). Although two of these myristylated ASFV 
proteins (28 and 13 kDa) are packaged into virus particles, their function and location 
in the virus is not yet determined. 
Polyprotein processing is the last post-translational modification which has 
been demonstrated in ASFV infected cells (Lopez-Otin et al., 1989; Simon-Mateo et 
al., 1993). This mechanism of protein expression is usually associated with 
retroviruses (Oroszlan and Luftig, 1990) and some positive-strand RNA viruses such 
as picornaviruses which express a single polyprotein from a monocistronic RNA 
transcript (Belsham, 1993). The ASFV VP220 polyprotein is translated late in 
infection from a single ASFV gene and is subsequently myristylated and processed, 
through an ordered cascade of proteolytic cleavages, into four individual proteins 
(VP150, VP37, VP34 and VP14). All the cleavage sites recognized in the VP220 
polyprotein have a Gly-Gly-X consensus sequence similar to that thought to be 
recognized in the maturation of adenovirus structural proteins and in the cellular 
polyubiquitin precursors (Lopez-Otin et al., 1989). The protease responsible for the 
processing of the ASFV polyprotein has however not been identified. The four ASFV 
proteins processed from the VP220 polyprotein are all located in virus factories and 
also represent major structural proteins in ASFV particles. This suggests that the 
ASFV polyprotein might be important for some step of virus morphogenesis, perhaps 
allowing the four major structural proteins to be present in proximity and/or in 
equimolar amounts. 
1.2.5 Partial sequence of the ASFV genome 
The sequence of a 55 kb region from the right end of the genome of a virulent ASFV 
isolate is now available (Dixon et al., 1993). This data shows that the ASFV genes 
are coded equally on both strands of the genome, in contrast to the poxvirus genome 
organisation in which genes close to the terminal regions of the genome are 
preferentially read towards the genome termini (Goebel et al., 1990; Smith et al., 
1991). The ASFV genes are generally closely spaced and rarely appear to overlap. 
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Apart from being rich in A and T bases, the upstream regulatory sequences do not 
appear to conform to any evident consensus sequence (Hammond, 1992; Dixon et al., 
1993). In contrast, the sequence alignment of poxviruses promoters has revealed 
consensus sequences the regulatory role of which has been confirmed by mutational 
analysis (Moss, 1990b; Moss et al., 1991). Vaccinia virus promoters for all three 
classes of VV genes (early, intermediate and late) consist of short (20-30 bp) 
upstream sequences, rich in A and T residues, which contain two critical regulatory 
elements (core and initiator) separated by a fixed length spacer (Davison and Moss, 
1989a, b; Baldick et al., 1992). Although there is no evident sequence correlation 
between VV and ASFV promoters, some ASFV genes were shown to be expressed 
by the vaccinia transcription machinery in vaccinia virus infected cells transfected 
with ASFV DNA (Hammond and Dixon, 1991). 
At least 65 open reading frames (ORFs) are present in the 55 kb right hand 
region of the genome and the predicted amino acid sequences of 15 of these ORFs 
have homologies to proteins of known function (table 1.2). As expected from the 
cytoplasmic site of ASFV replication, a number of ORFs encode proteins which have 
homologies with enzymes such as DNA topoisomerase type II and DNA ligase that 
are involved in DNA replication (Baylis et al., 1992; Garcia-Beato et al., 1992a; 
Hammond et al., 1992; Yanez and Vinuela, 1993), or with enzymes such as RNA 
polymerase subunits, transcription elongation factor TFS II and capping enzyme 
involved in mRNA synthesis and processing (Dixon et al., 1993; Lu et al., 1993; 
Neilan et al., 1993; Yanez et al., 1993a). Two ASFV ORFs encode predicted 
proteins which have homology with known virulence factors encoded by other 
viruses, including the ICP34.5 neurovirulence associated protein of herpes simplex 
virus (Chou and Roizman, 1990), and the protease inhibitor which in cowpox virus 
inhibits the interleukin-l{3 converting enzyme (Ray et al., 1992). 
Finally two ORFs encode predicted proteins which are homologous to enzymes 
involved in the post-translational modification of proteins. One predicted protein is 
similar to a serine protein kinase. This protein has been expressed in E. coli and 
shown to have the predicted enzyme activity (Baylis et al., 1993a). The second ORF 
has considerable homology to a family of ubiquitin conjugating enzymes (described 
\ 
in detail in § 1.3 below) and represents the first such enzyme identified encoded on 
a virus genome (Hingamp et al., 1992; Rodriguez et al., 1992b). 
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I ORF I Homology I Identity I 
gIL RNA polymerase VV: 21% 
(large subunit) Yeast: 27% 
g3L DNA ligase VV: 20% 
Yeast: 21 % 
T4: 23% 
g4R mRNA capping (large subunit) VV: 23% 
g10L Helicase VV (NTPase I): 18 % 
jlOL: 24% 
i2R RNA polymerase subunit Yeast (RPB5): 21 % 
Human (23 kDa): 28% 
i8R DNA topoisomerase type II Yeast: 22% 
Human: 24% 
jlL RNA polymerase subunit Yeast (RPB3): 23% 
j8L Protein kinase VV (BIR): 21 % 
Human (pim-l): 24% 
j9L Helicase VV (ETFI): 21 % 
VV (NTPase I): 28 % 
jl0L Helicase VV (AI8R): 20% 
jllR Nif S like Yeast: 25% 
klR dUTPase E. coli: 24% 
VV: 24% 
k9L RNA polymerase subunit VV (rpo30): 25 % 
Mouse (TFSII): 23% 
k12L Ubiquitin conjugating enzyme Yeast (UBCl-lO): 31-45% 
114L Neurovirulence factor HSV (ICP34.5): 51 % 
Table 1.2 Homology between the predicted protein products of ASFV open 
reading frames and proteins of known function. 
The table shows the protein sequence homologies of the predicted products of the 
open reading frames (ORFs) present in the right hand 55 kb of the Malawi LIL20/1 
ASFV isolate (Dixon et ai., 1993). The percentage of identical amino acids are also 
indicated. The percentages were calculated using the complete protein sequence apart 
from the HSV ICP34.5 protein in which the identity was calculated from a conserved 
40 amino acid carboxyl terminal domain. VV: vaccinia virus; Yeast: Saccharomyces 
cerevisiae; T4: bacteriophage T4; HSV: herpes simplex virus. 
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1.2.6 Taxonomic classification of ASFV 
The early observations of ASFY such as its particle structure, cytoplasmic site of 
replication and large DNA genome led to its classification in the lridoviridae family 
(Matthews, 1982). However, subsequent analysis has revealed that many 
characteristics of ASFY replication are similar to viruses of the Poxviridae family. 
Indeed the ASFY genome, which has terminal cross links and inverted terminal 
repeats is similar in structure to that of poxviruses, whereas the genomes of 
iridoviruses are circularly permuted. Moreover, in common with poxviruses, ASFY 
transcription is not dependent on host cell RNA polymerase II and the virions contain 
all the enzymes and factors necessary for early mRNA synthesis. Finally, expression 
of ASFY genes is temporally regulated in a manner similar to poxviruses since late 
gene expression is dependent on virus DNA replication. 
The sequencing of the ASFY genome has, however, shown that the genome 
organisation of ASFY genes is not co-linear with that of the orthopoxviruses (Goebel 
et al., 1990; Johnson et al., 1993). Furthermore, the presence of ASFY DNA but not 
poxvirus D ~ A A in the host cell nucleus indicates that there are important differences 
in the replication strategy of ASFY and poxviruses. On the basis of its distinctive 
features, ASFY has been removed from the family Iridoviridae and is now classified 
in a separate unnamed family of which ASFY is the only member (Brown, 1986). 
1.3 The ubiquitin conjugation system 
1.3.1 The ubiquitin polypeptide 
Ubiquitin is a small polypeptide found universally in eukaryotic cells, either free or 
covalently attached to cellular proteins (reviewed by Rechsteiner, 1988; Ientsch et al., 
1990; Hershko, 1991a; Hershko and Ciechanover, 1992; Jentsch, 1992). The amino 
acid sequence of ubiquitin is highly conserved in evolution, with at most 4 % 
divergence between yeast, plants and animals. Amongst the 76 amino acids of the 
ubiquitin polypeptide, 11 residues are acidic and 11 residues are basic giving the 
protein a neutral isoelectric point of 6.7. The molecular weight of ubiquitin is 8.5 
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Kda as determined by gel filtration, but its unusually high electrophoretic mobility in 
SDS-PAGE can lead to an apparent molecular weight as low as 5.5 KDa 
(Ciechanover et al., 1978). This is probably due to the incomplete denaturation of the 
protein which is consistent with the first described characteristic of ubiquitin: its 
unusually high stability. After treatment with urea, alcohol or thermal denaturation 
(up to 8SOC), ubiquitin can easily refold into its native conformation (Rechsteiner, 
1988). 
The crystal structure of ubiquitin (Vijaykumar et al., 1987a, b) shows that it 
has a packed globular structure, with 90 % of its residues involved in hydrogen-
bonded secondary structure which might account for the pronounced stability of the 
protein. The surface of ubiquitin can be divided into three physico-chemical regions: 
a basic face and an acidic face which are on opposite sides of the molecule and flank 
a hydrophobic region. The four C-terminal residues protrude from the core of the 
protein making the Gly76 residue available for conjugation to other proteins. 
1.3.2 The ubiquitin conjugation pathway 
All known ubiquitin-related functions are mediated through conjugation of ubiquitin 
to proteins. The mechanism of ubiquitin conjugation, which is now regarded as a 
central and universal eukaryotic post-translational modification, was originally 
determined in reticulocytes (Ciechanover et al., 1980; Hershko et al., 1980, 1983; 
Hershko, 1988). These studies show that the ligation of ubiquitin to cellular proteins 
is a multi-step process (figure 1.4). 
The first step is the ATP dependent activation of ubiquitin by a large (105 
kDa) El enzyme also known as the ubiquitin activating enzyme. Free ubiquitin, which 
is one of the most abundant small proteins in the cell, is available for activation from 
a large intracellular pool. The activation of ubiquitin consists of thiol ester bond 
formation between its free C-terminal Gly76 with an internal cysteine residue of El. 
The reaction involves the formation of a ubiquitin-AMP adenylate intermediate which 
accounts for the ATP requirement of ubiquitin conjugation. In the second step, 
activated ubiquitin is transferred from the E1 enzyme to one of a large family of 
ubiquitin carrier isozymes (E2s), also known as ubiquitin conjugating (UBC) 
enzymes. Again, a thiol ester bond covalently links ubiquitin by its C-terminal Gly76 
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Figure 1.4 The ubiquitin conjugation pathway. 
The diagram shows the steps and enzymes responsible for the conjugation of ubiquitin 
to cellular proteins. Ub: ubiquitin, El: ubiquitin conjugating enzyme, E2: ubiquitin 
conjugating enzyme (UBC), E3: ubiquitin ligase. 
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Figure 1.5 Structure of various types of ubiquitin conjugates. 
The lollipops represent ubiquitin molecules. Panel A: mono-ubiquitinated conjugate; 
Panel B: multi-ubiquitinated conjugate; Panel C: linear poly-ubiquitinated conjugate; 
Panel D: branched poly-ubiquitinated conjugate. 
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to a conserved internal cysteine residue of the UBC enzymes. 
The final conjugation step consists of the transfer of ubiquitin from the UBC 
enzyme to a specific protein substrate. The resulting ubiquitinated protein is known 
as a ubiquitin conjugate, in which ubiquitin is attached to the substrate protein via an 
amide bond between the C-terminal Gly76 of ubiquitin and the e-amino group of an 
internal lysine residue of the substrate. Many protein substrates have been shown to 
be multi-ubiquitinated (figure 1.5) (Hershko et aI., 1980; Hochstrasser, 1992; 
Jentsch, 1992). This phenomenon is the result of several ubiquitin molecules being 
conjugated either to different lysine residues of the substrate, or to the internal Lys48 
and Lys63 residues of previously conjugated ubiquitin (Chau et al., 1989; Chen and 
Pickart, 1990; Gregori et aI., 1990; Cook et aI., 1992a; Banerjee et aI., 1993). The 
latter type of poly-ubiquitination leads to the formation of linear and branched poly-
ubiquitin chains anchored to a single lysine of the protein substrate. 
The specificity for the protein substrate is usually dictated by the UBC 
enzyme, although in some instances a third enzyme (E3 or ubiquitin ligase) is also 
necessary for substrate recognition (Elias and Ciechanover, 1990; Sharon et al., 
1991; Sung et aI., 1991a; Madura et aI., 1993). By binding to specific UBC 
enzymes, the ubiquitin ligases are thought to complement or even modify the 
specificity of the UBC enzyme for protein substrates. An additional class of enzymes, 
the ubiquitin hydrolases, are responsible for the release of ubiquitin molecules from 
ubiquitin conjugates by hydrolysis of the Gly76-eNH2 isopeptide bonds (Wilkinson et 
al., 1989; Tobias and Varshavsky, 1991; Baker et at., 1992; Hadari et al., 1992; 
Eytan et al., 1993). Conjugated ubiquitin is therefore in equilibrium with the free 
ubiquitin pool, which suggests that ubiquitin conjugation is a dynamic process 
analogous to protein phosphorylation. 
1.3.3 Functions of the ubiquitin conjugation pathway in yeast 
Although the mechanisms of ubiquitin conjugation were originally determined in 
rabbit reticulocytes, the yeast Saccharomyces cerevisiae is now the model for the 
functional and genetic analysis of the ubiquitin pathway in eukaryotes (reviewed by 
Jentsch et aI., 1991; Jentsch, 1992). The yeast genes encoding many of the enzymes 
of the pathway have been identified (table 1.3), and in many instances homologous 
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I PROTEIN I GENE I FUNCTION I 
El UBAl Ubiquitin activating enzyme (105 lcDa). 
E2 Ubiquitin conjugating (UBC) enzymes 
UBCI· -Bulk proteolysis; Essential for early growth after 
germination. 
UBC2 -DNA repair; Sporulation; Cell division control 
S-G2 transition ; N-end rule with UBRI ubiquitin 
ligase (ex RAD6). 
UBC3 -Cell division control, Gl-S transition (ex CDC34). 
UBC4· -Bulk proteolysis of misfolded & abnormal proteins; 
Stress response (ex HSPl6). 
UBCS· -Similar function to UBC4. 
UBC6 -Integral ER membrane enzyme; Selective proteolysis 
(ex DOA2). 
UBC7 -Confers cadmium resistance; Selective proteolysis. 
UBC8 -Unknown. 
UBC9 -Cell division control at G2/M stage. 
UBClO -Peroxisome biogenesis (ex PAS2). 
Others -Other UBC enzymes probably remain be discovered. 
E3 UBRI -Ubiquitin ligase; Recognition of protein substrates 
by the N-end rule of proteolysis (mediated by UBC2). 
Others -Might be responsible for recognition of other degrons. 
Hydrolase YUHI -Ubiquitin hydrolases; Specifically cleave and recycle 
UBPI ubiquitin from ubiquitin conjugates or from ubiquitin 
UBP2 fusion precursors. 
UBP3 
Ubiquitin UBIl -UBIl to UBI3: fusions of ubiquitin with ribosomal 
UBI2 subunits; 'Chaperone' like function of ubiquitin in 
UBI3 ribosome assembly. 
UBI4 -Poly-ubiquitin precursor; Stress inducible. 
Protease PREl -26S protease (multicataIytic complex); Numerous 
PRE2 subunits, including the yscE protease complex (20S 
PRE3 proteasome); Degrades poly-ubiquitinated proteins and 
PRE4 has ubiquitin hydrolase activity. 
Others 
Table 1.3 The ubiquitin conjugation pathway in yeast 
The various yeast proteins involved in the ubiquitin pathway are indicated together 
with their encoding genes (the alternative names of genes encoding UBC enzymes are 
indicated in brackets with the prefix 'ex'). Genes that are underlined are essential for 
yeast survival. An asterisk ( .) marks a group of UBC genes of overlapping function 
where individual genes are not essential if at least one other gene in the group is 
functional. 
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genes have been found in animals and plants. The following outline of the major 
components of the ubiquitin pathway in yeast illustrates its wide and fundamental role 
in the eukaryotic cell. 
Ubiquitin is expressed either as a polyubiquitin precursor or as a fusion protein 
with various ribosomal proteins (Dworkinrastl et al., 1984; Ozkaynak et al., 1987; 
Warner, 1989). The ubiquitin moiety in the ribosomal fusion protein has been shown 
to enhance the efficiency of incorporation of the ribosomal proteins into mature 
ribosomes, suggesting a co-translational 'chaperone' role for ubiquitin (Finley et al., 
1989). The yeast UBI4 polyubiquitin gene, which has five ubiquitin genes arranged 
head to tail, is strongly induced during stress and is essential for yeast survival under 
these conditions (Finley et al., 1987). In both types of ubiquitin fusions, the 
precursors are rapidly processed by ubiquitin hydrolases into single ubiquitin 
molecules which then join the free ubiquitin pool. The yeast ubiquitin activating 
enzyme El is encoded by the single UBAI gene (McGrath et al., 1991). Deletion of 
the UBAI gene is lethal and this highlights the essential role played by the ubiquitin 
pathway in eukaryotic metabolism (Ciechanover et al., 1984; Finley et al., 1984; 
Gropper et al., 1991; Mitchell et al., 1991; Leyser et al., 1993; Mori, M. et al., 
1993). 
The key enzymes in the ubiquitin conjugation pathway which determine 
substrate specificity are the UBC (or E2) enzymes, 10 of which have been identified 
in yeast. Three UBC enzymes (UBC1, UBC4 and UBC5) have overlapping functions 
and are involved in bulk intracellular protein degradation (Seufert and Jentsch, 1990; 
Seufert et al., 1990; Treier et al., 1992; Girod and Vierstra, 1993; Girod et al., 
1993; Zhen et al., 1993). The ubiquitin conjugates generated by these UBC enzymes 
are poly-ubiquitinated which targets them for degradation by a ubiquitin-specific 
protease complex (see §1.3.5). Together, these three UBC enzymes mediate the 
intracellular turnover of normally occurring short lived proteins as well as misfolded 
and abnormal proteins. This latter role is especially important in cells under stress 
conditions. In addition, the yeast cadmium inducible UBC7 enzyme participates in the 
elimination of abnormal proteins generated during cadmium exposure (Vassal et al., 
1992; Jungmann et al., 1993). The yeast UBC6 enzyme is the only integral 
membrane UBC enzyme identified to date (Sommer and Jentsch, 1993). UBC6 is 
located in the endoplasmic reticulum (ER) with its catalytic domain facing the cytosol 
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where it is thought to mediate the selective degradation of ER membrane proteins. 
In contrast, the three yeast UBC2, UBC3 and UBC9 enzymes are all involved 
in sensitive regulatory functions. The UBC2 gene, previously identified as the DNA 
repair gene RAD6, encodes an enzyme with very pleiotropic functions (Jentsch et al., 
1987; Morrison et al., 1988; Sullivan and Vierstra, 1989; Reynolds et al., 1990; 
Schneider et al., 1990; Koken et al., 1991a, b; Woffendin et al., 1991). The 
phenotypes of yeast mutants with an inactive UBC2 gene include sensitivity to 
mutagens, defects in meiotic recombination and sporulation, slow growth as well as 
partial blocking of cell cycle progression (Siede, 1988; Picologlou et al., 1990; 
Ellison et al., 1991). Single mutations in the UBC2 active site cysteine have 
demonstrated that all the roles attributed to UBC2 are dependent on its ubiquitin 
conjugating activity (Sung et al., 1990, 1991b). It is possible that UBC2 has a 
number of distinct regulatory substrates or that its diverse functions are mediated by 
a single fundamental role in DNA metabolism. An additional role for UBC2, in 
cooperation with the E3 enzyme UBR1, is to mediate the degradation of intracellular 
proteins according to the N-end rule (see §1.3.4). The cellular importance of N-end 
rule-mediated proteolysis is not known since yeast mutants lacking this pathway have 
no significant phenotype (Bartel et al., 1990). The yeast UBC3 and UBC9 enzymes 
are located in the nucleus and are essential for the progression of cell division at two 
stages of the cell cycle (Goebl et al., 1988; Jentsch, 1992; Chen et al., 1993). The 
UBC3 gene (previously identified as CDC34) is necessary for the Gl to S transition 
of the cell cycle, whereas yeast mutants in the UBC9 gene are arrested in the G2/M 
phase of the cell cycle. The latest UBC enzyme to be identified in yeast is UBC 10 
which is essential for the biogenesis of peroxisomes, although its precise role is 
unknown (Wiebel and Kunau, 1992). 
The diversity of the functions attributed to UBC enzymes is apparently 
difficult to reconcile with their single ubiquitin conjugating catalytic activity. It is 
possible, however, that the apparently non-catabolic roles of several UBC enzymes, 
such as UBC2 and UBC3 which are responsible for DNA repair and cell cycle control 
respectively, are indirectly mediated by degradative processes. The targets of these 
UBC enzymes might be regulatory proteins, such as histones or cyclins, which are 
targeted for degradation by ubiquitination. A unifying proteolysis theory for the 
function of ubiquitin conjugation will, however, only be validated when specific 
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substrates for individual UBC enzymes are identified and the consequences of their 
ubiquitination are fully understood. 
1.3.4 The recognition of substrate proteins by UBC enzymes 
Although a variety of physiological substrates for ubiquitin dependent degradation are 
known (see § 1.3.5), the UBC enzymes responsible for their specific ubiquitination are 
mostly unidentified. Consequently, the mechanism of substrate recognition by the 
UBC and E3 enzymes is still poorly defined (reviewed by Ciechanover and Schwartz, 
1989; Rechsteiner, 1991; Hershko and Ciechanover, 1992; Jentsch, 1992). To date, 
the only physiological substrate of UBC enzymes that has been studied in detail is the 
yeast MATa2 transcriptional regulator. The naturally short-lived MATa2 repressor 
is poly-ubiquitinated in vivo which targets it for subsequent proteolysis (Hochstrasser 
et oZ., 1991). Two distinct ubiquitination pathways involving no less than four UBC 
enzymes (UBC4, UBC5, UBC6 and UBC7) are responsible for the ubiquitination of 
MATa2 (Chen et aZ., 1993). Furthermore, the UBC6 and UBC7 enzymes associate 
in a heterodimeric complex allowing them to specifically recognize the Degl 
ubiquitination signal of MATa2 which consists of the N-terminal 67 amino acids. 
This finding suggests that a network of interacting UBC enzymes may determine the 
substrate specificity of ubiquitin conjugation. The association of different 
combinations of UBC enzymes in distinct complexes would greatly expand the 
repertoire of substrates that could be specifically recognized and ubiquitinated. 
Comparison of the protein sequences of the UBC enzymes characterized show 
that all UBC enzymes have a conserved catalytic core domain of approximately 16 
kDa, which contains approximately 150 amino acids (Jentsch, 1992). The core 
domain has at least 35 % amino acid identity between all UBC enzymes, including a 
centrally located cysteine residue which is required for the formation of a thiolester 
bond with ubiquitin. In addition to the conserved core domain, certain UBC enzymes 
such as UBC2 and UBC3 have a C-terminal extension or tail. The sequences of the 
C-terminal tails of UBC enzymes are not related to each other and might contribute 
to the enzyme's substrate specificity, acting in cis rather than in trans as is the case 
with E3 ubiquitin ligases. This hypothesis has recently been substantiated by the study 
of chimeric UBC2/UBC3 constructs in yeast (Kolman et aZ., 1992; Silver et aZ., 
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1992). A chimeric UBC enzyme consisting of the catalytic core of UBC2 and the C-
terminal tail of UBC3 was capable of restoring the full UBC3 cell cycle function in 
mutant yeast cells carrying an inactivated UBC3 gene. However, this chimeric UBC 
enzyme retained at least some of the functions specific to UBC2, which indicates that 
the C-terminal tail expands rather than supplants the specificity of the catalytic core. 
Another approach for determining the interaction between UBC enzymes and 
their substrates involves detailed analysis of proteins known to be ubiquitinated. The 
study of the ubiquitin-dependent degradation of cyclins has identified a hypothetical 
'destruction box' of sequence RxxLxxIxN which is necessary for cyclin degradation 
and is located upstream of the ubiquitinated lysine site (Glotzer et al., 1991). It is not 
known whether cyclins are the substrates for the UBC enzymes known to be involved 
in cell division control. Other substrates for ubiquitin dependent degradation have 
been shown to contain stretches of sequence enriched in proline, glutamic acid, serine 
an threonine residues, referred to as PEST sequences (Rogers et al., 1986). A third 
ubiquitination signal is illustrated by the N-end rule of ubiquitin-dependent proteolysis 
which predicts the half life of a protein according to the identity of its N-terminal 
amino acids. This signal is known as the N-degron (Varshavsky et al., 1987; 
Varshavsky, 1992). In yeast this pathway is catalysed by the UBC2 enzyme in 
conjunction with the E3 ubiquitin ligase UBRI (Bartel et al., 1990; Dohmen et al., 
1991; Sharon et aZ., 1991; Sung et aI., 1991a). No physiological substrates for this 
pathway are known in yeast, but in Xenopus oocytes the c-mos proto-oncogene 
product (Mos) is rapidly ubiquitinated upon fertilization according to the N-end rule 
pathway and is subsequently degraded, following which the zygote enters mitosis 
(Nishizawa et al., 1992, 1993). 
1.3.5 The fate of ubiquitinated proteins 
It is becoming increasingly evident that the most common outcome of ubiquitination 
is proteolysis (reviewed by Hershko, 1988, 1991a, b; Rechsteiner, 1991; Hershko and 
Ciechanover, 1992; Hochstrasser, 1992; Varshavsky, 1992). Not only is the ubiquitin 
/ ATP-dependent pathway responsible for the bulk of non-lysosomal intracellular 
proteolysis, but recent observations also tentatively suggest that the ubiquitin and 
lysosomal degradation systems might be functionally interrelated (Doherty et al., 
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1989; Ciechanover et al., 1991b; Gropper et al., 1991; Mayer et al., 1991, 1992; 
Lenk et al., 1992; Simeon et al., 1992). The exact nature and extent of this putative 
link are, however, still unclear. 
One well defined pathway for the degradation of ubiquitin conjugates involves 
a large protease complex which is specific for poly-ubiquitinated proteins (Chau et 
al., 1989; Gregori et al., 1990). This ubiquitin-dependent protease is present in the 
cytosol and the nucleus and has been identified as a 26S (or 1500 kDa) multi-catalytic 
protease. The 26S protease consists of three subunits CF1, CF2 and CF3 which only 
associate into the 26S complex in the presence of ATP (Waxman et al., 1987; 
Driscoll and Goldberg, 1990; Seufert and Jentsch, 1992). The CF3 subunit has been 
identified as the 20S proteasome, which is a large cytosolic and nuclear protease 
(comprising some 12-15 related polypeptides) with three distinct endopeptidase 
activities (Kanayama et al., 1992). The eukaryotic 20S proteasome polypeptides are 
related to each other and to the two types of proteasomal polypeptides found in 
Archaebacteria. It is not known whether the eukaryotic 20S proteasome can function 
alone or if it is only active as part of the larger 26S protease. The CF1 and CF2 
. subunits of the 26S protease appear to be activators and inhibitors respectively of the 
20S proteasome, which suggests that substrate degradation is intricately regulated 
(Chu-Ping et al., 1992a, b; Li and Etlinger, 1992). The poly-ubiquitinated proteins 
recognized by the 26S protease are broken down into small oligopeptides, and a 
specific ubiquitin hydrolase activity associated with the 26S protease recycles intact 
ubiquitin molecules for further rounds of conjugation (Eytan et al., 1993; Papa and 
Hochstrasser, 1993). 
The presence of metabolically stable intracellular ubiquitin conjugates suggests 
that some functions of the ubiquitin pathway may be independent of proteolysis. In 
chromatin of higher eukaryotes for instance, up to 15 % of histone H2A is 
ubiquitinated, predominantly in the mono-ubiquitinated form, with no apparent 
subsequent degradation (Goldknopf and Bush, 1978; Matsui et al., 1979; Wu et al., 
1981). Variations in the levels of ubiquitinated histones are synchronous with cell 
division, which suggests a role for histone ubiquitination in modulating chromosomal 
DNA structure or accessibility (Hacques and Marion, 1989; Morl, M. et al., 1993). 
A growing number of transmembrane proteins have. been shown to be ubiquitinated 
but it is not known if these are subsequently degraded. These include the growth 
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hormone receptor (Leung et al., 1987), the lymphocyte homing receptor (St. John et 
al., 1986; Siegelman et al., 1986), the high-affinity IgE receptors (Paolini and Kinet, 
1993), the T cell antigen receptor (Cenciarelli et al., 1992) and the platelet-derived 
growth factor (PDGF) receptor (Yarden et al., 1986; Morl et al., 1992). 
Ubiquitination of the PDGF, IgE and T cell antigen receptors was shown to be 
induced by binding of the receptor ligand, suggesting a role for ubiquitination in 
transmembrane signal transduction. In the case of the PDGF receptor, ubiquitination 
has been shown to playa negative regulatory role in its mitogenic signalling, possibly 
by promoting the degradation of the ligand-activated receptor or by altering the signal 
transducing properties of the modified receptor (Mori, S. et al., 1993). 
1.4 The role the ubiquitin pathway in virus infections 
1.4.1 Involvement of the cellular ubiquitin system in virus infections 
Considering the numerous ramifications of the ubiquitin system in cellular 
metabolism, it seemed inevitable that the replication of viruses would be shown to 
involve the ubiquitin pathway. 
The simplest involvement is the specific packaging of free ubiquitin in avian 
leukosis virus (ALV) particles (Putterman et al., 1990). The adventitious packaging 
of ubiquitin is improbable since other small cellular pep tides are excluded from 
virions, and ubiquitin is present in virions at a concentration fivefold higher than in 
the cytosol. Although the function of the free ubiquitin in AL V particles is not 
known, it is conceivable that it associates non-covalently with virus proteins and plays 
a role in virion structure. In contrast, the structural proteins of several plant viruses 
are covalently ubiquitinated (Dunigan et al., 1988; Hazelwood and Zaitlin, 1990). 
These viruses might utilize a chaperone-like activity of ubiquitin for virus 
morphogenesis. Alternatively, these virus structural protein-ubiquitin conjugates could 
be the result of a host cyto-protective reaction which attempts to prevent infection by 
targeting virus proteins for proteolysis. The ubiquitin-dependent degradation system 
is, in fact, implicated in plant defence mechanisms against viral infections (Becker et 
al., 1993). In tobacco plants that over-express a ubiquitin analog which does not 
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support ubiquitin-dependent proteolysis because the Lys48 site of polyubiquitin branch 
formation is substituted for Arg, tobacco mosaic virus (TMV) replication is reduced 
and the host systemic acquired resistance system is activated, as indicated by the 
induction of pathogenesis-related proteins. The mechanism by which the ubiquitin 
pathway affects the plant defense mechanism is unclear, although it is speculated that 
a specific defence activator protein, normally inactivated by ubiquitin-dependent 
proteolysis, is stabilized in cells under stress or exposed to viral infection. 
Several lines of evidence also suggest that the ubiquitin pathway plays an 
important part in the animal host immune response to viral infections (figure 1.6) 
(reviewed by Driscoll and Finley, 1992; Goldberg and Rock, 1992; Howard and 
Seelig, 1993). This hypothesis stems from the observation that at least two major 
histocompatibility (MHC) class I gene products associate with the 20S proteasome 
(the major component of the 26S ubiquitin specific protease) to form the low 
molecular-weight polypeptide (LMP) particle. The LMP particle is suspected to be 
the cytosolic protease involved in class I antigen processing (Parham, 1990), by 
generating antigenic viral peptides that are transported into the lumen of the ER 
where they associate with nascent class I MHC molecules and are presented on the 
cell surface to cytotoxic T cells. Furthermore, the MHC gene products, which are 
associated with the proteasome, appear to cause subtle changes in the peptidase 
activities of the 20S and 26S proteasomes, and are induced by -y-interferon which is 
a property shared by many other components of the MHC presentation machinery 
(Yang et al., 1992; Driscoll et al., 1993; Gaczynska et al., 1993). In addition, an 
amino terminal modification of a virus protein that increases ubiquitin-dependent 
degradation by the N-end rule also enhances its presentation with class I molecules 
(Townsend et al., 1988). Finally, a direct link between the ubiquitin conjugation 
system and class I presentation was demonstrated in an antigen-presenting cell line 
with a thermolabile El activating enzyme (Michalek et al., 1993). Although growth 
of mutant cells at the non-permissive temperature did not inhibit class I-restricted 
presentation of an ovalbumin peptide neo-synthesized from a minigene, processing for 
class I presentation of full length ovalbumin introduced into the cytosol was inhibited. 
These results implicate the ubiquitin-dependent proteolytic pathway in the production 
of antigenic peptides. 
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Figure 1.6 The class I-restricted processing of antigenic peptides by the 
ubiquitin-dependent degradation pathway 
The diagram summarizes the current hypothesis concerning the ubiquitin-dependent 
processing and presentation of class I antigens. 
, . 
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Another interferon induced response in virus infected cells leads to the rapid 
expression of a ubiquitin cross-reactive protein (UCRP) (Ahrens et al., 1987, 1990; 
Haas et al., 1987). The 15 kDa UCRP, which is composed of a tandem di-ubiquitin 
like sequence, is induced by a- and ~ - i n t e r f e r o n s s in all cells responsive to these 
cytokines and is also slowly secreted from these cells. The intracellular form of the 
protein, which can be conjugated to other cellular proteins, might modulate the 
ubiquitin pathway or mediate some of the diverse effects of interferon stimulation 
(Loeb and Haas, 1992). 
1.4.2 Utilization of the ubiquitin system by viruses 
Several recent reports show that viruses may actively modulate or even hijack the 
ubiquitin pathway to their own advantage. The ubiquitin system may be utilized either 
to modulate host cell function for the viruses advantage or to regulate the virus 
replication cycle. 
The most striking example of virus induced modulation of host cell function 
utilizing the ubiquitin pathway is that of an E3 like enzyme encoded by the human 
papilloma virus (HPV) (Scheffner et al., 1990, 1992; Huibregtse et al., 1993). The 
HPV E6 gene product, in cooperation with the cellular E6-associated protein (E6-
AP), binds the host cell p53 tumour repressor thus inducing the ubiquitin-dependent 
degradation of p53. This degradation of p53 is partly responsible for the oncogenic 
property of HPV. In contrast, the picornavirus encephalomyocarditis virus (EMC) 
probably takes advantage of the ubiquitin system to regulate its replication cycle 
(Oberst et al., 1993). The EMC encoded protease 3C is indeed rapidly degraded by 
an ATP-dependent proteolytic system present in reticulocyte lysates, a property 
typical of the ubiquitin-dependent degradation pathway. 
Another example of a virus encoded component of the ubiquitin pathway is 
illustrated by the togavirus bovine viral diarrhoea virus (BVDV) (Meyers et al., 1989, 
1991). The cytopathogenic phenotype of two strains of BVDV were correlated with 
a genomic insertion of sequences 97% identical to ubiquitin. These BVDV ubiquitin 
insertions are thought to be present to provide a cleavage site in a virus polyprotein 
precursor (Meyers et ai., 1992). The baculovirus Autographa caiifomica nuclear 
polyhedrosis virus (AcMNPV) similarly encodes a protein with 76% identity to 
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ubiquitin which is essential for virus replication (Guarino, 1990). This viral ubiquitin 
homolog (v-ubi) can be attached to substrate proteins by the ubiquitin conjugating 
system. These v-ubi conjugates are, however, not as effectively targeted for 
degradation as ubiquitin conjugates and high molecular weight v-ubi conjugates are 
detected in virus nucleocapsids (Guarino, 1993). The v-ubi protein might therefore 
act as a ubiquitin analog which could interfere with the ubiquitin' system, perhaps by 
protecting virus proteins from proteolysis. In addition, a phospholipid modified 
ubiquitin molecule is a major component of AcMNPV particles, where it is anchored 
inside the virus envelope facing the virus capsid. The purpose of this novel membrane 
anchored ubiquitin is not known, although roles in virion assembly, virus stability and 
in early infection events have been proposed (Guarino, 1993). 
The UBC enzyme encoded by African swine fever virus is a novel example 
of a virus encoded key component of the ubiquitin system and is the subject of this 
study (Hingamp et aZ., 1992; Rodriguez et aZ., 1992b). 
1.5 Project aims 
The overall objective of this project is to determine the function of the African swine 
fever virus (ASFV) encoded ubiquitin conjugating enzyme (UBCv). The eukaryotic 
ubiquitin conjugating enzymes are so versatile that a priori speCUlations on the role 
of UBCv cover most of the stages of ASFV replication, as well as potential roles in 
manipulating either the host cell to facilitate virus replication or the host immune 
response. The most likely potential roles for UBCv include the uncoating of the virus 
capsid, the early to late switch in gene expression, the assembly of virus particles, 
the control of host cell gene expression and/or state of differentiation and interference 
with the host immune response. The study of the UBCv enzyme might further our 
understanding both of virus-host interactions, as well as the involvement of the 
ubiquitin system in virus infections. In addition, if the substrates for the UBCv 
enzyme can be identified, then ASFV will provide the first comprehensive model for 
ubiquitin conjugation. 
The project will involve three complementary approaches. The first will deal 
with the in vitro analysis of the UBCv enzyme activity. The second will examine 
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UBCv in ASFV infected cells, in order to obtain data on the expression and 
localisation of the enzyme. The construction of an ASFV mutant with an inactivated 
UBCv gene will also be part of this study. The third approach will concentrate on the 
identification of physiological substrates for UBCv. If successful, the genes for these 
protein substrates might in turn be characterized and sequenced. 
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Chapter 2 
UBCv gene sequence and in vitro activity 
---0---
The complete sequence of the right hand 55 kb region of the ASFV genome (Malawi 
LIL20/1 isolate) contains nearly 70 open reading frames (ORFs), 15 of which encode 
putative homologues of cellular enzymes (Dixon et ai., 1993). This study focused on 
the UBCv gene which was predicted to encode a protein with a convincing, albeit 
unexpected, homology to eukaryotic ubiquitin conjugating (UBC) enzymes. To verify 
that this homology was not coincidental, the ubiquitin conjugating activity of 
recombinant UBCv was assayed in vitro. 
2.1 Structure of the UBCv gene 
2.1.1 Nucleic acid sequence of UBCv from ASFV Malawi LIL20/1 
Malawi LIL20/1 is a highly virulent ASFV field isolate collected from ticks in East 
Africa (Dixon and Wilkinson, 1988). The sequencing of the right hand 55 kb of the 
genome of Malawi LIL20/1 (Dixon et ai., 1993) located the UBCv gene 
approximately 12 kb from the right hand terminus (figure 2.1). It is the thirteenth 
open reading frame on SalI fragment k and is read on the complementary strand of 
the genome (leftwards) and has therefore been named k13L. 
The 642 bp long k13L open reading frame (figure 2.2) has a 62 % A +T 
content which is close to that of 61 % calculated for the right hand 55 kb portion of 
the ASFV genome. This high A + T ratio confers a relatively low melting temperature 
to the dsDNA which might be important for ASFV replication in the cells of the soft 
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Figure 2.1 Location of UBCv on the ASFV genome. 
Panel A: Sal! map of the genome of the Malawi LIL20/1 isolate of ASFV (Dixon, 
1988). Panel B: Detail of the gene arrangement on Sal! fragment k showing the 
UBCv gene (k13L) encoded on the complementary DNA strand. 
UBCv gene sequence and in vitro activity 
- 39-
tick vector since these have a lower body temperature than mammals. The coding 
sequences contained in the right hand 55 kb region of the Malawi LIL20/1 genome 
were used to generate a standard codon preference table for ASPV genes (Devereux 
et al., 1984). When compared to this table, the codon usage throughout k13L does 
not present any bias, towards either typical coding or non-coding regions (figure 2 . ~ , ,
A). Only one rare ASFV codon, with an occurrence frequency of 9%, is present in 
the whole k13L ORF. In contrast, over 50 rare codons are distributed throughout the 
k13L ORF when compared to the codon preference of Escherichia coli (figure 2.3, 
B). 
The 30 bp sequence upstream of the k13L start codon is especially rich in A 
and T bases (43% and 30% respectively) which is similar to observations made for 
vaccinia virus early promoters (Davison and Moss, 1989a) and certain ASPV genes 
(Almazan et al., 1992; Hammond, 1992). The motifTAAAT which occurs upstream 
of late and some early vaccinia virus genes occurs at a position 9 bp upstream of the 
k13L start codon and has also been reported in some early ASFV genes (Hammond, 
1992). Transcriptional initiation sites of several ASFV genes have been mapped to 
positions a short distance (8 to 70 bp) upstream of AUG codons (Almazan et al., 
1992,1993; Yanez et al., 1993b), but promoters have not otherwise been defined and 
no consensus sequences are apparent by comparison of ASFV promoter sequences. 
A signal for the termination of ASFV gene transcription genes consists of at 
least seven consecutive Ts (Almazan et al., 1993). A 9T signal is first found 404 bp 
downstream from the stop codon of the k13L ORF. This suggests that the k13L 
messenger RNA is unduly long (1.1 kb), or that some alternative termination signal 
is recognized. Seventy percent of the ASFV genes identified so far do not have a 7T 
signal downstream from their ORF (Dixon et al., 1993). However, the analysis of 
ASFV mRNA by Northern blot hybridization with a UBCv specific probe has shown 
that the UBCv transcript is approximately 1.1 kb long (Rodriguez et al., 1992b), 
which suggests that the 9T sequence downstream from k13L might be the termination 
signal for UBCv transcription. 
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AAGGAATTAAACCAAGGAATTTAATTCATATTAAATAGCCATGGTTTCCA 
k13L -> M V 5 5 
GTTTTTTACTGGCAGAGTACAAAAACCTAATAGTGAATCCCTCTGAGCAT 
F L L A E Y K N L I V N P S E H 
TTCAAAATCTCAGTGAATGAAGATAATTTGACTGAATGGGATGTCATCTT 
F K I S V NED N L T E W D V I L 
AAAAGGCCCACCTGACACTCTTTATGAGGGAGGCTTATTCAAAGCAAAGA 
K G P PDT LYE G G L F K A K I 
TTGTCTTTCCTCCAAAATACCCATATGAACCACCCAGATTAACATTCACC 
V F P P K Y P YEP P R L T F T 
TCTGAAATGTGGCATCCCAATATCTACTCTGATGGGAAATTATGTATTTC 
S E M W H P N I Y 5 D G K L CIS 
TATCTTGCATGGAGACAATGCTGAAGAACAGGGAATGACTTGGTCTCCGG 
I L H G DNA E E Q GMT W SPA 
CTCAAAAGATTGATACCGTACTTCTTAGTGTAATTTCTCTGCTCAATGAG 
Q KID T V L L S V I S L L N E 
. 
CCAAATCCAGATTCTCCAGCAAATGTAGATGCAGCTAAAAGCTACCGTAA 
P N P D SPA N V D A A K S Y R K 
ATATCTATATAAAGAGGATTTAGAATCATACCCCATGGAAGTTAAAAAGA 
Y L Y KED L E 5 Y P MEV K K T 
CTGTCAAAAAATCATTGGATGAGTGTTCAGCGGAAGACATAGAATATTTT 
V K K 5 L DEC 5 A E DIE Y F 
AAAAATGTTCCAGTGAATGTTCTACCAGTACCCAGTGATGATTATGAAGA 
K N V P V N V L P V P 5 D DYE D 
TGAAGAAATGGAGGATGGCACCTATATCTTAACCTATGATGATGAGGATG 
E E M E D G T Y I L T Y D D E D E 
AAGAAGAGGATGAAGAGATGGATGATGAGTAGTGCTGATTTTAATGCATA 
E E DEE M D D E * 
ACATATTAGTTACTTACACTTTAGTGCTTAGATTTTAGTGTTTAAACTTT 
I a II b II c---
AGTGATTAGATTTTAGTGCTTAGATTTTAGTGTTTAAACTTTAGTGATTA 
~ I I d II b II C IL-I __ 
GATTTTAGTGCTTAGATTTTAATGTTTAAACTTTAGTGATTAGATTTTAG 
-d II e II c II d I 
TGCTTAGATTTTAATGTTTAAACTTTAGTGATTAGATTTTAGTGCTTAGA 
I e I I c I I d I I f-
TTTTGGTGTTTAAACTTTAGTACTTAGATTTTAGTGCTTAGATTTTGGTG 
__ -,II c II 9 II f IL 
TTTAAACTTTAGTGCCTAAATTTTAGTACTTAGATTTTAAGGTATATAAT 
-c II h II i I. 
TTTGGCTTGTTATAGCGAAAAAAAAATCAGAAAATTATATAATCTGTATA 
. 
TAATTTCTTGCTGATGTATATATATTATTTTTTTTTGTTTAAATGAAATT 
Lterm.:::J 
Figure 2.2 Nucleic acid sequence of the UBCv gene. 
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Complementary DNA sequence of a 1.1 kb region of Sal! fragment k of the Malawi 
LIL20/1 genome comprising the k13L ORF (UBCv gene). The protein translation of 
k13L is given on the second row. The downstream tandem repeats (a through i), the 
TAAAT upstream motif and the 9T putative termination signal are underlined. 
UBCv gene sequence and in vitro activity - 41 -
0 500 1,000 1,500 2,000 
A 1.5 Frame 1 
1.0 
0.5 
CD 
0.0 
0 1.5 c:: 
CD 
.... 
.S? 1.0 
CD 
.... 
a.. 0.5 c:: k14L 0 ~ ~
"8 0.0 () 
1.5 
1.0 
0.5 k13L (UBCv) ~ ~
0.0 . . . . . . . .. . . . . . . . . . . . . . . 
0 500 1,000 1,500 2,000 
B 1.5 
CD Frame 3 0 k13L (UBCv) c:: 1.0 CD 
.... 
CD 
-CD 0.5 .... 
a.. 
c:: 
0 0.0 
"8 .................. () 500 1,000 1, 00 2,000 
Figure 2.3 Statistical analysis of the codon usage in k13L. 
A synonymous codon 'preference' table for ASFV was calculated using 63 ORFs 
spanning the 55 kb right hand region of the Malawi LIL20/1 genome. In panel (A), 
the codon usage along a 2 kb region surrounding k13L was compared to the codon 
preference of ASFV. Values lower than 1.0 indicate that less preferred synonymous 
codons are used in the sequence analyzed. ORFs are represented by open boxes and 
rare codons (typical occurrence frequency of less than 10%) are indicated by ticks 
under the ORF boxes. The position of the k13L ORF is indicated. In panel (B), the 
codon usage was compared to the codon preference table of E.coli ECOHIGH.COD. 
Output is from the CODONPREFERENCE program of the University of Wisconsin 
GCG software package (Devereux et aI., 1984). 
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An array of tandem repeats is located in the intergenic region between k13L 
and k12L. This array consists of 20 repeated units of closely related 14 bp sequences. 
Although other intergenic arrays of tandem repeats exist elsewhere in the genome, 
their sequences are not related to each other and the function of these repeats is 
unknown. 
The nucleic acid sequence for the UBCv gene has also been reported for the 
attenuated BA71V isolate of ASFV (Rodriguez et al., 1992b). The UBCv gene in 
BA 71 V has similar features to the ones described above for Malawi LIL20/1 and the 
nucleic acid coding sequences are 91 % identical. 
2.1.2 Detection of UBCv in other ASFV isolates by peR 
To assess whether the UBCv gene is present in other ASFV isolates and may 
therefore have an important role in virus replication, the UBCv gene was amplified 
by polymerase chain reaction (PCR) from genomic DNA of 20 ASFV isolates which 
were obtained from infected domestic pigs or ticks in Africa and Europe. The DNA 
was extracted from virus purified from infected pig blood (Payne and Wilkinson, 
personal communication). The sequences of the oligonucleotides used as primers in 
the PCR are complementary to the 5' and 3' ends of the UBCv gene, either from 
Malawi LIL20/1 (Mw1 set) or from BA71V (Ba1 set) (Table 2.1). 
PCR using the Ba1 set of primers amplified a DNA fragment of the expected 
size (approximately 650 bp) from the nine ASFV genomes tested of European origin 
(figure 2.4, A). In contrast, PCR with Ba1 primers failed to amplify any sequences 
from the genomic DNA of seven African ASFV isolates, including Malawi LIL20/1 
(figure 2.4, B). However when using the Mw1 set of primers, the PCR amplified a 
DNA fragment of the expected size (650 bp) from eleven ASFV genomes of African 
origin (figure 2.4, C). This difference between the European and African ASFV 
isolates confirmed the previous groupings observed both by restriction enzyme site 
mapping of virus genomes and by PCR amplification of other ASFV sequences 
(Williams, Payne and Wilkinson, personal communication). 
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Set No. Posi- Restric- Oligonucleotide sequence 
tion tion site (5' to 3') 
UB3 5'end Pst! ACCGGTCTGCAGGGATGGTT 
TCCAG'ITITI fACT 
Mwl 
UB4 3'end HindIII GTGTGAAAGCTTCTACTCATC 
ATCCATCTCTT 
UB5 5'end Bamffi ACCGGTGGATCCATGGTTTCC 
AG1TITITACT 
Mw2 
UB6 3'end Bamffi GTGTGAGGATCCCTACTCATC 
ATCCATCTCTI 
UB? 3'end none TIACTCATCATCCATCTCTTC 
A 
Bal 
UB8 5'end none TAGCAGAGTACAGACACCTG 
A 
Table 2.1 Sequence of the oligonucleotides used as primers for the 
amplification by PCR of the k13L ORF. 
Start and stop codons are underlined. The nonsense nucleotide hexamers at the 5' 
ends of the oligonucleotides are intended to help binding of restriction enzymes during 
digestion. PstI, HindIII and Bamffi sites (in bold in the nucleotide sequence) were 
added to facilitate cloning into plasmid vectors (see §2.3.1 and §3.1.1). 
Eu 
A M123456789M 
600 bp - .. 
B Eu At -M12345678M 
600 bp -
c At 
M 1 2 3 4 5 6 7 8 9 10 11 12 M 
600 bp -
Figure 2.4 peR amplification of the UBCv gene from African and 
European isolates of ASFV. 
UBCv gene sequence and in vitro activity - 44 -
Figure 2.4 PCR amplification of the UBCv gene from African and European 
isolates of ASFV (facing page). 
A library of genomic DNA from ASFV isolates originating from Europe (Eu) or from 
Africa (At) was screened for the presence of the UBCv gene by PCR. The PCR 
primers used were complementary to the 5' and 3' ends of the UBCv gene sequence, 
derived either from the BA71V isolate (panels A and B) or from the Malawi LIL20/1 
isolate (panel C). PCR products were separated by 0.6% agarose gel electrophoresis. 
Side lanes (M): 100 bp DNA ladder, the position of the 600 bp marker (double 
intensity) is indicated. The ASFV isolates were for panel A lanes 1-9: ANG70, 
LIS57, LIS60, MAL78, SAR82, ITA83 , BEL85, TCN86, TCN87; panel B lanes 1-8: 
RSA85/l, TAN87, MOZ60, BUR84/1, BON83, CHA86, LIL20/1, DED86; panel 
C lanes 1-12: CHA86, NAM8212, BUR84/1, MOZ60, HIN54, KAT67 , KIM1, 
BAR2, BEL92/1, LIL20/1, LIV13/33, TAN87. 
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2.2 Amino acid sequence of UBCv 
2.2.1 Predicted polypeptide structure of UBCv 
The k13L ORF encodes a putative 213 amino acid UBCv protein with a predicted 
molecular weight of 24.7 kDa and an isoelectric point of 4.0. Computer predictions 
of the hydrophilicity of UBCv (figure 2.5, A) showed that it contained no extensive 
hydrophobic regions, indicating that UBCv was probably not membrane associated. 
Amongst the secondary structure features predicted for UBCv (figure 2.5, B), three 
a-helices and two (j-sheets were located in similar positions to those observed in the 
crystal structure of the Ath1 UBC enzyme from Arabidopsis thaliana (Cook et al., 
1992b). Two further (j-sheets and one a-helix present in Ath1 were not predicted in 
the relevant positions in UBCv. 
Scanning the UBCv sequence against a protein motif library (prosite, 06/93 
version, Bairoch, 1992) suggested that the UBCv sequence contained two potential 
post-translation modification sites. The first was an asparagine glycosylation site 
(NxTx; x is any residue apart from a proline) at position 29, and the second was a 
tyrosine phosphorylation site (KxxxDxxY) at position 38. Although these two sites 
were also detected in the UBCv sequence from BA71V, they were not present in 20 
other UBC enzyme sequences analyzed. The final motif detected spanned residues 74 
to 88 of UBCv and corresponded to the universal signature of the active sites of UBC 
isozymes. 
2.2.2 Comparison of UBCv amino acid sequence with other UBC 
enzymes 
The amino acid sequences of UBCv and nine yeast UBC isozymes were aligned and 
compared. A core structure which consists of approximately 150 amino acids at the 
N-terminus is conserved in all UBC enzymes and contains the catalytic site (Jentsch, 
1992). The sequence surrounding the active site cysteine is extremely well conserved 
(figure 2.6, A), except for a 10 amino acid insertion which is present in UBCv and 
the yeast UBC3, UBC6 and UBC7 enzymes. 
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Figure 2.5 Predicted hydrophilicity and secondary structure of UBCv 
Panel A: Hydrophilicity according to Kyte-Doolittle (KD, Kyte and Doolittle, 1982) 
across the peptide sequence of UBCv. Panel B: Secondary structure according to 
either Garnier-Osguthrope-Robson (GOR) or Chou-Fasman (CF) (Devereux et al., 
1984). Putative glycosylation sites are shown on the bottom row. Conserved {3-sheets 
and a-helices (compared to the structure of Athl, Cook et al., 1992b) are indicated 
in bold. Outputs are from the PEPTIDESTRUCTURE program of the University of 
Wisconsin GCG software package. 
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A carboxyl-terminal tail of variable length extends from the core region. The 
sequences of these tails are unrelated although they share a large proportion of acidic 
residues (figure 2.6, B). The 56 amino acid C-terminal tail of UBCv contains 26 
aspartic and glutamic acid residues (46%), including an uninterrupted track of 10 of 
these residues. 
The percentages of amino acid identity and similarity between UBCv and yeast 
UBCs are given in table 2.2. The identity of UBCv over the N-terminal conserved 
domain ranged from 25 % compared to UBC9 to 41 % compared to UBC7. When the 
acidic tails were included, the percentage similarity of UBCv was lowest compared 
to UBC6 and highest compared to UBC3 (23% and 51 % respectively). 
Yeast UBC enzyme Percent identity Percent similarity 
(core) (core + tail) 
UBCl 27% 25% 
UBC2 32% 43% 
UBC3 38% 51% 
UBC4 36% 40% 
UBC5 36% 41% 
UBC6 28% 23% 
UBC7 41% 46% 
UBC8 26% 29% 
UBC9 25% 27% 
Table 2.2 Percentage of amino acid identity and similarity between 
UBCv and yeast UBCI to UBC9 enzymes. 
The percentage of identical amino acids between the UBCs was determined using the 
conserved N-terminal regions (core). The percentage of similar amino acids over the 
whole length (core + tail) of the UBC polypeptides was determined using the 
PAM250 matrix (Dayhoff et al., 1983). Calculations were made using the 
DISTANCES program of the University of Wisconsin GCG package (Devereux et 
al., 1984). 
8 
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Figure 2.6 Alignment of the protein sequences of UBC enzymes from ASFV 
and yeast. 
Panel A (facing page): Alignment of the conserved catalytic core of UBC enzymes. 
Black boxes indicate residues that agree with the consensus (defined by a residue 
present in more than 5 sequences). Decreasing shades of grey represent decreasing 
degrees of conservation in residue substitutions. The star (*) marks the position of the 
active site cysteine. The insertion downstream from the active site is underlined. Panel 
B: Alignment of the carboxyl-terminal tail of UBC enzymes. Grey boxes indicate 
acidic amino acids (Asp and Glu). The alignment was produced by the GCLUSTAL V 
program of the University of Wisconsin GCG software package. Y1 to Y9 : UBCl to 
UBC9 from yeast (protein sequences were translated from the nucleotide sequences 
obtained from the EMBL and GBONL Y databases). Mw and Ba: sequence of UBCv 
from Malawi LIL20/l and BA 71 V ASFV isolates respectively. 
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Mse1 
Yst9 
Figure 2.7 Dendrogram of sequence similarity between various UBC enzymes. 
The length of the lines to the nodes joining the various UBC enzymes are proportional 
to their sequence divergence. Clustering of distinct groups of enzymes are boxed . The 
protein sequences of the UBC enzymes used to calculate the dendrogram were 
translated from nucleotide sequences in the EMBL and GBONLY databases. Yst: 
yeast (Sc), Wht: wheat, Dro: drosophila, Mse: mouse, Hum: human, Ath: 
Arabidopsis thaliana, Bov: bovine, Rhp: Saccharomyces pombe, Rat: rat, Asfmw: 
ASFV (Malawi LIL20/ I), Astba: ASFV (BA 71 V). Output is from the University of 
Washington PHYLIP software package. The tree was calculated according to the 
neighbour joining method using the percentage of similarity (PAM250 matrix, 
Dayhoff et al., 1983) in the UBC's core amino acid sequences. 
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The percentage similarity between 25 UBC enzyme sequences present in the 
database was used to plot a homology dendrogram (figure 2.7). This diagram 
suggested the existence of distinct UBC subgroups between which the sequence 
divergence was lower than 25 %. The clusterings partly reflected known similarities 
in UBC function such as enzymes involved in DNA repair or in bulk protein 
degradation. Although the UBCv enzyme did not appear to belong to any of these 
subgroups it shared the same phylogenetic branch as yeast UBC3 and UBC7 enzymes. 
2.3 UBCv in vitro enzyme activity 
2.3.1 Production of recombinant UBCv 
Many UBC enzymes have been expressed in E. coli and shown to retain their activity 
in vitro (Jentsch et al., 1987; Goebl et al., 1988; Sullivan and Vierstra, 1989; Seufert 
et al., 1990; Haas et al., 1991; Qin et al., 1991). Moreover, prokaryotic vectors are 
the preferred expression system for the study of UBC enzymes since they are devoid 
of contaminating endogenous enzymes of the ubiquitin pathway. 
The k13L ORF was amplified by PCR using as template DNA from 
bacteriophage Lambda clone LMw22 which contains the ASFV genome fragment San 
k (Malawi LIU20 isolate, Dixon, 1988). The UB3 and UB4 oligonucleotide primers 
(Table 2.1) used in the reaction contained sequences from the 5' and 3' ends of the 
k13L ORF and added PstI and HindIII restriction sites. The PCR reaction yielded a 
unique product of approximately 670 bp (expected length was 668 bp) (figure 2.8, A). 
The PCR product was digested with PstI and HindIII and ligated to 
PstIIHindIII digested plasmid vector pKK 233-2 to yield plasmid PHI (figure 2.9). 
The cloning process introduced four additional codons at the 5' end of the original 
k13L ORF (which translates into four non-authentic N-terminal residues Met1-Ala2-
Ala3-GII). The expression vector pKK 233-2 is derived from plasmid pBR 322 and 
has both ampicillin and tetracyclin resistance genes (Amann and Brosius, 1985). A 
Ptrc promoter (hybrid Ptrp-Iac promoter) and TlIT2 terminators are present on each 
side of a_ NcoIIPstIlHindIII polylinker. Expression of the gene cloned downstream 
A 
M M 
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Figure 2.8 Amplification of UBCv by peR and cloning in pKK 233-2. 
Primers UB3 and UB4 (see table 2.1) were used to amplify UBCv (k13L ORF) by 
PCR from Lambda clone LMw22 containing ASFV fragment Sail k. Panel (A) shows 
a 1 % agarose gel electrophoresis of the purified PCR product. Side lanes (M): 123 bp 
DNA ladder. The purified PCR product was cloned in the Pst! / HindIII site of 
plasmid pKK 233-2 to yield plasmid PHI. Panel (B) shows a 0.6% agarose gel 
electrophoresis of the PstI / HindIII digests of plasmid DNA from an E. coli colony 
transformed with PHI (lane 1) or with plasmid pKK 233-2 alone (lane 2). 
S t o p ~ ~ ~ D ... 
TCGAAGATGAGTAGTAG 
I I 
Hindlll 
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Figure 2.9 Diagram showing the subcloning of the UBCv gene in expression 
vector pKK 233-2. 
The UBCv gene was amplified by PCR using as template DNA from bacteriophage 
Lambda clone LMw22 which contains Sall fragment k of the Malawi LIL20/1 ASPY 
genome). The amplified UBCv gene was inserted into plasmid pKK 233-2 by double 
digestion of both the vector and the PCR product with Pst! and Hin.dIII restriction 
enzymes followed by ligation, yielding recombinant plasmid PHI. 
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from the Ptrc promoter is regulated by the lac operator and is therefore induced by 
adding isopropylthio-J3-D-galactoside (IPTG) to the cell culture. 
The ligated PHI plasmid was transformed into E. coli and ampicillin resistant 
colonies were selected. The efficiency of transformation was 4.1 if ampicillin resistant 
colonies per p.g of ligated DNA. Analysis of plasmid DNA from resistant colonies by 
PstI I HimlIII digestion showed that 50 % of the ampicillin resistant clones contained 
a 650 bp UBCv insert (figure 2.8, B). Clones harbouring the recombinant plasmid 
PHI were isolated for UBCv expression. 
Expression of the k13L ORF was induced in E. coli containing PHI by adding 
IPTG to cultures. Proteins in the resulting celllysates were then analyzed by SDS-
polyacrylamide gel electrophoresis (SDS/PAGE). Coomassie blue staining of proteins 
was not sufficiently sensitive to detect the expressed protein, consequently E. coli 
proteins were labelled with [35S]methionine at various times after induction with 
IPTG. Upon induction, 50% of the clones containing the PHI plasmid expressed a 
novel protein with an apparent molecular weight of 30 Kda (figure 2.10). This protein 
was not detected in induced cells c o n t a i n i n ~ ~ the vector pKK233-2 alone (data not 
shown). 
Expression of this 30 kDa protein was detected 10 minutes after induction and 
continued at a constant level for at least another 60 minutes (data not shown). This 
novel protein was likely to be UBCv despite the discrepancy between the apparent and 
predicted molecular weights of UBCv (30 kDa versus 24.4 kDa), since aberrant 
migration in SDS/PAGE was also observed with other UBC enzymes and might have 
been due to the freely extending acidic tail (Goebl et al., 1988; Morrison et al., 
1988; Sullivan and Vierstra, 1989). 
2.3.2 Purification and assay of a ubiquitin activating enzyme El 
A ubiquitin activating (EI) enzyme is an essential component for the in vitro assays 
of the UBCv enzyme. A homogenous preparation of E1 enzyme was purified from 
pig brain tissue by affinity chromatography on a ubiquitin-sepharose column as 
described in figure 2.11 (Ciechanover et al., 1982). 
UBCv 
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Figure 2.10 Expression of the UBCv protein in E. coli harbouring plasmid PHI. 
IPTG was added to an E. coli cell culture containing PHI in early exponential phase 
to induce expression of UBCv. The culture was incubated for 30 minutes before a 
pulse of e SS]methionine was added for 10 minutes. Cells were pelleted and lysed by 
adding sample buffer. Proteins were separated by 20% SDS/p AGE and detected by 
fluorography of the dried gel. Lane 1: cell lysate before induction; Lane 2: cell lysate 
30 min after induction. The arrow head shows the position of the novel UBCv protein. 
Molecular weights in kDa are indicated on the right. 
ubiqu itin & E3s 
Unbound 
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Figure 2.11 Diagram describing the purification of an El enzyme from pig 
brain. 
A soluble extract from a fresh piglet brain was depleted of endogenous ubiquitin by 
DEAE cellulose ion-exchange chromatography. The bound proteins, including El, 
were eluted by a high salt buffer and applied to a ubiquitin-sepharose affinity column. 
In the presence of ATP, the El enzyme covalently bound to the immobilized ubiquitin 
through a thiol ester link, whereas other protein contaminants were washed through 
the column. The El enzyme then was eluted off the column with an AMP and PPi 
buffer, a mixture that specifically reverses the binding reaction of El with ubiquitin. 
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Figure 2.12 Purity and in vitro activity of a ubiquitin activating enzyme E1 
from pig brain. 
Lane 1: Coomassie staining of 7-20% SDS/PAGE of proteins eluted off a ubiquitin 
affinity column loaded with piglet brain extract; lane 2: 10 minutes incubation of 
affinity purified E1 with [l 25I]Ubiquitin and ATP (autoradiography of 7-20% 
SDS/PAGE); lane 3: same reaction as in lane 2 but without ATP. Molecular weights 
in kDa are indicated to the right. 
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SDS/PAGE analysis of the affinity purified material followed by Coomassie 
blue staining (figure 2.12, lane 1) showed that the eluted material consisted of a 
protein doublet (Mwts 100 kDa and 107 kDa). These molecular weights are those 
expected for the two isoforms of the mammalian E1 enzyme (Cook and Chock, 
1992). 
A sample of the affinity purified preparation was tested for El activity by 
incubating it for 10 minutes with [125I]Ubiquitin in the presence of ATP. The products 
of the reaction were analyzed by non-reducing SDS/PAGE followed by 
autoradiography (figure 2.12, lane 2). In these conditions two radioactive ubiquitin 
adducts of 108 and 115 kDa were formed. These adducts were not detected when the 
reaction mixture was either submitted to reducing conditions (data not shown) or if 
ATP was omitted (figure 2.12, lane 3). 
These observations indicated that the affinity purified proteins were E1 enzyme 
isoforms capable of forming an ATP dependent thiolester bond with ubiquitin .. 
Furthermore the El preparation was free of UBC enzyme contaminants and was 
suitable for use in UBCv activity assays. 
2.3.3 In vitro assay of UBCv activity 
Recombinant UBCv was prepared from the crude soluble extract of an induced E. coli 
culture containing plasmid PHI. A sample of recombinant UBCv was incubated with 
[125I]Ubiquitin, purified pig brain El and ATP. After 15 minutes, the products of the 
reaction were analyzed by SDS/PAGE under non-reducing conditions (figure 2.13, 
lane 1). 
A single 37 kDa radioactive ubiquitin adduct was formed. This ubiquitin 
adduct was sensitive to reducing conditions (figure 2.13, lane 4) which indicated that 
the ubiquitin adduct was the result of a thiolester bond. Formation of the 37 kDa 
ubiquitin adduct was also both ATP and E1 dependent (figure 2.13, lanes 2 & 3). No 
El- ubiquitin adduct was visible, suggesting that ubiquitin activation was the rate 
limiting step. When recombinant UBCv was substituted for a protein extract from an 
E. coli culture containing the pKK 233-2 vector alone, no ubiquitin adduct was 
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- 84 
- 47 
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- 24 
- 16 
Ub 
Figure 2.13 Formation of a thiolester bond between UBCv and ubiquitin. 
Reaction mixtures were incubated for 15 minutes and contain in lanes 1 and 4: 
recombinant UBCv, [l2SI]ubiquitin, affinity purified pig brain El and ATP; lane 2: as 
lane 1 without El; lane 3: as lane 1 without ATP. The reactions were stopped by 
adding sample buffer with (lane 4) or without (lanes 1-3) ~ - m e r c a p t o e t h a n o l . . Reaction 
products were separated by 7-20% SDS/PAGE and detected by autoradiography of 
dried gels. The positions of ubiquitin (Ub) and of the UBCv-ubiquitin thiolester 
complex (UBCv-Ub) are indicated. Molecular weights in kDa are shown on the right. 
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observed (data not shown) confirming that the 37 kDa thiolester adduct consisted of 
UBCv - rt25I]ubiquitin. 
In vitro studies have shown that UBC enzymes with an acidic C-terminal tail 
can ubiquitinate histones (Jentsch et al., 1987; Goebl et al., 1988; Sullivan and 
Vierstra, 1989; Haas et al., 1991). In these experiments, ubiquitin-H2A conjugate 
formation occurred in a reaction that was not dependent on added E3 enzymes. To 
determine whether such a ubiquitin-histone conjugate could be formed by UBCv in 
an E3 independent reaction, histone H2A was added to the same reaction mixture as 
for the thiolester assay (recombinant UBCv,. pig brain E1, [125I]Ubiquitin and ATP). 
The incubation time was extended to 60 minutes and the products of the reaction were 
analyzed by reducing SDS/PAGE. The reducing conditions ensured that only 
isopeptide links rather than thiolester bonds were detected (figure 2.14). 
A complex mixture of radioactive adducts was formed that corresponded to 
three distinct classes of ubiquitin conjugates. These could be more easily identified 
by comparison with the control assay containing no added histones (figure 2.14, A). 
Surprisingly, when no protein substrate was present six ubiquitin conjugates were 
" 
formed with apparent molecular weights of 17, 36, 37, 42, 46 and 54 kDa. 
A number of other UBC enzymes (including the yeast UBC3 enzyme) have 
given rise to similar in vitro patterns of conjugation (Sung et al., 1988; Chau et al., 
1989; Arnold and Gevers, 1990; Braatz et al., 1992). These patterns were assigned 
to the UBC enzyme's ability to transfer ubiquitin to themselves, as well as to free or 
conjugated ubiquitin. These activities are known as auto- and poly-ubiquitination. The 
results obtained with UBCv suggest that it has such activities since the ubiquitin 
conjugates that are formed could correspond to Ub2 (17 kDa ubiquitin dimer), to two 
species of UBCv-Ub where ubiquitin is linked to different lysine residues of UBCv 
(36 and 37 kDa), and to poly-ubiquitinated forms of UBCv: UBCv-Ub2 (42 and 46 
kDa) and UBCv-Ub3 (54 kDa). Western blotting analysis using mono specific anti-
UBCv antiserum confirmed that the high molecular weight adducts consisted of 
UBCv-ubiquitin conjugates (S. Twigger, personal communication). 
The addition of histone H2A to the reaction resulted in the formation of two 
novel ubiquitin conjugates (figure 2.14, B, lane 1) which could correspond to mono-
and di-ubiquitin forms of H2A: H2A-Ub (26 kDa) and H2A-Ub2 (32 kDa). 
A 
69 kDa 
UBCv - (Ub)n 46 
30 
14 
B 1 2 3 4 
- 200 kDa 
- 100 
- 69 
- 46 
UBCv - (Ub)n 
30 
H2A-(Ub)n 
14 
Figure 2.14 Ubiquitin conjugate formation in the presence of 
UBCv. 
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Figure 2.14 Ubiquitin conjugate fonnation in the presence of UBCv (facing 
page). 
Reaction mixtures were incubated for 60 minutes and contained in panel A: 
recombinant UBCv, [12sI]Ubiquitin, pig brain E1 and ATP. Panel B, lane 1: as panel 
A with added histone H2A; lane 2: as lane 1 without E1; lane 3: as lane 1 without 
ATP; lane 4: as lane 1 with UBCv replaced by extracts from E. coli containing vector 
pKK 233-2 alone. Reactions were stopped by boiling in sample buffer containing {3-
mercaptoethanol. Reaction products were separated by 7-20% SDS/PAGE and 
detected by autoradiography of dried gels. The positions of ubiquitin (Ub), ubiquitiI\t 
polymers (UbJ, histone H2A-ubiquitin conjugates (H2A-Ub) and UBCv-ubiquitin 
conjugates (ASFV UBC-Ub) are indicated. Molecular weights in kDa are shown on 
the right. 
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The 17 kDa ubiquitin dimer and most of the UBCv auto-ubiquitination ladder were 
still visible in reactions in which H2A was added. Formation of all these conjugates 
was shown to be El, ATP and UBCv dependent (figure 2.14, B, lanes 2,3 & 4). 
The three classes of substrates for the UBCv enzymes were therefore UBCv 
itself, ubiquitin and histones. Conjugation assays with histone H2B and lysozyme 
showed that these substrates were also ubiquitinated by UBCv (data not shown). 
1.4 Discussion 
The analysis of the k13L ORF encoding UBCv revealed a structure typical of ASFY 
genes, indicating that UBCv was likely to be a functional gene. Observations such as 
the codon usage and the high A+T content of k13L suggested that the UBCv gene 
was not a particularly recent acquisition of the ASFY genome. This view was 
supported by the peR screening which suggested that the UBCv gene was a universal 
feature of African and European ASFY isolates. Moreover the tissue culture adapted 
BA 71 Y isolate (Tabares et al., 1987), which has undergone several genome 
rearrangements during tissue culture adaptation, also contained an intact UBCv gene 
(Rodriguez et al., 1992b). The ubiquitous presence of UBCv in ASFY, in spite of its 
location in the more variable region of the genome, supported the hypothesis that 
UBCv is potentially important for ASFY replication. 
The protein sequence deduced from the UBCv gene was homologous to 
eukaryotic UBC isozymes. Amino acid identity between UBCv and cellular UBC 
enzymes reached 40% which is higher than usually observed when comparing ASFY 
proteins to their cellular homologues (typically around 20%) as would be predicted 
since UBC enzymes are a very conserved protein family. The conserved N-terminal 
150 residues of UBC enzymes were also present in UBCv as was the active site 
cysteine. The C-terminal region of UBCv was similar to that of yeast UBC2, UBC3 
and UBC8 since all contain a large number of acidic residues. Overall however, 
UBCv did not appear to be closely related to any particular subtype of UBC enzymes, 
suggesting that UBCv might have evolved a novel function. 
The in vitro experiments demonstrated that recombinant UBCv could, in an 
El and ATP dependent reaction, form an adduct with ubiquitin. The UBCv enzyme . 
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could also covalently transfer ubiquitin to protein substrates. This evidence indicated 
that UBCv had the general in vitro characteristics of UBC enzymes. Furthermore the 
formation of ubi quit in conjugates catalyzed by UBCv was highly specific since UBCv 
ubiquitinated itself, ubiquitin and histones but none of the numerous E. coli proteins 
present in the assays. 
UBCv shares its histone ubiquitination property with the yeast UBC2 and 
UBC3 enzymes (Pickart and Rose,. 1985; Jentsch et al., 1987; Goebl et al., 1988; 
Sung et al., 1988; Prakash, 1989; Sullivan and Vierstra, 1989; Haas et at., 1991). 
Since all three enzymes have an acidic C-terminal extension, it is possible that ionic 
interactions with basic proteins such as histones might be involved in substrate 
recognition. Further evidence for the importance of the C-terminal tail in determining 
substrate specificity comes from experiments in which the C-terminal tail of UBC3 
was transferred to the N-terminal core of other UBC enzymes (Kolman et at., 1992; 
Silver et al., 1992). Since this portable determinant probably conferred substrate 
specificity, it is likely that the C-terminal tail of UBCv is important for the viral 
enzyme's substrate specificity and function. The lack of apparent homology between 
the tails of UBCv and other UBC enzymes suggested that UBCv had a distinct 
physiological target. This was also suggested from complementation experiments 
carried out with UBCv in yeast UBC mutants (Jentsch, personal communication). In 
a yeast UBC2 null mutant expressing UBCv, none of the wild type UBC2 phenotypes 
(DNA repair or sporulation) were restored although growth of the yeast mutant was 
slightly restored. The N-terminal core of the yeast UBC2 enzyme retained some of 
its functions in the absence of a C-terminal tail (Morrison et ai., 1988; Sung et al., 
1988; Prakash, 1989), partly through interactions with an E3 enzyme (Dohmen et at., 
1991; Sharon et al., 1991; Sung et at., 1991a; Madura et at., 1993). Thus the 
possibility that the function (or one of the functions) of UBCv is mediated by an E3 
enzyme (either cellular or virus encoded) can not be completely ruled out. 
The UBCv enzyme also shared an in vitro poly-ubiquitination property with 
UBC2 and UBC3 (Sung et at., 1988; Haas et at., 1991; Banerjee et at., 1993). From 
the results presented here, the exact nature of the poly-ubiquitinated conjugates 
formed by UBCv could not be resolved. They might have been the result either of 
successive ubiquitination at distinct lysine sites within the substrate, or of processive 
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ubiquitination of previously conjugated ubiquitin (poly-ubiquitin chains). The apparent 
capacity of UBCv to synthesize dimers of ubiquitin is similar to that of yeast UBC8 
(Chen and Pickart, 1990; Qin et al., 1991). Since in this reaction ubiquitin acted as 
a substrate, it is tempting to speculate that UBCv may also be capable of forming 
poly-ubiquitin chains. This hypothesis is supported by the prediction that the short 
insertion downstream from the active site of UBCv might be responsible for the 
catalysis of poly-ubi qui tin chains (Haas et al., 1991; Van Nocker and Vierstra, 1991; 
Cook et al., 1992b). 
The issue of poly-ubiquitin conjugate formation is important since it is thought 
to be responsible for targeting substrates for degradation and would therefore suggest 
that UBCv can target proteins for proteolysis (Chau et al., 1989; Gregori et al., 
1990). Although the ability to target substrates for degradation would support a UBCv 
role in virion uncoating, it would argue against a chaperone-like function for UBCv 
which might be required for certain functions such as virion morphogenesis. The 
ability of UBCv to poly-ubiquitinate itself might target UBCv for proteolysis, 
providing a feed back mechanism for control of UBCv activity in ASFV infected 
cells, a role similar to that proposed for the yeast UBC3 auto-ubiquitination property 
(Banerjee et ai., 1993). 
It must be stressed that in vitro assays may produce misleading artifacts for 
several reasons. Firstly, bacterial recombinant UBCv might not be properly folded 
or modified and might therefore not have the same activity as in vivo. Secondly, 
concentrations of the protagonists in the assay were entirely arbitrary and potential 
cofactors (such as E3 enzymes) might have been absent. Further analysis of the 
function of the UBCv enzyme was investigated by studies of UBCv during ASFV 
infection of cells. 
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Chapter 3 
Analysis of UBCv in ASFV infected cells 
---0---
The structure of the UBCv gene and the in vitro activity of recombinant UBCv both 
suggested that the ASFY encoded UBC enzyme was functional. This hypothesis was 
investigated further by looking at the expression of UBCv during ASFY infection of 
cells. Antibodies specific for UBCv were produced in rabbits and used to detect 
UBCv's presence in ASFY infected cells and ASFY particles. In addition, attempts 
were made to inhibit the UBCv enzyme activity during ASFY infection, the effects 
of which might help elucidate the role of UBCv during ASFY replication. 
3.1 UBCv expression in ASFV infected cells 
3.1.1 Preparation of antiserum against UBCv 
Immunological methods for the detection of proteins require high affinity, mono-
specific antibodies. Antisera were raised against UBCv in rabbits using antigens 
. which consisted of either synthetic peptides or whole recombinant UBCv (table 3.1). 
The sequence of the synthetic peptides covered either UBCv's highly conserved active 
site (with a high probability of antibody accessibility), or its N- and C-termini which 
were specific for UBCv and less likely to cross-react with the host's UBC isozymes. 
Two rabbits were immunized with whole recombinant UBCv purified from an 
. E. coli culture transformed with plasmid PH2. The PH2 plasmid was constructed 
(figure 3.1) by inserting the UBCv gene in frame with the glutathione-S-transferase 
(GST) gene of the expression vector pGEX-2T (Promega). The expression of the 
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I 
Antigen 
II 
a-serum I I Name I POSe I UBCv region I +Cys I Amount II Name I 
P9 75-94 Active site no 150 p.g LDI 
Pll 116-134 Downstream act. site yes 150 p.g LD3 
P17 1-19 N-terminus yes 150 p.g LD4/LD5 
P31 195-213 C-terminus yes 150 p.g LD6/LD7 
rUBCv 1-213 Recombinant UBCv N/A 15 p.g LD8 
rUBCv 1-213 Recombinant UBCv N/A 100 p.g LD9 
Table 3.1 Antigens used in the production of anti-UBCv antisera. 
The antigens used in the rabbit immunizations consisted either of synthetic peptides 
(Px) or of pure recombinant UBCv (rUBCv). The sequence of the antigen is referred 
to by its position in the UBCv polypeptide sequence (Malawi LIL20/1). When a 
cysteine residue was not present in the synthetic peptide sequence, a cysteine residue 
was added to its N-terminus (+Cys) in order to provide a site for linking to sepharose 
or a carrier protein. The amounts of antigen used for each inoculation are indicated. 
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Figure 3.1 Cloning of the UBCv gene in expression vector pGEX-2T 
The UBCv gene was amplified by PCR with the Mw2 set of primers (table 2.1) using 
as template DNA from bacteriophage lambda clone LMw22 (Dixon, 1988). The 
unique 650 bp fragment produced in the reaction was digested with BamBI. The 
pGEX-2T plasmid (Promega corporation) was digested with BamBI and 
dephosphorylated with calf intestine phosphatase (eIP). The digested UBCv insert and 
pGEX-2T vector were then ligated and transformed in E. coli. Clones expressing the 
GST-UBCv fusion protein were identified in E. coli cell lysates by Western blot 
analysis using UBCv anti-peptide antiserum. 
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resulting GST-UBCv fusion protein was driven by the IPTG inducible Ptac promoter. 
The GST-UBCv fusion protein could then be purified from the E. coli lysate by 
affinity chromatography on a glutathione-sepharose column for which the GST moiety 
has high affinity. The thrombin cleavage site between GST and UBCv allowed UBCv 
to be released from the column by elution with the thrombin protease. The proteolytic 
activity of thrombin resulted in the addition of a non-authentic Gly-Ser dipeptide at 
the N-terminus of UBCv. 
An E. coli culture containing plasmid PH2 was grown to mid-exponential 
phase and induced for 3 hours with IPTG. The resulting soluble cell lysate was 
applied to a glutathione-sepharose column and UBCv was released by cleavage on the 
column with thrombin. The degree of UBCv purity attained by this method was 
assessed by SDS/PAGE (figure 3.2). The preparation consisted mainly of two 
proteins (30 and 31 kDa) which were not present in an E. coli culture containing the 
pGEX-2T vector alone. The two proteins are likely to correspond to two forms of 
UBCv since they both cross reacted with the UBCv anti-peptide antiserum (figure 
3.3). The smaller of the two UBCv proteins might have been an early termination 
product since the UBCv coding sequence contained many codons which rarely occur 
in E. coli (see § 2.1.1). The other minor and faster migrating proteins were probably 
additional early termination or degradation products of UBCv which would not 
interfere with the production of anti-UBCv antisera. 
Approximately 1 mg of over 90 % pure UBCv was recovered from a 1 litre 
E. coli culture containing plasmid PH2. The relative low yield of UBCv recovery (the 
yield of recombinant proteins using pGEX-2T normally ranges from 5 to 10 mg per 
litre) was probably due to the ASFV codon usage which was not optimal for high 
expression in E. coli. The UBCv eluate from the glutathione-sepharose column was 
used with no further treatment for the rabbit immunizations. 
The nine anti-UBCv antisera were tested for their ability to detect recombinant 
UBCv in Western blots (figure 3.3). All the antisera detected the UBCv doublet and 
at least one of the smaller fragments. Nonetheless, at an equal dilution, the LD8 and 
LD9 antisera (figure 3.3, lanes 8 & 9) raised against recombinant UBCv were more 
sensitive than the anti-peptide antisera (figure 3.3, lanes 1-7). The LD9 antiserum was 
therefore used hereafter in all UBCv detection experiments. 
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Figure 3.2 Analysis of UBCv purified from an E. coli culture harbouring 
plasmid PH2. 
The GST-UBCv fusion protein was affinity purified on a glutathione-sepharose column 
from lysates of E. coli cells containing plasmid PH2. The four successive fractions 
eluted with thrombin were subjected to 10% SDS-PAGE and proteins were detected 
by silver staining (lanes 2-5). In lane 1, the E. coli culture contained the pGEX-2T 
vector alone. The position of the UBCv doublet is indicated. 
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Figure 3.3 Detection of recombinant UBCv using various anti-UBCv antisera. 
Recombinant VBCv was affinity purified from E. coli cell lysates containing plasmid 
PH2. Purified recombinant VBCv was subjected to 12% SDS-PAGE followed by 
Western blotting. The blotted proteins were probed with nine antisera (at the same 
dilution) raised in rabbits (see table 3.1) against either synthetic peptides (LD 1 to 
LD7) or whole recombinant VBCv (LD8 and LD9) (lanes 1 to 9 respectively). 
Enhanced chemo-luminescence (EeL) was used to detect bound antibodies. The 
position of the VBCv doublet is indicated. 
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3.1.2 Expression of UBCv in ASFV infected cells 
Pig monocytes were infected with the Malawi LIL20/1 ASFV isolate at a high 
multiplicity of infection and harvested at various times post-infection. Infected cell 
extracts were analyzed by SDS-PAGE followed by Western blotting. When the blots 
were probed with anti-UBCv antiserum (figure 3.4, B), a 29 kDa immunoreactive 
protein was detected in all the infected cell extracts but not in mock-infected 
monocytes. This protein was not detected with the pre-immune serum (figure 3.4, A) 
which provided further evidence that this 29 kDa protein was UBCv and demonstrated 
that UBCv was present in ASFV infected cells from at least 3 to 24 hours post-
infection. As estimated from the intensity of the bands, the amount of UBCv was 
approximately constant throughout the ASFV replication cycle. Since the number of 
adherent cells severely decreased after 24 hours of infection, the total amount of 
protein loaded on the gel for this time point was considerably lower than in early 
infection. This suggests that the relative concentration of UBCv in infected cells 
actually increased at 24 hours post-infection. 
ASFV infected pig monocytes were also pulse labelled with [35S]methionine 
and labelled proteins were immunoprecipitated with anti-UBCv antiserum. A 29 kDa 
protein was immunoprecipitated (figure 3.5) indicating that UBCv was synthesized 
in infected cells from at least 3 to 24 hours post-infection. Although UBCv was 
actively expressed throughout the ASFV replication cycle, its expression was 
particularly high early in infection (3 hours post-infection). 
A time course of infection was also carried out for the Uganda-A ASFV 
isolate which was adapted to grow in IBRS2 tissue culture cells. Infected cell extracts 
were analyzed by SDS/PAGE followed by Western blotting. The expression of ASFV 
proteins was monitored by probing the blots with pig hyperimmune anti-ASFV 
antiserum (figure 3.6, A). The early to late switch in protein expression was clearly 
visible between 10 and 24 hours post-infection, with the expression of 10 novel late 
proteins (Ll to LIO). When the blots were probed with anti-UBCv antiserum (figure 
3.6, B), an immunoreactive protein of 29 kDa was detected from 4 to 24 hours post-
infection. In this experiment the total amount of protein loaded on the gel at each time 
point was the same and the results show that the concentration of UBCv in infected 
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Figure 3.4 Steady state levels of UBCv in ASFV infected pig monocytes. 
Pig peripheral blood monocytes were infected with the Malawi LIL20/1 ASFV isolate 
at a high multiplicity of infection (MOl> 10). At 3, 6, 9, 12, 16 and 24 hours post-
infection, the proteins in infected cells were analyzed by 15% SDS/PAGE followed 
by Western blotting. The blots were probed either with anti-UBCv LD9 antiserum 
(panel B) or with the LD9 pre-immune serum (panel A). Detection of bound 
antibodies was performed by ECL. In lane M, monocytes were mock infected. The 
position of UBCv and molecular weight markers (in kDa) are indicated. 
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Figure 3.5 Expression of UBCv in ASFV infected pig monocytes. 
Pig peripheral blood monocytes were infected with the Malawi L ~ 2 0 / 1 1 ASFV isolate. 
At 3, 6, 12, 16 and 24 hours post-infection, the cells were incubated for one hour with 
e SS]methionine before being lysed. Soluble proteins were successively incubated with 
anti-UBCv LD9 antiserum and protein A-sepharose. Immunoprecipitated proteins were 
separated by 15% SDS/PAGE and detected by fluorography. In lane M, cells were 
mock infected. The position of UBCv and molecular weight markers (in kDa) are 
indicated. 
97 
55 
40 
31 
21 
14 
97 
55 
40 
31 
21 
14 
M 2 4 6 8 10 24 
M 2 4 6 8 10 24 
L1 
L2 
L3 
L4 
L5 
L6 
L7 La 
L9 
L10 
L1 
L2 
L3 
L4 
L5 
L6 
L7 La 
L9 
L10 
M 2 4 6 8 10 24 
M 2 4 6 8 10 24 
Figure 3.6 Effect of an inhibitor of DNA synthesis (AraC) on the level of 
UBCv in ASFV infected cells. 
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Figure 3.6 Effect of an inhibitor of DNA synthesis (AraC) on the level of 
UBCv in ASFV infected cells (facing page). 
Tissue culture IBRS2 cells were infected with the Uganda-A ASFV isolate in normal 
media (panels A and B) or in the presence of 50 jLg.mI-l of AraC (panels C and D). 
At 2, 4, 6, 8, 10 and 24 hours post-infection infected cell extracts were subjected to 
12.5% SDS/PAGE followed by Western blotting. The blots were probed either with 
pig hyperimmune anti-ASFV antiserun: ( p ~ e l s s A and C) or with anti-UBCv LD9 
antiserum (panels B and D). Bound antibodIes were detected by ECL. The position 
of UBCv, late proteins (Ll to LlO) and molecular weight markers (in kDa) are 
indicated. 
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cells increased steadily during ASFV replication. These results suggest that UBCv is 
stable since its relative synthesis is greatest early in infection but it accumulates to 
higher levels late in infection. 
Late ASFV gene expression depends on the replication of the viral genome 
and can be suppressed by adding an inhibitor of DNA synthesis such as cytosine-
arabinoside (AraC) to ASFV infected cells (Esteves et al., 1986; Santaren and 
Vinuela, 1986; Escribano and Tabares, 1987). To confirm that UBCv was an early 
ASFV protein, IBRS2 cells were infected with the U ganda-A ASFV isolate in the 
presence of AraC. The infected cell extracts were again analyzed at various times 
post-infection by SDS/PAGE followed by Western blotting. Probing the blots with 
anti-ASFV antiserum confirmed that AraC strongly inhibited the expression of ASFV 
late proteins since only low levels of two out of ten late proteins (L5 and L6) were 
detected (figure 3.6, C). When the blots were probed with anti-UBCv antiserum 
(figure 3.6, D), the UBCv enzyme was still detected from 4 to 24 hours post-infection 
in the presence of AraC although a slight decrease in UBCv immunoreactivity at 24 
hours post-infection was observed. The UBCv enzyme was therefore present early 
until late in ASFV infected cells although its expression was not dependent on the 
replication of the viral genome. This indicated that the UBCv enzyme was part of the 
persistent early category of ASFV proteins. 
3.2 Subcellular localization of UBCv 
3.2.1 UBCv localisation in ASFV infected cells 
Indirect immunofluorescence using anti-UBCv antiserum was carried out on fixed and 
permeabilized tissue culture IBRS2 cells infected with the Uganda-A ASFV isolate. 
Although no staining was observed in mock infected cells (figure 3.7, A), the specific 
UBCv signal in infected cells only rose slightly above background late in infection 
(figure 3.7, B). The staining by anti-UBCv antiserum appeared diffuse but confined 
to the cytoplasm, with no detectable staining of the plasma membrane, nucleus or 
viral factories. In a parallel experiment the ASFV viral factories were readily stained 
in infected cells using anti-DNA monoclonal antibodies (figure 3.8). 
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Figure 3.7 Indi.·ect anti-UBCv immunofluorescence of ASFV infected cells. 
Tissue culture IBRS2 cells were either mock infected (panel A) or infected with the 
Uganda-A ASFV isolate (panel B). At 16 hours post-infection, the cells were fixed 
and permeabilized in ice cold acetone/methanol. The fixed cells were probed with 
anti-UBCv LD9 antiserum followed by FITC conjugated secondary antibody . The 
photographs were taken with a Vickers incidence fluorescence microscope (x400 
magnification). 
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Figure 3.8 Indirect. anti-DNA immunofluorescence of ASFV infected cells. 
Tissue culture lBRS2 cells were either mock infected (panel A) or infected with the 
Uganda-A ASFV isolate (panel B). At 16 hours post-infection, the cells were fixed 
and permeabilizedin ice cold acetone/methanol. The fixed cells were probed with 
anti-DNA monoclonal antibodies (Boehringer Mannheim) followed by FITC 
conjugated secondary antibody. The photographs were taken with a Vickers incidence 
fluorescence microscope (x400 magnification). 
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Figure 3.9 Anti-UBCv inununogold labelling of ASFV infected cells, detail of 
a virus factory. 
Tissue culture IBRS2 cells were infected with the Uganda-A ASFY isolate. At 16 
hours post-infection , the cells were fixed and el1Jbedded in araldite. Thin sections were 
probed with anti-UBCv antiserum followed by gold labelled secondary antibodies. 
The photograph was taken with a Philips EM410 electron microscope (x26000 
magnification) . 
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Figure 3.10 Anti-UBCv immunogold labelling of ASFV infected cells, details of 
virus par1icles. 
Tissue culture IBRS2 cells were infected with the Uganda-A ASFV isolate, At 16 
hours post-infection , the cells were fixed and embedded in araldite. Thin sections 
were probed with anti-UBCv antiserum followed by gold labelled secondary 
antibodies. The photographs were taken with a Philips EM410 electron microscope 
(x60000 magnification). 
Analysis of UBCv in ASFV infected cells - 79 _ 
The tissue culture cells infected with ASFV were also analyzed by electron 
microscopy. The cells were fixed and thin sections were immunogold labelled with 
anti-UBCv antiserum. The gold labelled anti-UBCv antibodies were equally 
distributed between the cytoplasm and the viral factories without appearing to 
decorate any specific intracellular structure, although gold particles, sometimes in 
clusters, were occasionally seen associated with virus capsids (figure 3.9). At a higher 
magnification, gold labelled anti-UBCv antibodies could also be seen inside 'empty' 
and electron dense ASFV virions (figure 3.10). 
3.2.2 Detection of UBCv in purified ASFV particles 
To investigate the possibility that UBCv was present in ASFV virions, extracellular 
U ganda-A ASFV virus particles were purified by equilibrium centrifugation in Percoll 
density gradients (Carrasco sa et aZ., 1985). The protein content of the purified virus 
preparation was assessed by two dimensional gel electrophoresis (figure 3.11). 
Approximately 50 proteins were detected including the two major ASFV structural 
proteins, VP72 and VP150, which is consistent with previous observations made with 
ASFV virion proteins (Esteves et aZ., 1986; Urzainqui et aZ., 1987). Furthermore the 
virus preparation was free of vesicle contaminants since no proteins of above 150 kDa 
molecular weight could be detected (Carrascosa,AL et aZ., 1985). 
The purified ASFV preparation was fixed and thin sections were immunogold 
labelled using anti-UBCv antiserum (figure 3.12). Gold particles were clearly seen 
associated with approximately 50 % of the ASFV extracellular particles. The purified 
ASFV proteins were also separated by SDS/PAGE and Western blotted. Probing the 
blot with anti-UBCv antiserum revealed a single immunoreactive 29 kDa protein 
(figure 3.13, lane 2). This confirmed that UBCv was present in ASFV particles, 
albeit in low amounts since no major corresponding 29 kDa protein could be detected 
by silver staining (figure 3.13, lane 1). 
Acidic 
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Figure 3.11 Two-dimensional analysis of proteins in purified extracellular 
ASFV particles. 
The Uganda-A ASFV isolate was grown in IBRS2 cells and purified by equilibrium 
centrifugation in Percoll density gradients (Carrascosa et a/., 1985). The purified virus 
was subjected to isoelectric focusing (IEF) in the first dimension followed by 12.5% 
SDS/PAGE in the second dimension. The separated proteins were detected by silver 
staining. The positions of molecular weight markers (in kDa) and of the two main 
ASFV structural proteins VP72 and VP150 are indicated. 
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Figure 3.12 Anti-UBCv immunogold labelling of purified extracellular ASFV 
particles. 
Percoll purified ASFV particles (Uganda-A isolate) were fixed and embedded in 
araldite. Thin sections of ASFV particles were probed with anti-UBCv antiserum 
followed by gold labelled secondary antibodies. The photographs were taken with a 
Philips EM410 electron microscope (xl20000 magnification). 
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Figure 3.13 Presence of UBCv amongst the structural proteins of purified 
extracellular ASFV particles. 
Proteins from Perc oIl purified ASFV particles (Uganda-A isolate) were separated by 
15% SDSIPAGE and either silver stained (lane 1) or Western blotted (lane 2). The 
blot was probed with anti-UBCv antiserum and bound antibodies were detected by 
ECL. The positions of molecular weight markers (in kDa) and UBCv are indicated. 
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3.3 Inhibition of unCv activity during ASFV replication 
3.3.1 Effect of antisense UBCv oligonucleotides on UBCv expression 
The successful inhibition of virus gene expression by synthetic antisense 
oligonucleotides has been demonstrated with RNA and DNA viruses alike (Agrawal, 
1992; Bishofberger and Wagner, 1992) although no experiments involving ASPV 
have been reported. The expression of the targeted virus genes was shown to be 
severely reduced by incubating infected cells with antisense oligonucleotides 
complementary to the gene's 5' end (Matsukura et ai., 1989; Leiter et ai., 1990). 
Vero tissue culture cells infected with the BA 71 V ASPV isolate were chosen 
for the UBCv antisense experiments because the efficiency of oligonucleotide uptake 
by pig macrophages was undefined. The two synthetic oligonucleotides tested were 
either complementary to the coding strand of the 5' end of the UBCv gene (UBCV<-») 
or of random sequence (dN) (table 3.2). 
Vero cells were infected with the BA 71 V ASPV isolate in the presence or 
absence of the UBCv(-) and dN oligonucleotides. The infected cells were harvested at 
various times post-infection and analyzed by immunoblotting using anti-ASPY 
antiserum (figure 3.14, A). Both early and late ASPV proteins were expressed in the 
presence of either of the two oligonucleotides. At 8 hours post-infection however, the 
expression of late ASPV proteins appeared to be retarded in the presence of the 
[ Name I Target I Sequence (5' to 3') I 
UBCv(-) UBCv,5'end CTGCTATTAAAAACCTGGAAACCAT 
dN Random sequence d(AGCT)25 
Table 3.2 Sequence of the antisense oligonucleotides. 
The 24- and 25-mer oligonucleotides were phosphorothioate analogues (sulphur 
backbone) as it was shown that their resistance to nuc1eases increased their intra- and 
extra-cellular half-lives (Hoke et al., 1991; Agrawal, 1992; Thierry and Dritschilo, 
1992). The UBCv(-) oligonucleotide was complementary to the first 8 codons of the 
UBCv gene from the BA 71 V ASPV isolate (Rodriguez et al., 1992b). The start codon 
is underlined. 
A dN UBCv H 
M 4 8 24 M 4 8 24 M 4 8 24 
B dN UBCv(-) 
kDa 
97 
66 
40 
31 
21 
14 
M 4 8 24 M 4 8 24 M 4 8 24 
Figure 3.14 Effect of an antisense UBCv oligonucleotide on ASFV 
replication and on UBCv expression. 
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Figure 3.14 Effect of an antisense UBCv oligonucleotide on ASFV replication 
and UBCv expression (facing page). 
Vero tissue culture cells were pre-incubated either with no oligonucleotide (-), the 
UBCv(-) antisense oligonucleotide (25 j.tM) or the dN random oligonucleotide (25 j.tM) 
for 16 hours before infection with the BA 71 V ASFV isolate. At 4,8 or 24 hours post-
infection, the infected cells were harvested and analyzed by SDS/PAGE followed by 
Western blotting. The blots were either probed with hyperimmune pig anti-ASFV 
antiserum (panel A) or with anti-UBCv LD9 antiserum (panel B). Bound antibodies 
were detected by ECL. The positions of UBCv and molecular weight markers (in 
kDa) are indicated. 
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UBCv(-) and dN oligonucleotides. Probing the blots with anti-UBCv antiserum (figure 
3.14, B) showed that UBCv was expressed from 4 to 24 hours post-infection even in 
the presence of the UBCv(-) antisense oligonucleotide. Although a slight decrease in 
UBCv immunoreactivity was observed at all time points in the presence of the 
UBCv(-) antisense oligonucleotide, an even greater decrease was observed in the 
presence of the dN random sequence oligonucleotide. 
Taken together these results indicated that the synthetic UBCv(-) antisense 
oligonucleotide did not specifically affect UBCv expression and was therefore not 
suitable for inhibiting UBCv activity in ASFV infected cells. 
3.3.2 ASFV replication in cells impaired in the uhiquitin pathway 
The TS20 cells are temperature sensitive cell cycle mutants of the Chinese hamster 
E36 cell line (Kulka et al., 1988; Lenk et al., 1992). The defect in the mutant TS20 
cells is due to their thermolabile ubiquitin activating (El) enzyme. Since UBC 
enzymes are incapable of using ubiquitin without an El enzyme, the TS20 cells are 
unable to support ubiquitin conjugation at the non-permissive temperature. 
The TS20 and E36 wild type cells were infected for various durations with the 
Uganda-A ASFV isolate at the permissive or non-permissive temperature. The 
infected cell extracts were analyzed by immunoblotting using anti-ASFV antiserum. 
At the permissive temperature, the pattern of viral protein expression in both the 
TS20 and E36 cells was typical of ASFV infection in tissue culture cells (figure 3.15, 
A and C). Early ASFV proteins were detected from 2 to 8 hours post-infection and 
10 additional late ASFV proteins (Ll to LlO) were detected at 24 hours post-
infection. 
At the non-permissive temperature the infection appeared to proceed normally 
from 2 to 8 hours post-infection in the TS20 and E36 cells (figure 3.15, B and D). 
At 24 hours post-infection however late ASFV protein expression was altered in both 
cell types at the non-permissive temperature. In the E36 cells 4 out of the 10 late 
proteins were detected (L3, L5, L7 and L8), whereas in the TS20 cells only two late 
proteins could be detected (L4 and L5). Furthermore, in TS20 cells one late protein 
(Ll) was prematurely expressed from 4 hours post-infection onwards and two 
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Figure 3.15 ASFV protein expression in E36 and TS20 cells at the 
permissive and non-permissive temperatures. 
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Figure 3.15 ASFV protein expression in E36 and TS20 cells at the permissive 
and non-permissive temperatures (facing page). 
E36 wild type cells (panels A and B) or TS20 mutant cells (panels C and D) were 
infected with the Uganda-A ASFY isolate. From 2 hours before infection onwards the 
cells were incubated either at the 30°C permissive temperature (panels A and C) or 
at the 40.5°C non-permissive temperature (panels B and D). At 2, 4, 6, 8, 10 and 24 
hours post-infection the cells were lysed and the extracts analyzed by 12.5 % 
SDS/PAGE followed by Western blotting. The blots were probed with anti-ASFY 
hyperimmune pig antiserum and bound antibodies were detected by ECL. In lane M 
the cells were mock infected. The position of molecular weight markers (in kDa) and 
of late proteins (LI to LlO) are indicated. 
A B 
E36 TS20 
c D 
Figure 3.16 Indirect anti-ASFV immunofluorescence of E36 and TS20 
cells infected with ASFV at the non-permissive temperature 
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Figure 3.16 Indirect anti-ASFV immunofluorescence of E36 and TS20 celIs 
infected with ASFV at the non-permissive temperature (facing 
page). 
E36 wild type cells (panels A and C) and TS20 mutant cells (panels B and D) were 
infected with the Uganda-A ASFV isolate for either 3 hours (panels A and B) or 24 
hours (panels C and D). The cells were incubated from 2 hours before infection 
onwards at the 40.5°C non-permissive temperature. The infected cells were fixed in 
acetone/methanol and probed with anti-ASFV hyperimmune pig antiserum followed 
by FITC-conjugated secondary antibodies. The photographs were taken with a Vickers 
incidence fluorescence microscope (magnification: panels A and B x400, panels C and 
D x200). 
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persistent early proteins (14 and 16 kDa) were absent late in infection at the non-
permissive temperature. 
The ASFV infected TS20 and E36 cells were also observed at the non-
permissive temperature by immunofluorescence using anti-ASFV antiserum. The 
TS20 and E36 cells showed similar patterns of immunofluorescence at 3 hours post-
infection (figure 3.16, A & B). The cytosol of E36 and TS20 cells was diffusely 
stained and perinuclear viral factories were clearly visible. At 24 hours post-infection 
both TS20 and E36 cells were intensely stained indicating that high levels of viral 
proteins were present (figure 3.16, C & D). The number of remaining TS20 infected 
cells at 24 hours post-infection was however significantly higher (over three times) 
than for the infected E36 wild type cells, possibly indicating that cell lysis was 
delayed or inhibited. This phenomenon was not observed at the permissive 
temperature (data not shown). 
These results suggested that in cells defective in the ubiquitin conjugation 
pathway, the replication of ASFV proceeded normally through the early phase but the 
late phase of infection was partially impaired or delayed. Since in wild type cells the 
expression of late ASFV proteins was also altered at the non-permissive temperature, 
albeit not as much as in the mutant TS20 cells, it is likely that part of the ASFV late 
phase impairment in TS20 cells was due to heat shock. Because of the interference 
of heat shock stress with ASFV replication during the long incubation periods 
necessary for ASFV infection (over 36 hours), this system is not suited for further 
investigations into the nature of the ASFV late phase impairment in TS20 cells. 
3.3.3 Construction of an ASFV UBCv null mutant 
The role of several poxvirus genes has been elucidated by constructing mutant 'knock-
out' viruses (Blasco et al., 1991; Alcami and Smith, 1992; Johnson et al., 1993). In 
these experiments the targeted genes were inactivated by disruption with a reporter 
gene (figure 3.17). This general approach has also been shown to be applicable to 
ASFV (Rodriguez et al., 1992a). Efficient isolation of these mutant viruses can be 
achieved in tissue culture by using dominant selection reporters such as the neomycin 
resistance or guanine phosphoribosyltransferase (gpt). genes (Franke et al., 1985; 
Falkner and Moss, 1988). 
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Figure 3.17 Schematic representation of the generation of 'knock-out' 
mutants by homologous double DNA recombination. 
Cells infected with the virus are transfected with a DNA vector which contains a 
reporter gene flanked by sequences homologous to the viral gene to be disrupted. 
During the replication of the virus, the exogenous DNA is integrated in the viral 
genome by homologous double recombination. The progeny mutant viruses are then 
selected with the help of the reporter gene. 
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Cells of the macrophage lineage are the only cells in which virulent ASFV 
isolates replicate. Growth of these cells is not inhibited in the media used for these 
selection markers (Vydelingum, personal communication). These selectable markers 
Cannot therefore be used to isolate recombinant viruses expressing these marker genes 
in macrophages. The firefly luciferase gene was therefore chosen as the reporter in 
ASFV 'knock-outs' since although it confers no selection advantage, it is a very 
sensitive marker which can be used in all cell types since there is no background 
luciferase activity (Rodriguez et al., 1988; Kovacs and Mettenleiter, 1991; Rodriguez 
et al., 1992). Use of a reporter gene that can be used both in tissue culture and 
macrophage cells would enable the same constructs to be used to manipulate the 
genomes of both virulent and tissue culture adapted ASFV isolates. 
The PH3 transfer vector (figure 3.18) was constructed with UBCv gene 
sequences flanking a luciferase reporter gene driven by the p72 promoter (ASFV 
promoter for the late protein VP72). The UBCv gene was amplified by PCR from the 
genome of the BA71V ASFV isolate and ligated into the pGEM-T plasmid 
(Promega). The p72-luciferase cassette was cut out of the pGEM-p72/luc plasmid 
(generous gift from Dr. I.M. Hammond) and inserted in the TthlllI restriction site 
located in the centre of the UBCv gene, yielding plasmid PH3 in which the p72 
driven luciferase reporter is flanked by UBCv sequences 347 bp and 282 bp in length. 
The construction of plasmid PH3 was verified by the PCR amplifications of its 
various components using the primers described in table 3.3 (figure 3.19). The sizes 
of the PCR products were consistent with the desired PH3 construct (table 3.4). 
The PH3 plasmid was purified from E. coli and the activity of the luciferase 
reporter was tested in transient expression assays. PH3 plasmid DNA was transfected 
into tissue culture IBRS2 cells infected with the Uganda-A ASFV isolate. At 24 hours 
post-infection the infected cells were lysed and the extracts were mixed with a buffer 
containing coenzyme A and beetle luciferin. The luminescent reaction between the 
luciferase enzyme and its luciferin substrate was measured with a liquid scintillation 
counter. The luminescence of the infected cell extracts transfected with PH3 was over 
20.106 counts per minute (cpm). In contrast, the background luminescence of both 
non-infected and non-transfected cell controls remained below 50 cpm. 
ASFV Sail fragment SH (BA71V) 
u.I iiiI 
pGEM-T/UBCv 
3.6 kb 
f10ri 
Digest wit 
Tth1111 Blunt end 
& ligate 
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5.6 kb ori 
peR 
UBCv 
Figure 3.18 Construction of the PH3 transfer vector 
UB7 
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Figure 3.18 Construction of the PH3 transfer vector (facing page). 
The UBCv gene was amplified by PCR with primers UB7 and UB8 (table 3.3) using 
as template DNA from a plasmid clone (SH) containing the Sal! fragment H of the 
BA71V ASFV isolate (Almendral et al., 1984). The unique 650 bp PCR product was 
purified using a Magic PCR column (promega) and ligated in plasmid pGEM-T 
(promega) yielding plasmid pGEM-T/UBCv. The pGEM-T/UBCv plasmid was 
digested with the TthlllI restriction enzyme and the DNA ends generated were end 
filled using . the Klenow fragment of DNA polymerase and dNTPs, then 
dephosphorylated with calf intestinal phophatase (CIP). The p72-luc cassette was 
constructed by Dr. J. Hammond. Briefly, the p72 promoter was amplified by PCR 
with the p72-1 and p72-2 primers (table 3.3) from the genome of the Malawi LIL20/1 
ASFV isolate and the unique 250 bp PCR product was cloned in the Bamffi site of 
the pGEM-Iuc plasmid (Promega). The p72-luc cassette was then cut out of the 
pGEM-p72/luc plasmid with the HindIII and SfiI restriction enzymes and the DNA 
ends generated were end filled using the Klenow fragment of DNA polymerase and 
dNTPs. The 2 kb p72-luc fragment was purified from an agarose gel using the 
Geneclean kit (BiolOl) and ligated with the Tthll11 cut pGEM-T/UBCv vector. The 
ligation mixture was transformed in E. coli JMIOI cells and an ampicillin resistant 
Colony containing the PH3 plasmid was grown in 1 litre of LB and 370 fJ.g of PH3 
plasmid DNA was purified using a Magic Maxiprep column (Promega). 
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[Name I Position I Sequence (5' to 3') I 
UB7 UBCv, 3' end TTACTCATCATCCATCTCTTCA 
UB8 UBCv, 5' end TAGCAGAGTACAGACACCTG 
UB9 UBCv, liS 3' end CATAGTCTTCCATCAGGGTAA 
UB10 UBCv, liS 5' end ACTTGGTCTCCGGCTCAAA 
p72-1 p72, 5' end GAGCTCGTCGCGCTGACTGGCCAAAGGG 
p72-2 p72, 3' end GTCGACAAAAAGCTCCTCCTGATGCCAT 
Luc2 Luciferase, 3' end GTTACATTTTACAATTTGGACTTT 
Table j •• Se uence or the rlIllers used to ampliry the UBCv ene and verW q p g y 
the construction of plasmid PH3. 
The oligonucleotides were complementary to the UBCv gene from the BA 71 V ASFV 
isolate (UB7-UBlO) (Rodriguez et al., 1992b), the 250 bp region upstream of the 
Malawi LIL20/1 structural protein VP72 (p72) (P72-1 & p72-2), or the luciferase 
gene in plasmid pGEM-luc (Prom ega) (luc2). liS: insertion site of the luciferase 
reporter in UBCv (nucleotide position 300 in the BA 71 V UBCv sequence). 
[J Primers Fragment amplified Expected Observed size (bp) size (bp) 
PI UB8 UB9 UBCvL 260 250 
P2 UB8 p72-1 UBCvL+ Luc+p72 2185 2150 
P3 UB8 UB7 UBCvL+ Luc+p72+ UBCvR 2530 2500 
P4 Luc2 p72-1 Luc+p72 1925 1950 
P5 Luc2 UB7 Luc+p72+UBCvR 2270 2250 
P6 p72-2 p72-1 p72 250 250 
P7 p72-2 UB7 p72+UBCvR 595 600 
P8 UBI0 UB7 UBCvR 345 350 
Table 3.4 Sizes of the PCR products amplIfied from the PH3 plasmid. 
The components of plasmid PH3 were amplified by PCR (PI to P8) using the primers 
described in table 3.3. The expected and observed size of the PCR products are 
indicated. UBCvL/R: left and right UBCv arms, p72: ASFV VP72 promoter, Luc: 
luciferase gene. 
A 
B 
Ub7 Luc2 ~ ~ ~ ~
I UBCvlL1 
<OIII(i 
Ub9 
M 
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Figure 3.19 Verification of the PH3 construct by peR amplifications. 
Eight PCR amplifications, PI to P8, were carried out with plasmid PH3 as template 
DNA (see table 3.4). The peR primers were complementary to locations on plasmid 
PH3 indicated in panel A. Panel B: analysis by 1 % agarose electrophoresis of the PI-
P8 PCR products (lanes 1 to 8 respectively). The sizes of the DNA markers (M) are 
indicated to the right. 
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Figure 3.20 Detection of ASFV luminescent plaques transiently expressing 
the luciferase reporter 
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Figure 3.20 Detection of ASFV luminescent plaques transiently expressing the 
luciferase reporter (facing page). 
A diagram of the method used for the detection of luminescent ASFV plaques is 
shown in panel A. IBRS2 cells were grown to confluence in 25 mm diameter tissue 
culture inserts with 0.45 J,tm pores (Falcon). The cells were infected with ASFV 
(Uganda-A, 0.1 multiplicity of infection) for one hour and then transfected for 5 
hours with 2 J,tg of PH3 plasmid DNA (Lipofectin, Gibco BRL). The cells were 
overlayed with 1 % agar and incubated at 37°C for a further 16 hours. The cells were 
then incubated with beetle luciferin and a plasma membrane permeabilizing agent 
(nigericin, Sigma) before exposing the inserts to high sensitivity film (Tmax 400ASA, 
Kodak) for 1 hour at 37°C. The film was developed (HC1lO, Kodak) showing the 
presence of luminescent ASFV plaques (panel B). 
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A technique was also developed for the detection of ASFV plaques expressing 
the luciferase reporter (figure 3.20, A). Using this method, luminescent plaques could 
be detected in ASFV infected cells transfected with plasmid PH3 (figure 3.20, B). 
Progeny viruses of ASFV infected cells transfected with plasmid PH3 were 
harvested and passaged in fresh cells. The presence of ASFV mutants in the progeny 
was tested by luminescence plaque assays and scintillation counting. Despite repeated 
attempts, no luciferase activity was detected in passages after the initial transfection 
with the PH3 plasmid (data not shown). The failure to isolate a mutant ASFV with 
a luciferase disrupted UBCv gene suggested that the UBCv gene was essential for 
ASFV replication. 
3.4 Discussion 
The UBCv enzyme was detected by Western blotting both in primary pIg 
macrophages infected with the virulent ASFV Malawi LIL20/1 field isolate and in 
tissue culture cells infected with attenuated Uganda-A and BA 71 V ASFV isolates. 
These findings supported the hypothesis that the UBCv gene apparently present in all 
ASFV isolates was functional (§ 2.1.2). The UBCv enzyme was expressed both in the 
early and late phases of ASFV replication, in agreement with the reported presence 
of UBCv mRN A in early and late BA 71 V infected cells (Rodriguez et ai., 1992b). 
Furthermore the intracellular concentration of UBCv increased throughout the 
replication of ASFV which indicated that the UBCv protein had a long half-life. This 
suggested that UBCv does not target itself for proteolysis as the UBCv auto-
ubiquitination activity observed in vitro might have suggested. Moreover, no ladder 
of products above the UBCv enzyme band was detected in infected cells, indicating 
that UBCv is probably not auto-ubiquitinated in vivo. 
The UBCv enzyme was faintly detected by immunofluorescence in the 
cytoplasm of ASFV infected cells only late in infection. This staining was typical of 
soluble cytosolic antigens which are difficult to resolve by immunofluorescence. A 
higher resolution was achieved by electron microscopy which confirmed that UBCv 
was not associated with any subcellular structure. The finding that UBCv was present 
in ASFV particles by both immunogold labelling and immunoblotting was surprising 
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since UBCv was not detected by immunofluorescence in high concentration in viral 
factories where virion morphogenesis takes place. The presence of UBCv in ASFV 
particles might be spurious and not essential for its function since many other 
cytosolic proteins such as actin and J3-tubulins are also detected in purified virus 
particles (see §1.2.1). Alternatively, UBCv may be packaged inside ASFV virions 
and may not be accessible to antibodies. 
It was not possible to inhibit UBCv expression in ASFV infected cells using 
antisense oligonucleotides. The concentration of viral mRNA might have been too 
high for the antisense oligonucleotides to have any notable effect. Alternatively the 
oligodeoxynucleotides-mRNA heteroduplexes might have been dissociated by the 
putative helicases of unknown function or activity encoded by the ASFV genome 
(Baylis et al., 1993b; Nellen and Lichtenstein, 1993; Roberts et al., 1993). 
The late phase of ASFV replication appeared to be impaired at the non-
permissive temperature in a cell line (TS20) with a thermo sensitive E1 enzyme which 
is defective in the ubiquitin conjugation pathway. The partial inhibition of ASFV 
replication might be explained by the incomplete shut-off of E1 enzyme activity at the 
non-permissive temperature (Kulka et al., 1988). The defect of ASFV replication in 
TS20 cells was consistent with the UBCv enzyme playing an important role in ASFV 
replication, although the possibility that this defect might be the result of the 
inhibition of one or more of the host's cell UBC enzymes could not be ruled out. 
Since early ASFV replication was apparently unaffected in TS20 cells at the non-
permissive temperature, it was unlikely that UBCv played a role in early replication 
events such as virus uncoating. 
An ASFV mutant with the UBCv gene disrupted by the luciferase reporter 
gene could not be isolated. This experiment was therefore inconclusive since only a 
positive result would have allowed a definite conclusion to be drawn. In addition, 
since there was no unequivocal evidence for the successful insertion of the luciferase 
reporter in a known non-essential region of the ASFV genome (Vydelingum, personal 
communication), it cannot be definitely concluded that the UBCv gene is essential for 
virus replication in tissue culture. 
On the basis of the UBCv in vivo analysis, it is not possible to assign a 
specific role to the UBCv enzyme in ASFV replication. It seems more likely however 
that UBCv participates in late ASFV replication since the enzyme accumulates at this 
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late stage and early replication was not apparently inhibited in cells defective in 
ubiquitin conjugation. Possible roles for UBCv late in replication are in viral DNA 
replication, late gene expression, virion morphogenesis or virus release. The results 
obtained also do not eliminate a possible host cell modulating function for UBCv. 
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Chapter 4 
Characterization of ubiquitin conjugates in ASFV 
particles 
---0---
An important part in both the biochemical and functional characterization of the 
UBCv enzyme is the identification of its physiological substrates. Apart from 
exhaustive in vitro testing of potential substrates of both viral and cellular origin 
(using the system described in §2.3), this aim could be achieved by searching for 
novel ubiquitin conjugates in ASFV infected cells. Ubiquitin conjugates can be 
detected in cell extracts by immunological techniques using commercial anti-ubiquitin 
antisera that recognize both free and conjugated ubiquitin (Haas and Bright, 1985; 
Haas, 1988; Magnani et aI., 1991). Any novel ubiquitinated proteins thus identified 
in infected cells would be potential substrates of the UBCv enzyme which could then 
be characterized further. 
4.1 Analysis of ubiquitin conjugates during ASFV replication 
4.1.1 Presence of ubiquitin conjugates in ASFV infected cells 
The ubiquitin conjugates present in ASFV infected tissue culture cells were examined 
at various times post-infection following separation by SDS/PAGE by immunoblotting 
using a commercial anti-ubiquitin antiserum (Dakopatts). This antiserum is raised in 
rabbits against bovine ubiquitin conjugated to the keyhole limpet haemocyanin carrier 
protein and recognizes ubiquitin either free or conjugated to cellular proteins. 
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Figure 4.1 Analysis of ubiquitin conjugates in ASFV infected cells. 
Tissue culture IBRS2 cells were infected with the Uganda-A ASFV isolate. At 
2,4,6,8,10 and 24 hours post-infection, infected cell extracts were analysed by 12.5% 
SDS/PAGE followed by Western blotting. The blot was probed with affinity purified 
anti-ubiquitin antiserum (Dakopatts) and bound antibodies were detected by EeL. M: 
mock infected cells. Molecular weight markers (in kDa) are indicated to the left. 
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The anti-ubiquitin immunoblot of ASFV infected cell extracts is shown in 
figure 4.1. The same broad range of anti-ubiquitin immuno-reactive proteins was 
detected at all time points post-infection. These ubiquitin conjugates were similar to 
those present in mock infected cells, indicating that they were normal cellular 
ubiquitin conjugates and were not specifically induced by virus infection. Nonetheless, 
a significant increase in the overall intensity of anti-ubiquitin immunoreactivity above 
30 kDa was observed early and very late in ASFV infection (2 to 4 and 24 hours 
post-infection) . 
A duplicate blot of the infected cell extracts was also reacted with anti-ASFV 
antiserum (see §3.1.2 figure 3.6, A) which confirmed that normal ASFV induced 
protein expression had taken place up to 10 (early) and 24 (late) hours post-infection. 
Since the total amount of protein loaded was the same in each lane of these gels, 
variations in levels of ubiquitin conjugates did not result from variations in quantities 
of protein loaded. These results showed that although the pattern of ubiquitin 
conjugates was unaltered in ASFV infected cells, a non-specific increase in the 
concentration of high molecular weight ubiquitin conjugates was observed during 
early and very late ASFV replication. 
4.1.2 Subcellular localization of ubiquitin conjugates in ASFV infected 
cells 
Tissue culture cells were infected with ASFV and observed by immunofluorescence 
using anti-ubiquitin antiserum. The cytoplasm of mock infected cells was weakly 
stained (figure 4.2, A), whereas prominent perinuclear structures reminiscent of 
ASFV viral factories were intensely stained by anti-ubiquitin antibodies late in ASFV 
infection (figure 4.2, B). 
Fixed and permeabilized ASFV infected cells were also probed with rabbit 
anti-ubiquitin antiserum together with a mouse monoclonal antibody that recognizes 
the ASFV structural protein VP72 which is found in viral factories (Carrasco sa et at., 
1986). The bound primary antibodies were then detected using FITC-conjugated anti-
rabbit IgG and rhodamine-conjugated anti-mouse IgG antisera. The double staining 
A B 
c D 
Figure 4.2 Indirect anti-ubiquitin immunofluorescence of ASFV 
infected cells. 
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Figure 4.2 Indirect anti-ubiquitin immunofluorescence of ASFV infected cells 
(facing page). . 
Tissue culture IBRS2 cells were either mock infected (panel A) or infected with the 
Dganda-A ASFV isolate (panels B, C and D). At 16 hours post-infection, t h ~ ~ cells 
were fixed and permeabilized in ice cold acetone/methanol. In panels A, Band C, the 
fixed cells were probed with anti-ubiquitin rabbit antiserum followed by FITC 
conjugated secondary antibody. Panel D shows the saine field as panel C but probed 
with anti-VP72 mouse monoclonal antibodies followed by rhodamine conjugated 
secondary antibodies. The 'photographs were taken with a Vickers incidence 
fluorescence microscope (x400 magnification). 
' .. \ 
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showed that the anti-ubiquitin staining observed late in ASPV replication (figure 4.2, 
C) co-localized with the viral factories identified by the anti-VP72 antibodies (figure 
4.2, D). The speckled anti-VP72 staining of the cytoplasm of ASPV infected cells 
was not seen with the anti-ubiquitin antiserum and probably represented mature virus 
particles migrating to the plasma membrane. 
Thin sections of ASPV infected cells were probed with gold labelled anti-
ubiquitin antibodies and observed by transmission electron microscopy (TEM). The 
gold labelled anti-ubiquitin antibodies were associated with ASPV virions in viral 
factories (figure 4.3, A). In contrast to the immunofluorescence analysis, TEM also 
showed that mature ASP V virions migrating to the plasma membrane (figure 4.3, B) 
and enyeloped extracellular virions (figure 4.3, C) were decorated by the anti-
ubiquitin antibodies. 
The position relative to the virus capsid of 115 gold particles was measured 
for 52 virions with a clear hexagonal outline (figure 4.4). This showed that 70% of 
the gold labelled anti-ubiquitin antibodies were situated inside the virus capsid. The 
most frequent location for anti-ubiquitin antibodies was either between the virion 
nucleo-protein core and the internal membrane or in the virus capsid. The ubiquitin 
conjugate locations identified by the gold labelled antibodies are similar to those 
determined for the VP37 core/internal membrane protein and the VP72 capsid protein 
of the BA71V ASPV isolate (Carrasco sa et al., 1986). 
The majority of the ubiquitin antigens were therefore encapsidated in the 
virions which might explain why intact mature ASPV particles migrating to the cell 
membrane could not be detected with the anti-ubiquitin antibodies by 
immunofluorescence. However, strong staining of viral factories with anti-ubiquitin 
antiserum could be observed by immunofluorescence, probably because of the 
presence in these factories of immature virions with incomplete capsids that were 
permeable to the anti-ubiquitin antibodies. 
4.1.3 Presence of uhiquitin conjugates in purified ASFV particles 
The presence of ubiquitin conjugates in viral factories and mature virions suggested 
that ASPV structural proteins might be ubiquitinated. To investigate this possibility, 
proteins in purified extracellular ASPV particles (Percoll purified, see §3.2.2) were 
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Figure 4.3 Anti-ubiquitin immunogold labelling of ASFV 
infected cells. 
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Figure 4.3 Anti-ubiquitin immunogold labelling of ASFV infected cells. 
Tissue culture IBRS2 cells were infected wi th the Uganda-A ASFY isolate. At 16 
hours post-infection the cells were fixed and embedded in araldite. Thin sections were 
probed with goat anti-ubiquitin anti serum followed by gold labelled secondary 
antibodies. The detail s of a virus factory (x32000, facing page panel A), mature 
intracellular virions (x 13000, panel B) and an extrace llular ASFY particle (x320000, 
panel C, facing page) are shown. The photographs were taken using a Philips EM410 
electron microscope. 
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Figure 4.4 Position relative to the ASFV capsid of gold labeUed anti-ubiquitin 
antibodies. 
The relative position of 115 gold particles was measured in 52 ASFV virions. A 
relative position of zero refers to the centre of the virus particle and a relative 
position of 1 corresponds to the virus capsid (panel A). In panel B the observed 
frequency (in percentage) of the relative positions of the gold particles is represented 
as a line graph. 
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Figure 4.5 Presence of ubiquitinated structural proteins in purified 
extracellular ASFV virus particles. 
Percoll purified ASFV extracellular particles (see §3.2.2) were separated by 12.5% 
SDS/pAGE. The separated proteins were either Western blotted and probed with anti-
ubiquitin antiserum (lane 2) or silver stained (lane 1). Bound antibodies on the protein 
blot were detected by EeL. The positions of the ubiquitin conjugates described in 
§4.1.3 are shown on the right. The position of molecular weight markers (in kDa) are 
indicated to the left. 
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separated by SDS/PAGE and analyzed by immunoblotting using anti-ubiquitin 
antiserum (figure 4.5, lane 2). Three strongly immuno-reactive proteins were detected 
with apparent molecular weights of 58, 18 and 5 kDa. Four additional proteins (51, 
38, 30 and 23 kDa) cross-reacted weakly with the anti-ubiquitin antiserum. The 58, 
38, 18 and 5 kDa anti-ubiquitin immuno-reactive proteins (hereafter referred to as 
UB58, UB38, UB18 and UB5 respectively) were the most likely candidates for 
genuine ubiquitin conjugates since they were consistently detected with five anti-
ubiquitin antisera tested, irrespective of the batch or manufacturer (data not shown). 
The UB5 protein was likely to correspond to free ubiquitin since ubiquitin was 
shown to migrate with an apparent molecular weight of 5.5 kDa in SDS/PAGE 
(Ciechanover et al., 1978; Wilkinson,KD, 1988). The silver staining of purified 
ASFV particle proteins (figure 4.5, lane 1) suggested that UB5 was an abundant 
component of purified ASFV particles. The high molecular weight ubiquitin 
conjugates (UBI8 to UB58), although only minor ASFV structural proteins, were 
potential substrates for the UBCv enzyme and were therefore further characterized. 
4.2 Characterization of the ubiquitin conjugates in ASFV 
virions 
4.2.1 Preliminary attempts to purify ubiquitinated ASFV structural 
proteins 
Possible approaches to further characterize the ASFV ubiquitinated structural proteins 
include protein purification followed either by N-terminal protein sequencing or by 
the production of specific antisera. The antisera could then be used to screen 
expression libraries containing either virus or cellular DNA and sequences of inserts 
in immunoreacting clones could be determined to obtain the amino acid sequence of 
the encoded protein. Protein sequences obtained using either method could be used 
to search databases to identify these substrates. Both these methods require substantial 
amounts of the proteins of interest purified to near homogeneity. To achieve this, 
three semi-preparative purification techniques were tested to obtain large quantities 
of purified ASFV ubiquitinated structural proteins. 
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Figure 4.6 Preparative liquid phase isoelectric focusing of ASFV structural 
proteins. 
Percoll purified extracellular ASFV particles (see §3.2.2) were solubilized and 
subjected to liquid phase IEF (Rotofor, Biorad). The pH of the 20 focused fractions 
collected is indicated in panel A. The proteins in each of the 20 fractions were 
analysed by 12% SDS/PAGE followed by Western blotting. The blotted proteins were 
probed with anti-ubiquitin antiserum and bound antibodies were detected by EeL 
(panel B). 
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The first method used preparative liquid phase isoelectric focusing (IEF) 
(Rotofor, Biorad). Percoll purified ASFY particles were solubilized in 8 M urea / 2 % 
NP40 and the resulting structural proteins were separated according to their isoelectric 
point (PI) into 20 fractions ranging from pH3 to pHIl (figure 4.6, A). The 20 
fractions were separated by SDS/PAGE and analyzed by immunoblotting using anti-
ubiquitin antiserum (figure 4.6, B). This showed that the ASFY ubiquitin conjugates 
were focused in fractions 8 to 10 (PI 6.3 to 7.5). Since the majority of ASFY 
Structural proteins also focused in these neutral fractions (data not shown), 
purification of ubiquitin conjugates from other virion proteins was not sufficient and 
this method was not pursued further. 
The use of anti-ubiquitin affinity chromatography offered an alternative semi-
preparative approach for the purification of ASFY ubiquitin conjugates. An affinity 
column was prepared by conjugating anti-ubiquitin antibodies to a crosslinked agarose 
matrix (Sulfolink, Pierce). Approximately 70 Ilg of anti-ubiquitin antibodies were 
linked to 1 ml of the gel matrix. The ASFY structural proteins were solubilized by 
sonicating Percoll purified ASFY particles in a disruption buffer containing 10 % 
NP40 and 1 M NaCl. The solubilized ASFY structural proteins were then 
concentrated and re-diluted in PBS buffer to remove the NP40 and NaCI before 
loading on the anti-ubiquitin column. The column was washed with a low salt buffer 
(0.2 M NaCl) and bound proteins were eluted with a high ionic strength buffer (2 M 
NaCI). The elution of proteins was monitored by measuring the UY absorbance 
(OD280) of the column effluent (figure 4.7). 
The protein content of the wash and eluate fractions was analysed by 
SDS/PAGE followed by silver staining. Surprisingly, although a strong absorbance 
peak (0.5 OD280) was recorded following the low salt wash, no proteins could be 
detected in this fraction by silver staining (figure 4.8, lane 2). The UY absorbance 
spectrum of the wash fraction revealed an absorbance maximum for A=260 nm (data 
not shown) which indicated that the wash material probably consisted entirely of 
DNA. 
In contrast to the wash fraction, several proteins were detected in the fraction 
eluted with the high salt buffer (figure 4.8, lane 3). The two most abundant proteins 
in the eluate migrated with apparent molecular weights of 12 and 140 kDa. A further 
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Figure 4.7 Purification of ASFV structural proteins by anti-ubiquitin affinity 
chromatography. 
Percoll purified extracellular ASFV particles (see §3.2.2) were solubilized and applied 
on a chromatography column consisting of anti-ubiquitin antibodies immobilized on 
an agarose gel matrix. The loaded column was washed with increasing concentrations 
of NaCI in PBS ([NaCl], right axis) and the protein content of the column effluent 
was monitored by UV absorbance (OD280 , left axis). The absorbance peaks 
corresponding to unbound ASFV structural proteins (unbound), non-specific bound 
proteins (wash) and anti-ubiquitin specific ASFV proteins (eluate) are indicated. 
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Figure 4.8 Analysis of the ASFV structural proteins eluted from the anti-
ubiquitin affinity column. 
The anti-ubiquitin affinity purified proteins contained in the wash (lane 2) and eluate 
(lane 3) fractions were analysed by 12.5% SDS/PAGE followed by silver staining. The 
silver stain of total ASPV proteins is shown in lane 1. The proteins contained in the 
eluate fraction were also analysed by immunoblotting using anti-ubiquitin antiserum 
(lane 4). The positions of molecular weight markers (in kDa) are indicated to the left. 
Characterization of ubiquitin conjugates in ASFV particles - 111 _ 
12 minor proteins were aiso eluted with the high salt buffer (5, 16, 18, 23, 30, 38, 
43, 46, 58, 72, 90, and 100 kDa). The diffuse silver staining in the upper portion of 
the eluate lane was typical of DNA contamination. This was confirmed by the UV 
absorbtion spectrum of the eluate fraction which showed that DNA (Amax=260 nm) 
accounted for 75% of the absorption measured at 280 nm (data not shown). 
The ASPV structural proteins purified by anti-ubiquitin affinity 
chromatography differed from those previously detected in Western blots and only the 
5 kDa affinity purified protein (likely to represent free ubiquitin) was recognized by 
anti-ubiquitin immunoblotting of the eluate fraction (figure 4.8, lane 4). This variation 
was probably the result of the differing antigenic properties of native compared to 
SDS denatured ubiquitin conjugates. Nonetheless, some of the minor affinity purified 
proteins migrated with molecular weights similar to those previously observed in anti-
ubiquitin immunoblots of whole virus (namely UBI8, UB30, UB38 and UB58). These 
might not have been present in sufficient quantity in the affinity chromatography 
eluate to be efficiently detected by immunoblotting. 
The eluate fractions from four successive affinity purifications (each using 500 
/lg of solubilized ASPV virions) were pooled which produced approximately 10 /lg 
of anti-ubiquitin affinity purified proteins. The purified proteins were separated by 
SDS/P AGE, transferred to a PVDP membrane and stained with Coomassie blue. The 
protein bands, although faint, were individually excised and subjected to automated 
N-terminal protein sequencing (Model 473A, Applied Biosystems). As was feared 
from the weak signal obtained by Coomassie staining, the amounts of blotted proteins 
proved insufficient to recover protein sequence data by the Edman degradation 
method. This approach to the purification of ASPV ubiquitinated structural proteins 
was abandoned since the poor yield, which probably resulted from the relatively low 
affinity interaction between the proteins and anti-ubiquitin antibodies, meant that 
prohibitively large amounts of antibodies would have to be used. 
4.2.2 Detergent extraction of ubiquitinated ASFV structural proteins 
The ASPV attachment protein VP12 which was shown to be situated outside the virus 
capsid (Carrasco sa et aZ., 1993) was partially purified from extracellular ASPV 
virions by gentle extraction with the non-ionic detergent n-octyl-/3-D-glucopyranoside 
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(OG) (Carrasco sa et ai., '1991; Alcami et ai., 1992). Since electron microscopy 
suggested that a subset of the ubiquitinated ASFV structural proteins were also located 
outside the virus capsid, it was likely that some ubiquitin conjugates would be 
released from ASFV virions by treatment with OG detergent. 
A suspension of Percoll purified ASFV extracellular particles in PBS (1 
mg.ml-I ) was incubated with various concentrations of OG for 16 hours. The 
suspension was then centrifuged on a 25 % sucrose cushion to pellet subviral ASFV 
particles and the soluble proteins contained in the supernatant were concentrated and 
analyzed by SDS/PAGE. 
The separated proteins were silver stained (figure 4.9, A) and, as expected, 
the number of structural proteins present in the supernatant increased as the 
concentration of OG detergent used was increased. The supernatant proteins were also 
analyzed by immunoblotting using anti-ASFV antiserum (figure 4.9, B) indicating that 
most immuno-reactive proteins detected in whole virus were gradually released after 
OG treatment. 
The VP72 ASFV structural protein was the only protein extracted at OG 
concentrations below 0.25%, whereas most ASFV structural proteins were extracted 
when the concentration of OG exceeded 0.5 %. The supernatant obtained after 
treatment with 0.25 % OG contained 9 major proteins of molecular weights 10.5, 12, 
14, 18,21,34,35, 72 and 150 kDa. The 12 kDa protein was probably the previously 
characterized VP12 ASFV attachment protein described above. Thus the mild 0.25 % 
OG treatment was likely to extract only ASFV structural proteins located in or outside 
the ASFV capsid. 
The OG extraction of ubiquitin conjugates was monitored by immunoblotting 
using anti-ubiquitin antiserum (figure 4.9, C). The four ASFV ubiquitin conjugates 
(UB5 to UB58) were all extracted with detergent concentrations of 1 % and above, but 
only UB18 was significantly extracted by the mild 0.25 % OG detergent treatment 
although small amounts of UB58 were also extracted at this concentration. It was 
therefore likely that UB18 was located either in or outside the capsid, whereas the 
other ASFV ubiquitin conjugates (including free ubiquitin) were probably 
encapsidated in the virion. 
The single 18 kDa protein detected in the supernatant of ASFV particles 
treated with 0.25 % OG and analyzed by silver staining (figure 4.10, lane 2) was 
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Figure 4.9 Extraction of ASFV structural proteins with the non-ionic 
detergent octyl-glucopyranoside 
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Figure 4.9 Extraction of ASFV structural proteins with the non-ionic 
detergent n-octyl-/1-D-glucopyranoside (OG) (facing page). 
Percoll purified extracellular ASFV particles (see §3.2.2) were either untreated (V) 
or incubated with various concentrations ofOG in PBS (0,0.1,0.25,0.5,1, and 5% 
OG). Particulate material was removed by centrifugation and the solubilized proteins 
were analysed by 12.5% (panels A and B) or 17.5% (panel e) SDS/PAGE. The 
separated proteins were silver stained (panel A) or Western blotted and probed with 
either anti-ASFV hyperimmune serum (panel B) or anti-ubiquitin antiserum (panel e). 
The bound antibodies were detected by EeL. The positions of the ubiquitin 
conjugates are indicated to the right and the position of molecular weight markers (in 
kDa) are indicated to the left. 
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Figure 4.10 Purification of the UB18 ubiquitin conjugate by gentle extraction 
with 0.25% n-octyl-P-D-glucopyranoside. 
Detail of the 10 to 20 kDa region of the 12.5% SDS/pAOE analysis of the detergent 
extraction of ASFY structural proteins presented in figure 4.9. Lane 1: silver stain of 
total ASFY structural proteins, lane 2: silver stain of the 0.25% 00 supernatant; lane 
3: silver stain of the 1 % 00 supernatant; lane 4: anti-ubiquitin immunoblot of the 
0.25% 00 supernatant. The positions ofUB18 and molecular weight markers (in kDa) 
are indicated. 
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probably the UB18 ubiquitin conjugate detected by immunoblotting (figure 4.10, lane 
4). This 18 kDa protein (UBI8) was well separated by SDS/PAGE from other 
proteins in the 0.25% OG fraction although some closely migrating virus proteins 
were present in the 1 % OG fraction (figure 4.10, lane 3). At least 25 % of total UB18 
was present in this fraction as estimated by the intensity of silver staining and 
immunoreactivity. Thus OG extraction of ASFV structural proteins followed by 
SDS/PAGE could be used to purify sufficient quantities of UB18 from ASFV virions 
for further characterization. This method was however not suited for the purification 
of other virus ubiquitin conjugates (UB5, UB38 and UB58) since these were only 
. released, together with most of the virus structural proteins, when high OG 
concentrations were used. 
4.2.3 Identification of the putative ubiquitinated ASFV structural 
protein UB18 
A large scale extraction with 0.25 % OG was carried out starting with 2 mg of Percoll 
purified Uganda-A ASFV particles which produced approximately 250 IJ.g of OG 
extracted structural proteins. The detergent extracted proteins were separated by 
SDS/PAGE and blotted onto a PVDF membrane. The blotted proteins were either 
stained with Coomassie blue or probed with anti-ubiquitin antiserum which showed 
that a protein clearly stained with Coomassie blue migrated at the same position as 
the UB18 anti-ubiquitin immunoreactive protein (data not shown). The Coomassie 
stained band corresponding to UB18 was excised from the blot and subjected to 
automated N-terminal protein sequencing (Model 473A, Applied Biosystems). If 
UB18 consisted of a ubiquitin polypeptide covalently linked via its C-terminus to an 
internal lysine of an unknown protein (referred to as USB1), then the N-termini of 
both ubiquitin and its conjugated USBI protein should be available for sequencing. 
The first seven cycles of Edman degradation applied to UB18 (table 4.1) each 
generated one clearly predominant amino acid presumably corresponding to USBl. 
For the first five cycles a secondary residue was also detected that corresponded to 
the known N-terminal sequence of mammalian ubiquitin (Wilkinson, 1988). 
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I I Primary I Secondary 
I Cycle I Residue I Raw yield II Residue I Raw yield I 
1 Pro 32.5 Met 26 
2 Ser 22.6 GIn 6.3 
3 Asp 15.2 lIe 2.4 
4 Met 8.8 Phe 3.1 
5 Lys 7.6 Val 0.84 
6 GIn 10.6 - -
7 Phe 8.3 - -
Table 4.1 Identity of the first 10 amino acid residues detected during the N-
terminal sequencing of UB18. 
The UB18 protein was blotted on a PVDF membrane and subjected to 10 cycles of 
Edman degradation (Model 473A, Applied Biosystems). The amino acids generated 
were identified by their retention factor during reverse phase HPLC. The column 
'Primary' shows the most abundant amino acid for each cycle and the column 
'Secondary' shows amino acids detected in smaller quantity that correspond to the 
sequence of ubiquitin. The amount in pmol of each residue (adjusted by subtracting 
the background read for the previous residue) estimated by UV absorbance is given 
in the column 'Raw yield'. 
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The observed molar ratio between the amino acid raw yields of ubiquitin and 
USB1 was as low as 1: 10 which was inconsistent with the 1: 1 molar ratio expected 
of a mono-ubiquitinated USB1 protein (or the 2: 1 ratio expected of a bi-ubiquitinated 
USB1 protein). This phenomenon was similar to that reported during the N-terminal 
protein sequencing of the ubiquitinated lymphocyte homing receptor (Siegelman et at., 
1986) and could be attributed to an incomplete blocking of the ubiquitin N-terminus 
either prior to its integration into the UB18 conjugate or during subsequent 
purifications of UB18. Alternatively this discrepancy in the molar ratios might have 
indicated that the weaker ubiquitin signal was the result of unspecific contamination 
with free ubiquitin. The presence of a non-specific free ubiquitin contaminant in the 
blot was unlikely since no ubiquitin sequence was detected during the N-terminal 
sequencing of the 12 kDa ASFV attachment protein excised from the same blot (Kytes 
and Bailey, personal communication). 
The plot of the amino acid raw yields against the residue number (figure 4.11) 
showed that the repetitive yield for the ubiquitin sequence was significantly lower 
than for the USB1 sequence (46% versus 80%) and the starting amounts of ubiquitin 
and USB1 was extrapolated to approximately 41 and 32 pmoles respectively. The 
figure of 41 pmoles for ubiquitin was probably somewhat overestimated as a result 
of the artificially high quantity of Metl attributable to contaminant proteins which 
share an N-terminal methionine. Thus although the sequencing of ubiquitin was less 
efficient than that ofUSB1, both were probably roughly equimolar in UB18 consistent 
with it being a mono-ubiquitinated USB1 conjugate. 
The characterization by N-terminal sequencing of the iso-2-cytochrome-c 
ubiquitin conjugate (Sokolik and Cohen, 1991) showed that the raw amino acid yields 
of the lysine residues to which ubiquitin was conjugated was significantly lower than 
expected. This was due to the retention in the blot of the lysines at the fork of the 
branched heterologous protein which were linked via their e amino group to the C-
terminus of ubiquitin. The raw yield of the Lys5 of USB1 was not significantly lower 
than expected, indicating that ubiquitin was probably not conjugated to this lysine site 
in USBl. 
The sequence of the N-terminal 7 amino acids of the USB1 polypeptide was 
used to screen protein sequence databases. A single 100% amino acid match was 
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Figure 4.11 Plots of the raw yields of the USBl and ubiquitin sequences against 
the sequencing cycle number. 
The raw amino acid yields (table 4.1) of the USB1 (panel A) and ubiquitin (panel B) 
sequences are plotted against the sequencing cycle number. The repetitive yield 
corresponds to the slope of the line which correlates most closely to the experimental 
raw yields and the starting amounts of protein are extrapolated from cycle O. The 
identity of the amino acids are indicated. 
8 
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Figure 4.12 Sequence comparison between the N-terminus of UBl8 and the 
predicted translation product of the USBl ORF encoded by ASFV. 
The nucleotide sequences of the USBl ORF from the BA7lV and E75 ASFV isolates 
are shown together with their predicted translation products. The N-terminal protein 
sequence of USBl determined experimentally is shown in bold. The sequence of the 
putative promoter is shown in bold. 
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found with the N-terminus of the predicted translation product of an ASFV open 
reading frame situated in the conserved central region of the genome of the BA 71 V 
isolate (figure 4.12). This ORF had not been previously described and was only 
partially contained in the upstream region of the sequence determined for the 
otherwise unrelated ASFV C'204L gene (prados et aI., 1993). An essentially similar 
partial USB1 ORF was also present in the genome of the E75 ASFV isolate (Alfonso 
et al., 1992). However, a single G/C deletion in the E75 sequence of USB1 
(corresponding to the initiation A TG in the BA 71 V sequence) indicated that the first 
E75 initiation methionine would correspond to Met4 in the Ba71 V sequence. 
Consequently the predicted N-terminus of the polypeptide translated from the E75 
USB1 ORF would not provide a complete match with the N-terminal sequence of . 
USB1 determined experimentally. 
The sequence of C'204L from the BA 71 V ASFV isolate published by Prados 
and co-workers included the first 108 bp of the 5' end of the USB1 ORF, the stop 
codon of which was presumably further downstream. The USB1 ORF was encoded 
on the complementary strand of the ASFV genome and was preceded by an AIT rich 
upstream sequence (including a TAAAAT motif 10 bp upstream of the initiation. 
codon) which agreed with the typical structure of ASFV promoters. These 
observations suggested that the UB18 ubiquitin conjugate identified in ASFV virions 
was a ubiquitinated virus protein encoded by the USB1 ORF found in the genome of 
the BA 71 V ASFV isolate. 
4.3 Discussion 
The first step in the search for a substrate for UBCv was to compare the ubiquitin 
conjugates present in non-infected and ASFV infected cells. The anti-ubiquitin 
immunoblotting suggested that ASFV replication did not lead to the production of any 
visible novel ubiquitin conjugates. Some novel ubiquitin conjugates present in low 
amounts however might not have been detected because of the low sensitivity of the 
anti-ubiquitin antiserum. Furthermore the often short half-life inherent to ubiquitin 
conjugates might have contributed to the elusiveness of potential UBCv substrates 
targeted for degradation. 
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Although no novel ubiquitin conjugates were detected in ASFV infected cells, 
a significant increase in the overall concentration of cellular ubiquitin conjugates was 
observed early in ASFV replication. Such a phenomenon is unlikely to result from 
an inhibition of ubiquitin dependent proteolysis since it would then be expected that 
many previously degraded cellular ubiquitinated proteins would be detected following 
their stabilization. The observed increase in ubi qui tin conjugate concentration is more 
likely to be attributed to a general stimulation of ubiquitin conjugation. This 
hypothesis is supported by the observation that the levels of cellular ubiquitin mRNA 
increase during early ASFV infection probably as a result of cell stress (Ferreira et 
al., 1993) which is known to induce the expression of the genes for ubiquitin and 
several UBC enzymes (Jentsch et al., 1991; Jentsch, 1992). 
The anti-ubiquitin immunofluorescence analysis of ASFV infected cells showed 
that the subcellular localization of ubiquitin conjugates was dramatically altered during 
infection. The anti-ubiquitin immunoreactivity appeared highly concentrated in viral 
factories late during ASFV replication which indicated a possible association of 
ubiquitin conjugates with virions. This was confirmed by anti-ubiquitin 
immunoblotting of purified ASFV extracellular particles which suggested that free 
ubiquitin and several ubiquitin conjugates (UB18, UB38 and UB58) were present in 
virions. Furthermore, electron microscopy of ASFV particles probed with· 
immunogold labelled anti-ubiquitin antiserum suggested that most ubiquitin conjugates 
were located inside the virus capsid, although some ubiquitin conjugates were also 
observed in the capsid. The position in the virion of these ubiquitin conjugates suggest 
that they may participate in the capsid structure or in the close interaction between 
the capsid and the virus lipid membranes. 
The treatment of ASFV particles with detergent indicated that UB18 was 
readily extracted from virions, making it a prime candidate for the ubiquitin 
conjugates localized by electron microscopy in the capsid. The characteristics 
exhibited by UB18 are similar to those of the ASFV capsid protein VP72 and 
attachment protein VP12 which suggests that UB18 might also be involved in early 
infection events (e.g. virus entry or uncoating). The N-terminus of the UB18 ASFV 
structural protein was sequenced indicating that it probably consisted of a mono-
ubiquitinated USBI protein. The N-terminal 7 amino acid sequence of USB 1 matched 
exactly the translation product of a previously partially sequenced ASFV ORF. The 
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complete sequence of this putative USB1 gene will have to be determined in order to 
compare the predicted molecular weight of its product to that observed for UB18. If 
one ubiquitin polypeptide of 8 kDa is conjugated to USB1 then the translation product 
of the USB1 gene is expected to have a Mw of approximately 10 kDa. Should the 
predicted molecular weight of the product of the USB1 ORF be greater than 10 kDa 
then it is likely that the observed UB18 structural protein is the result of proteolytic 
processing. The N-terminal proline amino acid of USB1 determined experimentally 
is in an identical position to that of the Mos protein kinase which was shown to be 
degraded in Xenopus eggs via the ubiquitin dependent pathway (Nishizawa et al., 
1992, 1993). It is therefore possible that USB1 is ubiquitinated by the N-end rule 
pathway although it is not clear how UB18 would then avoid being degraded to its· 
amino acid constituents by the ubiquitin dependent protease. 
The ASFV ubiquitinated structural proteins such as UB18 are novel ubiquitin 
conjugates detected in ASFV virions and are therefore potential substrates for the 
UBCv enzyme. However, to demonstrate that these ubiquitinated virus structural 
proteins are not substrates of host cell UBC enzymes, it will be necessary to show 
that these ubiquitin conjugates are not formed during infection with an ASFV mutant 
with an inactive UBCv enzyme. It will also be interesting to determine if USB1 can 
be ubiquitinated by UBCv in vitro. 
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Chapter 5 
General discussion and future prospects 
---0---
Analysis of the nucleotide sequence of the ORF encoding the UBCv enzyme showed· 
it had the characteristics of a functional ASFY gene and that it was probably not a 
recently acquired gene (§2.1). This view is supported by the detection of UBCv 
transcripts in ASFY infected cells (Rodriguez et al., 1992b) and by the apparent 
presence of the UBCv gene in all the ASFY isolates tested. Furthermore, although 
the predicted protein sequence of UBCv has diverged considerably from all other 
known eukaryotic UBC enzymes (§2.2), the residues necessary for the enzyme's 
catalytic activity are present since, as demonstrated in §2.3.3, E. coli expressed 
UBCv enzyme is active in vitro. The presence in the predicted UBCv protein 
sequence of a C-terminal extension to the catalytic core, together with the ability of 
UBCv to ubiquitinate histones in vitro, suggests that UBCv recognizes it substrates 
without a trans-acting E3 enzyme. UBCv poly-ubiquitinated substrates in vitro, 
including UBCv itself and histones. This might indicate that its physiological 
substrates are targeted for ubiquitin-dependentdegradation. However, the UBCv auto-
ubiquitination property observed in vitro may be artefactual since auto-ubiquitination 
of UBCv was not detected in ASFY infected cells by Western blotting using anti-
UBCv antiserum (§3.1.2). Results obtained in vitro may not reflect the in vivo 
enzyme activity and must be treated with caution. The potential proteins targeted by 
UBCv for degradation might include virus capsid proteins during uncoating, short 
lived virus regulatory proteins or cellular proteins which might include those involved 
in the host cell cytoprotective response. However, analysis of the total cellular 
ubiquitin conjugates present in ASFY infected cells did not detect novel ubiquitin 
conjugates generated during infection, although an increase in pre-existing ubiquitin 
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conjugates was observed (§4.1.1). This general increase in ubiquitin conjugation may 
result from stress induced activation of the cellular ubiquitin pathway. The failure to 
detect novel ubiquitin conjugates could be misleading since poly-ubiquitinated 
proteins, which are intrinsically unstable, often go undetected (Ciechanover et aZ., 
1991a). This obstacle might be overcome by adding, to ATP depleted ASFV infected 
cells, some non-hydrolysable ATP analogues which support ubiquitin conjugation but 
inhibit degradation of ubiquitin conjugates (Johnston and Cohen, 1991). The putative 
virus induced ubiquitinated proteins would then be stabilized and could then be 
detected by immunoblotting using anti-ubiquitin antiserum. This approach could be 
extended to in vitro assays, containing radiolabelled ubiquitin and recombinant UBCv, 
and using ASFV infected cell1ysates as a source of potential substrates. 
The UBCv enzyme is a persistent early cytosolic protein which is expressed 
throughout the replication of ASFV (§3.1 and §3.2). The presence of UBCv during 
early infection suggests that it may take part in early replication events, such as in the 
preparation of the virus genome for replication. By analogy to the proposed role of 
eukaryotic UBC enzymes in controlling the structure and replication of chromatin 
(possibly through ubiquitination of histones, Mori, M. et aZ., 1993), it is conceivable 
that the modification by UBCv of viral DNA-associated proteins is a necessary step 
for the replication of the ASFV genome. Alternatively, UBCv might playa role in 
the formation of virus factories, possibly by participating in the alteration of the host 
cell cytoskeleton (Murti et aI., 1988b). However, the involvement of UBCv in these 
early events is unlikely since early ASFV replication seems to proceed normally in 
TS20 cells which are grown at the non-permissive temperature to inactivate the E1 
enzyme (§3.3.2). An exact evaluation of the impairment of ASFV replication in these 
mutant cells could provide useful hints on the role of UBCv. Important data which 
could be obtained from ASFV infected TS20 cells would include the analysis of virus 
DNA synthesis, late ASFV gene expression (possibly using transfected reporter genes 
driven by a late promoter to detect the onset of late gene expression) and the release 
as well as the infectivity of progeny virus particles. Nonetheless, it must be noted that 
the impaired ASFV replication phenotype observed in the TS20 cells might result 
from inhibition of the cellular ubiquitin conjugation pathway rather than of UBCv 
specifically. 
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Since some persistent early ASFV proteins are known to participate in virus 
assembly (Santaren and Vinuela, 1986; Escribano and Tabares, 1987; Camacho and 
Vinuela, 1991; Prados et al., 1993), it is possible that, rather than an early event, the 
UBCv enzyme is implicated in a late replication event such as virus morphogenesis. 
The ubiquitination of virus structural proteins by UBCv might be necessary for their 
integration into virions and may involve a chaperone-like role for ubiquitin. 
Alternatively, ubiquitination of virus DNA-associated proteins might allow packaging 
of the virus genome in virions. However, the UBCv enzyme would then be expected 
to be located in the virus factories where virus assembly takes place, rather than 
throughout the cytosol as shown experimentally (§3.2.1). A role for ubiquitination in 
virus assembly is also suggested by the findings that high concentrations of ubiquitin 
conjugates are located in virus factories (§4.1.2) and that several ASFV structural 
proteins in extracellular virus particles are ubiquitinated (§4.1.3). These proteins may 
be substrates of UBCv, although it cannot be ruled out that these ubiquitinations are 
carried out by cellular UBC enzymes. Finally, the presence of the UBCv enzyme in 
purified virus particles (§3.2.2) might indicate that UBCv has a role immediately 
upon virus entry (i.e. before translation of early virus proteins), such as in virus 
uncoating. This would imply that, as well as free ubiquitin which is found in virions 
(§4.1.3), an El enzyme would have to be packaged in virions. Furthermore, unless 
the ubiquitination by UBCv of the substrate protein is in itself sufficient to promote 
uncoating, an immediate early role for UBCv in virus un coating would imply that 
virus particles also contain the ubiquitin-dependent 26S protease. This hypothesis 
could be tested by searching for ubiquitin conjugation activity in purified virus 
particles in vitro. If ubiquitin conjugation activity was detected in purified virions 
supplemented with ATP and labelled ubiquitin, this would demonstrate that an El 
enzyme is also packaged in virus particles. If structural protein degradation is 
observed upon addition of purified ubiquitin-dependent 26S protease to this virion in 
vitro system, this might strongly suggest that UBCv directed ubiquitination 
participates in virus uncoating. 
The pattern of ubiquitinated ASFV structural proteins detected by 
immunoblotting in virus particles does not appear to correspond to poly-ubiquitinated 
forms of the same protein substrate, since ladders of conjugates differing in size by . 
that of ubiquitin monomers (8 kDa) were not observed (§4.1.3). It is more likely that 
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several distinct structural proteins are ubiquitinated. Some of these ubiquitin 
conjugates are located close to the virus nucleo-protein core whereas others are 
located more externally in the virus capsid (§4.1.3). The N-terminal sequence of one 
such capsid ubiquitin conjugate (UB18) confirmed that it is a mono-ubiquitin 
conjugate and showed that it is a virus encoded protein. Little is known about the 
function of mono-ubiquitin conjugates which include histones, although they do not 
seem to be good substrates for ubiquitin-dependent degradation. Since ubiquitin is a 
substrate for certain cellular UBC enzymes, it is possible that the single ubiquitin tag 
of UB18 could act, upon virus entry, as a primer for the formation by cellular UBC 
enzymes of a poly-ubiquitin chain. This could lead to the degradation of UB18 and 
participate in virus uncoating, although, if this is the case, it is unclear how UB18 . 
could escape degradation in the cytoplasm during virus assembly in the previous 
replication cycle. The ASFV gene encoding the ubiquitinated UB18 structural protein 
can now be sequenced and subcloned in a bacterial expression vector. The production 
of recombinant UB18 will allow its expression, location and post-translational 
modification to be followed in ASFV infected cells and virus particles using 
antibodies raised against recombinant UB18. In addition, recombinant UB18 could be 
used to determine whether it is a substrate for UBCv in vitro. A similar approach to 
that used to characterize UB18 might also be applicable to the other ubiquitin 
conjugates detected in ASFV virus particles. 
The study of the phenotype of an ASFV mutant with an inactivated UBCv 
gene could provide valuable information about the function of UBCv. Although the 
generation of mutants is routinely carried out with vaccinia virus, the mutagenesis of 
ASFV is still in its infancy. The attempts to replace the UBCv gene in ASFV with 
a gene disrupted with the luciferase reporter were unsuccessful (§3.3.3). Since a 
positive control consisting of the luciferase reporter inserted in a known non-essential 
region of the ASFV genome was not available, this experiment did not conclusively 
demonstrate that the UBCv gene is essential for ASFV infection. It is possible that 
using a transfer vector with longer homologous flanking regions disrupted by a 
selectable reporter (such as neomycin resistance or guanine phosphoribosyltransferase) 
would increase the efficiency of both recombination and mutant isolation and enable 
the UBCv gene to be disrupted. However if the UBCv gene is essential for virus 
replication, it would not be possible to generate a null mutant and a conditional lethal 
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mutant would have to be generated. This could be achieved by placing the UBCv 
gene under control of an inducible promoter using the lac operon/lac repressor system 
used in vaccinia virus (Zhang et al., 1992). Conditional expression is achieved by 
inserting the lac operator adjacent to the transcription start site of the targeted gene 
in a recombinant virus that constitutively expresses the E. coli lac repressor. The 
expression of the targeted gene is then dependent on the addition of IPTG. Since this 
strategy would require the generation of a double recombinant, a simpler and perhaps 
more flexible approach would consist of constructing an ASFV mutant with a gene 
encoding a thermosensitive UBCv enzyme. It has been shown that the substitution of 
a single conserved proline residue of UBC enzymes (corresponding to Pro6l in the 
sequence of UBCv) to a serine residue results in thermolabile UBCts enzymes (Ellison 
et al., 1991). A UBCvts gene could be obtained by site directed mutagenesis of the 
cloned wild type UBCv gene and the mutated gene product activity could then be 
tested in vitro at various temperatures. If the engineered UBCvts enzyme was indeed 
thermolabile, the genomic UBCv gene could be replaced by the UBCvts gene by 
homologous recombination, thus allowing UBCv activity to be shut off at any stage 
of the ASFV replication cycle by a shift to the non-permissive temperature. 
Alternatively, an ASFV UBCv null mutant could be generated by disrupting 
the UBCv gene by insertion with a reporter gene if the host cell constitutively 
expresses UBCv. A cell line expressing the UBCv gene under control of a eukaryotic 
promoter such as the SV40 promoter could be generated using standard techniques 
(Ausubel et al., 1991b). The cell line expressing UBCv would complement the 
deficiency of the ASFV UBCv null mutant, thus enabling such a lethal mutation to 
be constructed. The phenotype of the null mutant could then be studied in a wild type 
cell line not expressing UBCv. In addition, the cell line expressing UBCv could be 
useful to determine whether UBCv interferes with any of the host cell's metabolic 
functions. This approach could also be applied to investigate the possible involvement 
of UBCv in disturbing the host immune response. Indeed the natural host cells for 
ASFV infection are principally monocytes and macrophages and the latter play an 
important part in antigen presentation to T and B cells. Since the ubiquitin system is 
involved in antigen processing, it is tempting to speculate that the ASFV encoded 
UBCv enzyme might affect this process and might therefore be a factor responsible 
for the peculiar host immune response to ASFV. Although it is not clear how UBCv 
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could disrupt the ubiquiiin-dependent class I antigen processing, this hypothesis could 
be tested by expressing UBCv in macrophages or in tissue culture cells manipulated 
(as described by Michalek et aI., 1993) to be artificially class I a n t i g e n ~ p r e s e n t i n g g
(APC). These UBCv expressing APC cells could then be evaluated for their ability 
to present antigens by measuring T cell stimulation. 
The ultimate aim of this study was to determine the function of the UBCv 
enzyme in the life cycle of ASFV. Although it is clear that the precise role of the 
UBCv enzyme is still elusive, the results presented here have narrowed the range of 
potential UBCv functions as well as identified several potential substrates for the 
enzyme and provide a basis on which to design further experiments. 
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Chapter 6 
Materials and methods 
---0---
6.1 Materials 
6.1.1 Suppliers 
Unless stated otherwise, all the chemicals and reagents were purchased from BDH 
Chemicals or from Sigma Chemical Company and were of analytical grade or of the 
highest grade available. The restriction endonucleases and other molecular biology 
enzymes were obtained from Boehringer Mannheim or from Promega and the 
reactions were carried out using the recommended buffers supplied by the 
manufacturer. The radioisotopes were from New England Nuclear (NEN, Dupont). 
The conjugated antisera were purchased from Dako (Dakopatts, Denmark) and from 
Amersham International. The phosphorothioate oligonucleotides were purchased from. 
the Oswel DNA Service (Department of Chemistry, University of Edinburgh). The 
media for cell culture were purchased from Gibco BRL Life Technologies. 
The following ~ t e m s s were generously provided as gifts: 
E. Vinuela 
Universidad Autonoma, 
Madrid, Spain. 
Prof. R.J. Mayer 
Dept. Biochem., 
Nottingham, UK. 
Dr. J.M. Hammond 
IAH, Pirbright, UK. 
Anti-VP72 monoclonal antibodies, clone 17L.D3, 
ASPV BA 71 V isolate, 
plasmid clones containing BA 71 V DNA. 
TS20 and E36 cell lines, 
Iodinated ubiquitin. 
p72-Luc DNA construct. 
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6.1.2 Standard' buffers 
The compositions of standard buffers were as follow: 
Blocking solution 
5% dried low-fat skimmed milk 
(Sainsbury's) in PBS-T 
Buffer C 
120 mM NaCI 
5 mM Tris-HCI pH 7.5 
2% NP40 
Gel destain 
7.5 % acetic acid 
25 % methanol 
Gel stain 
25 % isopropanol 
10 % acetic acid 
0.05% Coomassie blue 
IPTN buffer 
0.5 M NaCI 
20 mM Tris-HCI pH7.5 
2 mM EDTA pH8.0 
0.2% NP40 
LB (Luria-Bertani) medium 
1 % tryptone 
0.5 % yeast extract 
172 mM NaCl 
M9 minimal medium 
22 mM glucose 
90 mM Na2HP04 
8.5 mM NaCI 
22 mM KH2P04 
18.7 mM NH4CI 
NETN 
·50 mM Tris-HCI pH7.5 
150 mM NaCI 
5 mM EDTA 
0.05% NP40 
Orange G (lOx) 
0.25% orange G 
30 % glycerol 
PBS (Phosphate buffered Saline) 
136 mM NaCl 
2.7 mM KCI 
10 mM Na2HP04 
17 mM KH2P04 
pH7.4 (adjusted with HCl) 
PBS-T 
0.1 % Tween 20 in PBS 
peR Buffer 
10 mM Tris-HCI pHS. 3 
50 mM potassium chloride 
1.5 mM MgCl2 
0.01 % w/v gelatin 
SDS/PAGE running buffer 
25 mM Tris-base 
200 mM glycine 
0.1 % SDS 
Sample Buffer 
2% SDS 
20% glycerol 
0.01 % bromophenol blue 
62.5 mM Tris-HCI pH6.S 
100 mM DTT or 5% 
I1mercaptoethanol 
Solution I 
50 mM glucose 
25 mM Tris-HCl pHS 
10 mM EDTA 
Solution II 
200 mM NaOH 
1% SDS 
Solution III 
3 M potassium acetate 
11.5 % glacial acetic acid 
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TAE (SOx) 
2 M Tris-base 
4 M sodium acetate 
2 mM EDTA 
pHS.O 
TBS 
140 mM NaCI 
20 mM Tris-Hcl pH7.5 
TE 
10 mM Tris-HCl pH7.5 
1 mM EDTA 
pHS.O 
TFB 
10 mM Mes 
100 mM RbCl 
45 mM MnCl2 
10 mM CaCl2 
3 mM hexaminecobaltic chloride 
100 mM Tris-HCI, pH 8.5 
Transfer buffer 
40 mM glycine 
4S mM Tris-base 
0.1 % SDS 
20 % methanol 
. " .. '.. . ~ ~
V e r s e n e ~ ~Trypsin 
136 mM NaCl 
5.3 mM KCI 
5.5 mM glucose 
6.5 mM NaHC03 
0.02 % trypsin 
0.01 % versene (EDTA) 
0.1 % phenol red 
6.1.3 Viruses 
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The Malawi LIL20/1 ASFV isolate was used in all pig monocyte and macrophage 
infection experiments. The Malawi LIL20/1 isolate was isolated from ticks collected 
in Malawi (Lilongwe, Central Region) following outbreaks in November 1983 
(Haresnape et al., 1988). The Malawi LIL20/1 ASFV isolate has been passaged twice 
in pigs, maintaining its high virulence characteristics, and was grown in primary pig 
monocytes cultures. 
The Uganda-A ASFV isolate was used in all IBRS2 tissue culture infection 
experiments. The Uganda-A isolate was derived from the UGA59 ASFV field isolate 
(isolated in Uganda in 1959 from the spleen of an infected pig, Detray,DE, 1960) that 
was adapted to grow in IBRS2 tissue culture cells. The passage number of the 
U g a n d a ~ A A isolate in IBRS2 cells is not known. 
The BA 71 V ASFV isolate was used in all VERO tissue culture infection 
experiments. The BA71V isolate was derived from the BA71-5 field ASFV isolate 
(isolated in 1971 from the spleen of an infected pig in Badajoz, Spain) that was 
adapted to grow in VERO cells (Enjuanes et al., 1976a; Ley et al., 1984). 
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6.2 Methods 
6.2.1 Nucleotide and amino acid sequence analysis 
The analysis of the DNA and predicted protein sequences was carried out using the 
University of Wisconsin GCG software package (Genetics Computer Group, Inc.) 
(Devereux et al., 1984). The PHYLLIP PHYlogeny Inference Package (version 3.5c, 
produced by Joe Felsenstein, University of Washington) was used to make the 
phylogenic analysis of UBC enzymes. 
6.2.2 DNA manipulations 
All the DNA manipulations including polymerase chain reaction, restriction enzyme 
digestion, DNA ligation, plasmid transformation in E. coli, E. coli plasmid 
preparation and analysis on agarose gels were performed according to methods 
adapted from Sambrook et al., 1989. 
Polymerase chain reaction 
The polymerase chain reactions (PCR) were performed on a thermal cycler (MJ 
Research Inc.) programmed for a 5 minutes denaturing step at 95°C, followed by 25 
cycles consisting of a 2 minutes denaturing step at 92°C, a 2 minutes hybridization 
step at 50°C and a 3 minutes primer extension step at 72°C. The PCR reactions 
contained 50 ng of template DNA, 5 units of Taq polymerase (Boehringer), 200 IlM 
of dNTP's and 100 pmoles of the oligonucleotide primers in a final volume of lOO1l1 
PCR buffer. A 50 III mineral oil overlay was added to prevent evaporation during the 
amplification process. A 5 III aliquot of amplified DNA was analyzed by 0.6% 
agarose gel electrophoresis and visualised under short wavelength UV light. The 
remainder of the amplified DNA was purified with Magic PCR Purification kits 
(Promega) and r e s ~ s p e n d e d d in 50 III TE. 
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Agarose gel electrophoresis 
The DNA samples in Ix orange G were analyzed by electrophoresis in 0.6%-1 % 
agarose gels containing lxTAE buffer and 1 J.'g.ml-1 ethidium bromide. The DNA was 
visualised under UV light. 
Extraction of DNA from low melting point CLMP) agarose gels 
A 50 ml 0.8% LMP agarose gel containing 1 J.'g.mt1 ethidium bromide was prepared 
in lxTAE buffer and run for 2-3 hours at 80 Volts. The DNA band was visualised 
under long wavelength UV light and excised from the gel with a fresh scalpel blade. 
The DNA was extracted from the gel slice using the Genec1ean kit (Bio101) and 
resuspended in 50 J.'l of TE. 
Small scale plasmid purification (mini-prep) 
A single bacterial colony was inoculated into 5 ml LB containing 50 J.'g.mt i 
ampicillin and cultured overnight at 37°C with vigorous shaking. 1.5 ml of culture 
was pelleted in a microfuge for 2 minutes and the supernatant discarded. The pellet 
was resuspended by vortexing in 100 J.'l solution I and held at room temperature for 
5 minutes. 200 J.'l of solution II was added and mixed by inversion before incubating 
on ice for 5 minutes. 150 J.'l of solution III was added and the tube was vortexed 
gently to mix the contents. After a further 5 minutes on ice the mixture was pelleted 
in a microfuge for 5 minutes at 4°C. The supernatant was transferred to a fresh tube 
and extracted once with an equal volume of phenol, once with an equal volume of 
chloroform and once with an equal volume of ether. The DNA was precipitated by 
the addition of 2 volumes of ethanol, holding for 20 minutes at room temperature and 
pelleted for 5 minutes in a microfuge. The resulting pellet was resuspended in 50 J.'l 
of TE containing 10 J.'g.ml-1 RNAse A and stored at -20°C until required. 
Large scale plasmid purification (maxi-prep) 
500 ml of LB medium containing 50 J.'g. mt1 ampicillin was inoculated with a single 
colony of E. coli and cultured at 37°C overnight with vigorous shaking. The cells 
were pelleted at 6000 rpm for 20 minutes in a Sorvall RC-5B centrifuge (SS34 rotor), 
resuspended in 10 ml of solution I and held at room temperature for 5 minutes. 20 
ml of solution II was added, the solution mixed and held on ice for 10 minutes, 15 
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ml solution III was then' added and the mixture held on ice for a further 10 minutes. 
The mixture was pelleted at 13,000 rpm for 20 minutes at 4°C in a Sorvall RC-5B 
centrifuge (SS34 rotor), and the supernatant decanted. The DNA in the supernatant 
was precipitated by the addition of 0.6 volumes of isopropanol then incubated at room 
temperature for 20 minutes and pelleted at 10,000 rpm for 30 minutes at room 
temperature in a Sorvall RC-5B centrifuge (SS34 rotor). The DNA pellet was 
resuspended in S ml of TE containing S g CsCI and S mg ethidium bromide and was 
transferred to a quickseal ultracentrifuge tube (Beckman). The tube was filled with 
liquid paraffin, heat sealed and centrifuged overnight at 55,000 rpm at 20°C in a 
Beckman LS-90 ultracentrifuge (70.1 Ti rotor). The supercoiled plasmid DNA (the 
lower of 2 bands visualised under long wavelength UV light) was collected using a . 
hypodermic needle and syringe. The ethidium bromide was removed from the solution 
by extraction with an equal volume of CsCl saturated isopropanol, and the DNA was 
precipitated by adding 3 volumes of ethanol and incubation at room temperature for 
30 minutes. The DNA was pelleted in a microfuge for 5 minutes, resuspended in 500 
1'1 of TE and the OD26O nm was determined. The concentration was adjusted to 500 
J.'g.ml-1 with TE and the DNA was stored at -20'C until required. Alternatively the 
Magic Maxiprep columns (Prom ega) were used according to the manufacturer's 
instructions. 
Preparation of competent E. coli 
A single bacterial colony was seeded into 25 ml of LB medium and incubated at 3JlC 
with agitation until the OD600 nm of the culture was between 0.4 and 0.6. The 
bacteria were pelleted and resuspended in 2.5 ml of TFB and held on ice for 5 
minutes. 100 1'1 of dimethylformamide (DMF) was added and the bacteria were 
incubated for a further 5 minutes on ice. 100 1'1 of 2.25 M DTT in 40 mM potassium 
acetate was then added and the cells were held on ice for a further 5 minutes. Finally, 
100 1'1 DMF was added and the cells were held on ice until required (up to S hours). 
Transformation of competent cells 
200 1'1 of competent cells were mixed with the plasmid DNA and held on ice for 45 
minutes. The mixture was then heat shocked at 42°C for 2 minutes and incubated at 
37°C in 500 1'1 of LB for 1 hour. The transformation mix was then plated out onto 
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LB agar containing the necessary antibiotics and reagents required for plasmid 
selection. 
Preparation of synthetic oligonucleotides 
The oligonucleotides were synthesized by Dr. M. Ryan and Dr. P. Thomas (JAH, 
Pirbright) using an automated DNA synthesizer (Model 381A, Applied Biosystems). 
The oligonucleotides were removed from the support column by 3 washes of 300 JlI 
each of undiluted ammonia solution. The washes were pooled and incubated at 56°C 
for 18 hours followed by rapid cooling on ice and rotary evaporation of the ammonia. 
The dried pellet was resuspended in 500,ul distilled water and the DNA concentration 
was adjusted to 10 pmol.Jltl. The oligonucleotides were stored at -20°C until 
required. 
6.2.3 Radioactive labelling of E. coli proteins 
The TG 1 E. coli strain (lac Iq) was used for all experiments. An E. coli colony 
harbouring plasmid PHI or plasmid pkk233-2 was grown overnight in 5 ml of M9 
minimal medium. The cells were then spun down and resuspended in 1 ml of M9 
medium. After 1 hr incubation at 37°C, IPTG was added to a final concentration of 
1 mM. The labelling of proteins was achieved by adding 100 ,uCi of eSS]methionine 
to the cells, incubating for 5 minutes before pelleting and lysing the cells in 100 JlI 
of sample buffer containing 100 mM DTT. The samples were boiled for 5 minutes 
prior to SDS/PAGE analysis. 
6.2.4 Protein analysis by SDS/PAGE 
Proteins in sample buffer were analyzed on 12.5%, 15%, 17.5%, 20% or gradient 
7-20% resolving SDS-polyacrylamide gels, usually 0.75 mm or 1.5 mm thick 15 x 
17 em slab gels (Gibeo BRL Life Technologies), with a 4% stacking gel, according 
to a method adapted from Laemmli, 1970. The gels were run with Ix running buffer 
at 20-70 rnA at room temperature except for the analysis of ubiquitin thiolester bonds 
where gels were run at +4°C. The proteins separated by SDS/PAGE were stained 
with coomassie blue by soaking the gel in stain solution for 1 hour then in destain 
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solution overnight. The gels were silver stained with the Silver Stain Plus kit (Bio-
Rad) or the Silver Stain kit (Stratagene) following the manufacturer's instructions. 
The gels were dried on Whatman 3MM paper on a heated (80°C) slab drier, or were 
dried at room temperature between two sheets of clear cellulose. The gels containing 
[ 35S]methionine labelled proteins were fluorographed in 1 M sodium salicylate for 30 
minutes before drying and autoradiography was carried out with Kodak intensifying 
screens on Fuji X-Ray film at -70°C. 
6.2.5 Two-dimensional analysis of proteins 
The isoelectric focusing (IEF) first dimension separation was carried out in 12 cm 
long tube gels (1.5 mm inside diameter). The ampholytes used were a mix (4:1 v/v 
ratio) of 40% ampholytes pH 5/7 (Sigma Chemicals) and 40% ampholytes pH 3/10 
(Bio-Rad). The tube gels contained 3.325% acrylamide 10.175% bisacrylamide 1 9 
M urea 1 2 % NP40 1 5 % ampholytes 1 0.1 % ammonium persulfate (APS) 1 0.075 % 
TEMED and were polymerized overnight. The anode solution consisted of 15 mM 
orthophosphoric acid and the cathode solution was 50 mM sodium hydroxide. The 
protein samples (purified ASFV particles, 5 p.g of protein per tube gel) were 
solubilized in 9 M urea 1 100 mM DTT 1 4% NP40 1 2% ampholites 10.1 % SDS and 
were loaded on tube gels pre-run at 175 V for 15 minutes, 200 V for 30 minutes and 
400 V for 1 hour. The loaded tube gels were run at 700 V for 19 hours with external 
cooling of the b u f f e r ~ . . The tube gels were then extracted, incubated in sample buffer 
(for a maximum of 5 minutes) and overlayed on a standard 12.5% SDS/PAGE slab 
gel with a single well. The second dimension was run as described in §6.2.4 (protein 
analysis by SDS/PAGE). 
6.2.6 Purification of the ubiquitin conjugating (E1) enzyme from pig 
brain tissue 
This procedure is derived from the methods described by Ciechanover et al., 1982 
and Hershko et al., 1983. Half a piglet brain (30 g) was homogenized on ice for 1 
minute at maximum speed in 150 ml (20% suspension) of 20 mM Tris-HCI 1 1 mM 
DTT 1 1 % glycerol 1 3 mM potassium phosphate buffer pH 7.1. The homogenate was 
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centrifuged at 30,000 g for 30. minutes at 4°C. A batch ion-exchange chromatography 
was achieved by adding to the supernatant 150 g of pre swollen DEAE cellulose 
(Whatman) previously equilibrated with 3 mM potassium phosphate /1 mM DIT pH 
7.0. After agitation for 30 minutes on ice, the slurry was centrifuged 5 min at 1800 
rpm and the supernatant was decanted (fraction I). The pellet was washed three times 
with 300 ml of 3 mM potassium phosphate buffer / 20 mM KCl / 1 mM DIT pH 
7.0. The bound proteins were eluted by adding 100 ml of 20 mM Tris-HCl/ 1 mM 
DIT / 0.5 M KCL pH 7.2. The slurry was agitated 10 minutes on ice and 
centrifuged 10 minutes at 2200 rpm. The supernatant was dialysed overnight at +4°C 
against 8 litres of 20 mM Tris-HCl / 0.2 mM DIT / 100 mM MgCl2 pH 7.4 to 
produce pig brain fraction II. 
The fraction II was concentrated with spin concentrators (Centriprep-lO, 
Amicon) to 6 ml and adjusted to 20 mM ATP. A ubiquitin affinity column was 
constructed by conjugating ubiquitin (Sigma Chemical Company) to a cross-linked 
agarose matrix (Sepharose-4B, Pharmacia LKB). Ubiquitin was conjugated (5 mg.mt1 
gel) to the cyanogen bromide pre-activated sepharose gel according to the 
manufacturer's instructions. The concentrated fraction II was loaded on the ubiquitin 
affinity column equilibrated with 5 mM ATP / 10 mM MgCl2 / 50 mM Tris-HCl / 
0.2 mM DIT pH7.S. The loaded column was incubated for S minutes at room 
temperature and then washed with 6 ml of SO mM Tris-HCl pH 7.S. The ubiquitin 
activating enzyme (E1) was specifically eluted with 6 ml of SO mM Tris-HCl/2 mM 
, AMP / 0.04 mM NaPPi pH 7.5. The AMP/PPi E1 eluate was then concentrated 10 
times with spin concentrators (Centriprep-30, Amicon) and stored in SO ttl aliquots 
at -70°C. 
6.2.7 Preparation of recombinant UBCv for in vitro assays 
An E. coli colony harbouring plasmid PHI was grown in 1 litre of LB medium at 
37°C with agitation to an optical density (OD600) of 0.3. The UBCv expression was 
then induced by adding IPTG to a final concentration of 1 mM. The culture was 
incubated a further 90 minutes at 37°C with agitation. The cells were then pelleted 
and resuspended in 10 ml of SO mM Tris-HCl pH 7.5 / 0.1 mM DIT / 1 mM 
EDTA. The cells were lysed by freeze/thawing three times and centrifuged at 20,000 
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rpm (Beckman SWTi) for 30 minutes at +4°C. A fraction II was prepared from the 
supernatant (as described for E1 in §6.2.6) by chromatography on a 20 ml DEAE 
cellulose column (100 ml wash followed by a 50 ml elution). The dialysed fraction 
II was concentrated 25 times with spin concentrators (Centriprep-10, Amicon) and 
used for UBCv activity assays. 
6.2.8 UBCv thiolester assay 
A 60 Jtl mixture containing 10 Jtl of E. coli fraction II (UBCv), 15 Jtl of affinity 
purified E1, 0.1 units of inorganic pyrophosphatase (Boehringer) and [l2SI]ubiquitin 
(3.106 cpm) in 5 mM DIT / 5 mM MgCl2 / 10 mM ATP / 50 mM Tris-HCl pH 7.5 
was incubated at 37°C for 15 minutes. The reaction was stopped by adding sample 
buffer. The products of the reaction were analyzed by SDS/PAGE with or without 
boiling with 2 % ~ - m e r c a p t o e t h a n o l l for 3 minutes prior to loading. The E1 thiolester 
assay was carried out using the same conditions without adding UBCv. 
6.2.9 Ubiquitin conjugation assays 
The conjugation assays were carried out in the same way as the thiolester assays 
except that 50 Jtg of a substrate protein was added to some reactions and the 
incubation time was extended to 60 minutes. The reaction mixtures were boiled in 2 % 
~ - m e r c a p t o e t h a n o l l for 3 minutes prior to analysis by SDS/PAGE. 
6.2.10 Synthesis of oligopeptides 
The oligopeptides used for rabbit immunizations were synthesized by Mr R. Staple, 
Mrs J. Oxtoby and Dr T.R. Doel (IAH, Pirbright) using an automated Beckman 
System 990 Synthesizer. The dehydrated peptides were resolubilized in sterile double 
distilled water and stored at -200C. 
6.2.11 
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Purification of recombinant UBCv for rabbit 
immunizations 
Recombinant UBCv was purified from a 1 litre culture of an E. coli colony containing 
plasmid PH2. The fusion protein purification protocol was performed essentially as 
described by Ausubel et aI., 1991a. Briefly, a 1 litre culture (LB medium /50 Ilg.ml-1 
ampicillin) of bacteria containing plasmid PH2 in mid-exponential phase (0.3 OD6(0) 
was induced with 0.1 mM IPTG and incubated for a further 3 hours at 37'C with 
vigourous agitation. The cells were then pelleted, the medium was discarded and the 
cells were resuspended in 10 ml of ice cold PBS. The cells were lysed by sonication 
and Triton X-IOO was added to a final concentration of 1 %. The lysate was 
thoroughly mixed and the cellular debris was pelleted by centrifugation at 10,000 g. 
The supernatant was decanted and mixed for 5 minutes with 1 ml of a 50 % 
glutathione-agarose slurry (Promega). The agarose beads were then pelleted by 
centrifugation in a microfuge, the supernatant was discarded and the beads were 
resuspended in 50 ml of ice-cold PBS. The beads were washed again twice with 50 
ml of ice-cold PBS. The beads were then washed twice in 10 ml of ice-cold 1 % 
Triton X-IOO in PBS and were washed twice in cleavage buffer (2.5 mM CaCl2 / 50 
mM Tris-HCI pH7.5 / 150 mM NaCl). Finally the beads were resuspended in 500 
1-'1 of cleavage buffer containing 50 I-'g of thrombin protease (Boehringer Mannheim). 
The slurry was incubated for 1 hour at room temperature before pelleting the beads 
in a microfuge. The supernatant was decanted (fraction 1) and the beads were washed 
four times with 500 1-'1 of cleavage buffer (fractions 2-5). All the fractions (containing 
purified recombinant UBCv) were stored at -20"C until required. 
6.2.12 Rabbit immunizations 
The inoculations of rabbits were carried out by Mr L. Pullen (JAH, Pirbright). For 
the raising of anti-peptide serum, the rabbits first received (day 1) 150 I-'g of peptide 
in Freund's complete adjuvant, by both intramuscular OM) and subcutaneous (SC) 
injections. The rabbits then received two 150 I-'g 1M and IC boost injections in 
Freund's incomplete adjuvant at 21 and 42 days. The rabbits were bled on day 63 and 
the clotted blood was centrifuged at 5000 x g before aliquoting the serum supernatant 
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at -20°C. The raising of antisera against recombinant UBCv in rabbits was carried in 
the same way, using doses of either 15 J.Lg (LD8) or 100 J.Lg (LD9) of purified UBCv 
protein. 
6.2.13 Affinity purification of anti-peptide antisera 
The anti-peptide rabbit antisera were purified by affinity chromatography. The 
preparation of the affinity peptide-sepharose columns and the purification of 
antibodies were carried out using the ProtOn Kit 1 (Multiple Peptide Systems) 
following the manufacturer's instructions. 
6.2.14 Purification of pig monocytes and macropbages 
The monocytes and macrophages were isolated from pig peripheral white blood cells 
by virtue of their adherence to tissue culture plates. Normal pig blood was collected 
in heparin (10 Lu.lml), dispensed into 25 ml aliquots and stored on ice for 5 minutes 
before being centrifuged at 1800 rpm for 10 minutes at 4°C in an IEC Centra-7R 
centrifuge (lEC 210 rotor). The buffy coat was removed with a 5 ml pipette and 
mixed with 5 ml of ice cold Eagles medium. Two buffy coat suspensions were then 
carefully layered onto 15 ml of Lympho-Paque (Nycomed Pharmaceuticals) in a 50 
ml Falcon tube and centrifuged at 1800 rpm for 30 minutes at 4°C (as above). The 
interface white blood cell fraction was collected with a 10 ml pipette and washed 
twice in 20 ml of ice cold Eagles by resuspending the cells and centrifuging at 1800 
rpm for 5 minutes at 4°C (as above). The remaining erythrocytes were then flash 
lysed by briefly resuspended cells in 10 ml of sterile distilled water and rapidly 
adding 10 ml of 2 x Eagles. Finally, the leucocytes were resuspended to a 
concentration of 107 cells.ml-1 in ice cold Eagles supplemented with 10% porcine 
serum. The suspension was dispensed in 5 ml aliquots into 6 cm diameter petri dishes 
and incubated at 37°C overnight in a 5% CO2 incubator. The medium was then 
decanted and non-adherent cells washed off with warm Eagles plus 10% porcine 
serum. The media was replenished and the remaining cell population were incubated 
as above until required. All media contained antibiotics (30 J.Lg.mt l benzyl penicillin 
and 1 J.Lg.ml-1 streptomycin) as well as a fungicide (2.5 J.Lg.mI-1 amphotericin B). 
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6.2.15 Cultivation of tissue culture cells 
The IBRS2 and VERa tissue culture cells were grown as monolayers in Dulbeccos 
modified Eagles medium (DMEM) supplemented with 10% foetal calf serum in a 
humidified atmosphere containing 5 % CO2 and maintained at 37°C. The TS20 and 
E36 tissue culture cells were grown as monolayers in alpha-MEM medium 
supplemented with 10% foetal calf serum in a humidified atmosphere containing 10% 
CO2 and maintained at 32°C. All the media contained antibiotics (30 Ilg.mt1 benzyl 
penicillin and 1 Ilg.ml-1 streptomycin) as well as a fungicide (2.5 Ilg.mI-1 amphotericin 
B). 
Confluent cell sheets were sub-cultivated by decanting the medium, washing 
the cells with Ca2+ IMg2+ free PBS and adding 0.05 ml.cm-2 of versene/trypsin. After 
5-10 minutes incubation the cells became detached and were resuspended in the 
appropriate medium. The IBRS2 and VERa cells were routinely split 1:5, whereas 
TS20 and E36 cells were split between 1: 10 and 1: 15. All cells were cultivated in 
plastic dishes or flasks (Falcon). 
6.2.16 Time courses of ASFV infection 
The 6 cm diameter petri dishes containing the target cells were washed with warm 
medium and incubated for one hour at 37°C (32°C or 40.5°C with TS20 and E36 
cells) in 1 ml of serum free medium containing ASFV at a multiplicity of infection 
(Mal) of 10 to insure synchronized infection. With pig monocytes and macrophages, 
the infection was carried out with the ASFV isolate Malawi LIL20/1, whereas the 
Uganda-A isolate was used with IBRS2, TS20 and E36 cells and the BA71V isolate 
was used with VERa tissue culture cells. The dishes were then washed with warm 
PBS and incubated with 5 ml of medium supplemented with 10% serum until the 
desired time point was reached. The dishes were then washed with warm medium 
\ 
before lysing the cells with 300 III of buffer C. The cell lysates in buffer C were 
stored at -20°C until required. The frozen cells lysates were then rapidly thawed and 
spun down before aliquots were mixed in sample buffer for SDS/PAGE analysis. 
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6.2.17 Immunoprecipitation analysis 
Cell were infected as described (§6.2.16) and were pulse labelled with [3sS]methionine 
at various times post-infection. One hour before collection, the pig monocyte and 
macrophage dishes were washed with warm methionine free Eagles and incubated for 
one hour at 37°C in the presence of 100 ILCi of eSS]methionine in 1 ml of methionine 
free Eagles. The cells were then washed with warm methionine free Eagles before 
being lysed in 300 ILl of buffer C. The celllysates were pelleted in a microfuge for 
5 minutes and the supernatant stored at -700C until required. 
The immunoprecipitation was carried out by adding 10 ILl of antiserum and 
500 ILl of IPTN buffer to 100 ILl of the labelled cell extract. The contents were mixed 
by inversion and incubated at room temperature for one hour before gently mixing 
with 20 ILl of NETN washed Staphylococcus aureus pansorbin. The mixture was 
incubated for a further 30 minutes at room temperature and then centrifuged 5 
minutes. The supernatant was discarded and the pellet was washed successively in 
500 ILl of NETN and 500 ILl of TBS. Finally, the pellet was resuspended in sample 
buffer and analyzed by SDS/PAGE and fluorography. 
6.2.18 Immunoblotting analysis 
The proteins to be analyzed by immunoblotting (blotting of proteins for N-terminal 
sequencing is described in §6.2.28) were first separated by SDS/PAGE (§6.2.4) and 
were then transferred by Western blotting to a nitrocellulose membrane (Hybond C-
Super, 0.45 ILm pores, Amersham). The transfer was carried out on a Bio-Rad semi-
dry transblotter using Transfer buffer under a 0.8 mA.cm-2 current for 1 to 1.5 hours. 
The blot was then washed in PBS, air dried and stored at 4°C until required. When 
the blot was to be probed with anti-ubiquitin anti"serum, the pre-wetted membrane was 
briefly autoclaved before use to enhance detection sensitivity (Swerdlow et at., 1986). 
The protein blots were stained with gold using the Proto-Gold kit (BioCell 
Research Laboratories) according to the manufacturer's instructions. Immunodetection 
was carried out by first incubating the blots in Blocking solution (§6.1.2) for 1 hour 
at 37°C with gentle agitation, followed by incubation in the same conditions with 
primary antiserum diluted in fresh blocking solution. The dilutions of primary antisera 
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were 11200 for anti-UBCv serum (LD9) and 1:25 to 1:50 for anti-ubiquitin serum 
(Sigma or Dako). The blots were washed 3 times in PBS-T and incubated as above 
with secondary antiserum (HRP-conjugated anti-rabbit IgG, Dako) diluted 1:2000 in 
blocking solution. The blot was then thoroughly washed 5 times in PBS-To The 
detection of bound HRP-conjugated antibodies was carried out using enhanced 
chemiluminescence (ECL kit, Amersham) according to the manufacturer's 
instructions. 
6.2.19 Immunofluorescence of ASFV infected cells 
The tissue culture cells were grown to near confluence on glass (IBRS2 and VERO) 
or plastic (TS20 and E36) chamber slides (Gibco-BRL Life Technologies). Mock or 
ASFV infected cells were washed in PBS and fixed in ice cold methanol/acetone (111 
v/v) for 5 minutes. The fixed slides were air dried and preferably used immediately 
for immunofluorescence, or were stored shortly at +4°C until required. 
The slides were rehydrated in PBS for 15 minutes and incubated with foetal 
calf serum (FCS) for 15 minutes at 37°C. The slides were then incubated for one hour 
at 37°C with primary antiserum diluted in PBS-T plus 10% FCS. Primary antiserum 
dilutions were 1:50 for anti-UBCv (LD9), 1:20 for anti-ubiquitin (Sigma), 1:10 for 
anti-DNA (Boehringer). The slides were then washed 3 times in PBS-T and incubated 
for 30 minutes at 37°C with secondary antiserum at a 1 :40 dilution in PBS-T plus 
10% FCS. The secondary antisera were either FITC-conjugated (Dako or Boehringer) 
or TR-conjugated (Texas Red, Amersham). For double staining, the primary 
antiserum was composed of a mixture of rabbit anti-ubiquitin and mouse anti-VP72 
(1:50 dilution of 17L.D3 monoclonal supernatant) and the secondary antiserum was 
a mixture of FITC-antirabbit and TR-antimouse antisera. Finally, the slides were 
washed 5 times for 5 minutes in PBS-T and a coverslip was mounted with 10% PBS, 
2 % DABCO (anti FITC fading agent) in glycerol. The slides were observed with a 
Vickers incident fluorescence microscope at a 40xlO magnification. The photography 
was carried out with Fujichrome 400 ASA film with 15 seconds to 2 minutes 
exposures. 
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6.2.20 Immunogold labelling and electron microscopy 
IBRS2 cells infected with ASFV were fixed for 1 hour at 37°C in 2 % formaldehyde 
I 0.5 % glutaraldehyde (Bio-Rad) I 1 % sucrose I 2 mM CaCl2 in 0.1 M sodium 
cacodylate buffer pH7.3. The cells were scraped off the dishes, pelleted in a 
microfuge and washed 3 times in 0.1 M cacodylate buffer pH7.3 I 3 % sucrose I 2 
mM CaCI2• The cells were stored in the wash buffer at 4°C. All the subsequent 
manipulations were carried out by Dr T. Self (Nottingham University). The fixed 
cells were embedded in araldite, thin sliced, probed with gold labelled anti-ubiquitin 
antibodies and observed by electron microscopy (Philips EM41O). 
6.2.21 . Purification of extracellular ASFV particles 
The culture adapted ASFV U ganda-A isolate was seeded (at a multiplicity of infection 
of approximately 0.01) on confluent IBRS2 cells in 850 cm2 roller bottles (Falcon). 
The cells were incubated at 37°C until 100% cytophathic effect (CPE) was observed 
(usually three to four days). All subsequent operations were performed at 4°C. The 
cell debris were pelleted by centrifugation at 2000 rpm for 30 minutes in a Mistral 
6L centrifuge (rotor No.59563). The pellet was discarded and the supernatant 
centrifuged for a further 60 minutes at 18,000 rpm in a Beckman LS-M 
ultracentrifuge (Type 19R rotor). The virus pellet was resuspended in 50 ml of PBS 
and Percoll (Pharmacia) was added to a final concentration of 45 % (w/v). The Percoll 
gradient was centrifuged for 30 minutes at 20,000 rpm in a Beckman LS-M 
ultracentrifuge (Type 42.1 rotor). The lower band containing the virus was collected 
and its Percoll concentration re-adjusted to 45 %. The second gradient was respun as 
above and the virus band collected. The refraction index of this band was 1.343, 
corresponding to 53% Percoll indicating a density of approximately 1.09 g.mt1• This 
preparation was diluted in PBS and spun at 30,000 rpm for 30 minutes (as above). 
Percoll forms a solid pellet, whereas the virus forms a loose pellet which can be 
collected separately. The virus thus collected was resuspended in PBS and the last 
operation was repeated. Finally, the virus was resuspended in PBS and stored at -
70°C. The protein concentration in the purified virus preparation was approximately 
1 mg.ml-1 (Protein Assay kit, Bio-Rad). 
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6.2.22 Liquid phase preparative isoelectric focusing (IEF) 
Preparative IEF of purified virus was carried out using the Rotofor system (Bio-Rad) 
essentially as recommended by the manufacturer. Briefly, 1.4 ml of purified virus 
was dissolved by 15 seconds sonication (Soniprobe model 7530A, Dawe Instruments) 
in 10 ml of IEF running solution (8 M urea, 10 mM DIT, 2 % NP40, 2 % ampholites 
(Biolyte pH 3-10, Bio-Rad)). The Rotofor cell was pre-equilibrated twice with 55 ml 
of distilled water for 5 minutes, followed by 1.5 hours pre-focusing with 40 ml of 
IEF running solution at 12 W (550 V, 22 rnA). The 10 ml of solubilized virus was 
loaded in the Rotofor cell central port and focusing was achieved in 1 hour 40 
minutes at 12 W. The final voltage stabilized at 1045 V. The 20 fractions of 3 ml 
each were harvested and their pH measured with pH papers (Whatman). 400 p.l of 5 
M NaCI was added to each fraction before dialysis in Visking tubing (24 A pores) 
against 5 litres of PBS at 4°C. The buffer was changed at 1, 20, 23 and 26 hours. 
The PBS buffer was then exchanged for 20% polyethylene glycol (PEG 6000, 
Kochlight) in PBS and the Rotofor fractions were dialysed for a further 16 hours. 
Finally, 300 p.l of sample buffer was added to the concentrated 600 p.l fractions 
before storing at -20°C. 
6.2.23 ASFV infections in the presence of antisense 
oligonucleotides 
VERa cells were grown to near con fluency in 6 well plates (Falcon) and incubated 
overnight in DMEM supplemented with 1 % foetal calf serum (FCS) and containing 
25 p.M of the antisense phosphorothioate oligonucleotides. The media was then 
decanted and the cells were incubated with the BA 71 V ASFV isolate (Mal of 1) in 
DMEM for 1 hour. The infectious media was then decanted and replaced with 
DMEM I 1 % FCS I 25 p.M antisense oligonucleotides. The cells were incubated for 
a further 4, 8 or 24 hours before removing the media and lysing the cells with sample 
buffer. The celllysates were harvested and stored at -20°C until required. 
6.2.24 
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Generation of ASFV mutants by homologous double 
recombination 
IBRS2 or VERO cells were grown to near confluence in tissue culture inserts (0.45 
J-lm pores, Falcon). The medium was decanted and the cells were incubated for 1 hour 
with the U ganda-A (for IBRS2 cells) or BA 71 V (for VERO cells) ASFV isolates (at 
an MOl of 10). The infectious medium was then decanted and the cells were washed 
twice with warm DMEM. The cells were then transfected by lipofection (Lipofectin, 
Gibco BRL Life Technologies) with the transfer vector DNA (plasmid PR3 DNA 
purified with Magic Maxipreps, Promega). For each tissue culture insert, 2.5 J-lg of 
PR3 plasmid DNA in 50 J-li of sterile water was mixed with 50 J-li of diluted 
.Lipofectin (10 J-li Lipofectin added to· 40 J-li of sterile water). The DNA/Lipofectin 
mix was incubated at room temperature for 15 minutes before being added to the 
infected cells covered with 200 J-li of DMEM. The tissue culture inserts were then 
incubated at 37°C for 4-5 hours before removing the media and replacing it with 
DMEM supplemented with 1 % foetal calf serum. The infected/transfected cells were 
then incubated at 37°C until over 75% CPE was observed (usually 2 to 3 days). The 
medium was then collected, the cellular debris was pelleted and the virus in the 
supernatant containing potential ASFV recombinants was used (at a 1: 10 dilution in 
DMEM) to infect fresh tissue culture cells. The cells infected in the second round 
were then tested for luciferase activity as described in §6.2.25 (below). 
6.2.25 Detection of luciferase activity in ASFV plaques 
Cells in tissue culture inserts were incubated for 1 hour with progeny ASFV collected 
from cells transfected with the PR3 transfer vector. The infectious medium was then 
decanted and replaced with an agar overlay (DMEM I 1 % low melting point agarose 
I 1 % foetal calf serum). The overlayed infected cells were then incubated for 24-48 
hours at 37°C before 1 ml of developer medium was added to each insert. The 
developer medium was composed of DMEM supplemented with 3.5 mM KCI I 60 
mM NaCI I 2.6 mM MgS04 / 1 J-lM nigericin I 0.6 mM ATP / 40 mM DIT 15 J-lM 
beetle luciferin (Promega) and adjusted to pR7.5 with sodium bicarbonate. The tissue 
culture inserts were then immediately laid in a dark room on 400 ASA black and 
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white film (Tmax, Kodak). The film was exposed to the tissue culture inserts for 30 
minutes and was then developed with HCIlO (Kodak) and fixed with Hypam (Ilford). 
Essentially the same procedure was used to detect luciferase activity in ASFV 
infected cells transiently expressing the reporter gene (i.e. in ASFV infected cells 
transfected with the PH3 transfer vector). 
The Luciferase Assay System (Promega) was used according to the 
manufacturer's instructions to measure the luciferase activity in ASFV infected cells. 
Briefly, infected cells were washed twice in warm PBS and lysed with a minimal 
volume of ice cold lysis buffer (1 % Triton X-lOO / 10% glycerol / 25 mM Tris-
phosphate pH7.8 / 2 mM DIT / 2 mM 1,2-diaminocyc1ohexane-N,N,N' ,N'-
tetraacetic acid). The cellular debris was pelleted in a microfuge and for each assay, 
20 Jotl of the supernatant was mixed with 100 Jot! of 530 JotM ATP / 470 JotM luciferin 
/270 JotM coenzyme A / 33.3 mM DIT / 0.1 mM EDTA / 2.67 mM MgS04 II mM 
(MgC03)Mg(OHh • 5H20 / 20 mM tricine. The photoemission of the reaction mixture 
was immediately measured in counts per minute (cpm) in the [3H] window of a 
scintillation counter (Model 1209 Rackbeta, LKB Wallac). 
6.2.26 Affinity chromatography of ASFV ubiquitinated 
structural proteins 
The anti-ubiquitin affinity column was constructed by conjugating 2.8 mg of anti-
ubiquitin antibodies (purified immunoglobulin fraction, Dako) through disulfide bonds 
to a 1 ml cross-linked agarose gel (Sulfolink, Pierce). The anti-ubiquitin antibodies 
were partially reduced in 3 ml of 0.1 M phosphate buffer pH6 containing 50 mM {3-
mercaptoethylamine and 5 mM EDTA. The reducing reaction was allowed to proceed 
for 2 hours at 37°C before the reaction mixture was applied on a desalting column (p6 
matrix, Biorad) equilibrated with 50 mM tris pH8.8 / 5 mM EDTA. Using this 
procedure, only the two hinge disulfide bonds of the antibody molecules are reduced 
(Pierce). Approximately 250 Jotg of reduced immunoglobulins were collected from the 
column effluent and were mixed with 2 ml of Sulfolink slurry (1 ml of gel). The 
conjugation of the antibodies to the Sulfolink gel was performed according to the 
manufacturer's instructions. Approximately 70 Jotg of anti-ubiquitin antibodies were 
linked to the gel (binding efficiency of 30 % ). The gel was then packed in a plastic 
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column and washed with 20 ml of PBS. 
The affinity purification of ubiquitinated ASFV structural proteins was carried 
out with 500 p.g of Percoll purified ASFV particles. The structural proteins were 
solubilized by sonicating ASFV particles in a PBS buffer containing 1 M NaCl / 2 % 
NP40. The solubilized proteins were then repeatedly concentrated in spin 
concentrators with 3 kDa molecular weight cut-off membranes (Centricon-3, Amicon) 
and diluted in PBS until the concentration of NaCI was lowered to 140 mM. The 
ASPV structural proteins (in 0.5 ml of PBS) were then loaded on the anti-ubiquitin 
affinity column equilibrated with PBS. The optical absorbance at A=280 nm (OD280) 
of the effluent was monitored on-line and 0.5 ml fractions were collected. The flow 
rate was maintained at 0.05 ml.min-1 with a peristaltic pump until all the protein 
sample was loaded. The flow rate was then set at 0.5 ml.min-1 and the column was 
washed with PBS until the OD280 returned to baseline. The column was then washed 
with 0.1 M NaCI in PBS until the OD280 returned to baseline, followed by 2 M NaCI 
in PBS. The effluent fractions corresponding to the various OD280 peaks were then 
concentrated in spin concentrators (Centricon-3, Amicon) and rediluted in sample 
buffer ready for analysis by SDS/PAGE. 
6.2.27 Detergent extraction of ASFV structural proteins 
Percoll purified ASPV particles (250 p.g.ml-1 of protein) were incubated with 0.1 % 
to 5 % n-octyl-fj-D-glucopyranoside (OG) in PBS for 2 hours at 4°C. The detergent 
treated samples were then carefully layered onto a 25 % sucrose (in PBS) cushion and 
centrifuged at 20,000 rpm in a Beckman SW50.1 rotor for 15 minutes. The 
supernatants, free of ASPV particles, were then concentrated in spin concentrators 
(Centricon-3, Amicon) and rediluted in sample buffer ready for SDS/PAGE analysis. 
6.2.28 Purification of proteins for N-terminal sequencing 
P ~ o t e i n s s in sample buffer were loaded on 17.5% SDS/PAGE 1.5 mm thick slab gels 
that had been allowed to polymerize overnight. The gels were run overnight at a 
constant voltage of 75 V and the cathode buffer contained 0.1 mM thioglycolate. The 
gels were then transferred using a tank electroblotter (Transphor TE series, Hoefer 
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Scientific Instruments) to a PVDF membrane (Immobilon P, Millipore). The transfer 
b'uffer was composed of 10 mM CAPS pH 11 in 10% methanol, and the transfer was 
carried out overnight at a constant voltage of 25 V with external cooling of the 
buffer. Once the transfer was completed, the membrane was washed in double 
distilled water and the blotted proteins were stained by incubating the PVDF 
membrane in 0.025% coomassie blue in 40% methanol I 0.1 % acetic acid for 1-5 
minutes. The membrane was then destained in 50 % methanol until the protein bands 
were clearly visible. The stained bands corresponding to the proteins of interest were 
then carefully cut out and submitted to N-terminal sequencing. 
6.2.29 N-terminal sequencing of ASFV structural proteins 
The N-terminal sequencing (Edman degradation) of ASFV structural proteins blotted 
to PVDF membranes was carried out by Drs J. Kytes and K. Bailey (Nottingham 
University) using an automated sequencer (Model 473A, Applied Biosystems). 
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